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Investigation of a role for the endosomal 
deubiquitylase USP8 in cancer cell survival pathways 
Alice Emma Louise Howarth 
Ubiquitylation is a reversible post-translational modification regulated by a 
number of enzymes. E1 activating, E2 conjugating and E3 ligase enzymes 
facilitate the modification of proteins by adding the 8.5kDa protein, ubiquitin, 
to lysine residues. The presence of seven internal lysine residues within 
ubiquitin itself allows the construction of complex chains with different chain-
linkages. This complexity means that ubiquitylation plays a role in a number 
of cellular events including protein degradation. This signal is reversed 
through the action of deubiquitylases (DUBs).   
 
One of the roles for ubiquitylation is the targeting of proteins for lysosomal 
degradation and DUBs are important for this function. USP8 is an endocytic 
deubiquitylase involved in the regulation of a number of cell surface proteins. 
USP8 is important for endosomal sorting and the trafficking of cargo for 
degradation by the lysosome of a number of substrates.  More recently USP8 
has been linked to the regulation of cell viability of some cancer cells with a 
purported link to the PI3K-AKT cell survival pathway.  
 
In this thesis I identify a role for USP8 in the survival of EGFR-mutant, 
gefitinib-resistant, non-small cell lung cancer cells. Depletion of USP8 
induces apoptosis in these cells. I confirm a link with the PI3K-AKT signalling 
pathway evidenced by a synthetic lethal effect of inhibiting this pathway when 
combined with USP8 depletion.  
 
In addition I identify a novel link between USP8 and the NRF2-KEAP1 
reactive oxygen species (ROS) management pathway. USP8 depletion 
decreases protein levels of the NRF2 inhibitor, KEAP1. USP8 depletion 
sensitises NSCLC cells to induction of ROS.  
 
I conclude that USP8 is a DUB involved in a number of pathways including 
cell survival.  
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Chapter one: Introduction 
1.1. The discovery of ubiquitin-dependent protein 
degradation. 
The concept of protein-turnover was first proposed in the late 1930s when 
studies using nitrogen isotope fed mice provided evidence for amino acid 
biosynthesis and recycling (Schoenheimer, Rittenberg et al. 1938). In the 
1950s Christian De Duve and colleagues discovered a key degradative 
organelle involved in protein degradation, the lysosome, and characterised a 
number of pH sensitive lysosomal enzymes (see 1.2) (De Duve, Pressman et 
al. 1955, De Duve and Wattiaux 1966). For a long time, lysosomal 
degradation was thought to be the only pathway for protein degradation. 
However Poole et al. showed that blocking lysosomal degradation did not 
prevent the breakdown of the majority of cytosolic proteins (Poole, Ohkuma 
et al. 1977).  
In 1977, Etlinger and Goldberg reported that degradation of a mutated form 
of haemoglobin in a cell-free reticulocyte lysate assay required ATP (Etlinger 
and Goldberg 1977). Proteolysis was optimal at a pH of around 7.8, which 
precluded the activity of acidic pH dependent lysosomal hydrolases.  
Shortly after, Hershko, Ciechanover and Rose not only confirmed the 
reliance on ATP for proteolysis in the cell-free reticulocyte assay but also 
identified a small protein that was fundamental in this protein breakdown. Key 
to this discovery was the fact that they had separated the cell-free lysates 
into three fractions - I, IIA and IIB (Hershko, Ciechanover et al. 1979). Within 
fraction I they found a factor which they named ATP-dependent proteolysis 
factor 1 (APF-1). This was a small, 8.5kDa protein that was required to 
activate the ATP-dependent proteolytic activity of the combined IIA and IIB 
fractions. By the early 80s Ciechanover, Hershko and colleagues had shown 
that this small protein was conjugated to other proteins and that this 
modification required ATP (Ciechanover, Heller et al. 1980, Hershko, 
Ciechanover et al. 1980, Ciechanover 2005). Additionally, they reported that 
this protein could form chains (Hershko, Ciechanover et al. 1980). This work 
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eventually won Hershko, Ciechanover and Rose the 2004 Nobel Prize for 
Chemistry (Wilkinson 2005).  
Prior to this, Goldstein and colleagues had identified a protein important for 
lymphocyte differentiation. They named this protein ubiquitin due to its 
ubiquitous expression profile (Goldstein, Scheid et al. 1975, Schlesinger and 
Goldstein 1975, Schlesinger, Goldstein et al. 1975). In the late 70s two 
articles suggested that ubiquitin was conjugated to histone H2A. The two 
proteins combined had been referred to as a nuclear protein, A2F, but 
analysis of the sequence and identification of an isopeptide bond suggested 
that A2F was a conjugate of these two proteins (Goldknopf and Busch 1977, 
Hunt and Dayhoff 1977). 
In 1980, Wilkinson and colleagues suggested that APF-1 was, in fact, 
ubiquitin – a theory that was proven by comparison of the amino acid 
sequence of the two proteins (Ciechanover, Elias et al. 1980, Wilkinson, 
Urban et al. 1980, Wilkinson 2005).  
 
1.1.1. Ubiquitylation: a reversible post-translational modification 
Ubiquitiylation is a reversible post-translational modification in which the 
carboxy (C)-terminal glycine of ubiquitin is covalently linked to proteins 
predominantly at lysine residues. Ubiquitin contains itself 7 internal lysine 
residues allowing a daisy-chain of ubiquitin moieties to be added. This results 
in the formation of a series of chain linkages (Figure 1.1). Additionally, linear 
chains can be formed by the binding of a second ubiquitin moiety (distal 
ubiquitin) to the amino (N)-terminal methionine of the first (proximal ubiquitin). 
These chains can become more complex still by the formation of mixed 
and/or branched chain linkages (figure 1.1.B) (Ye and Rape 2009, Heride, 
Urbe et al. 2014).  
The system can be likened to phosphorylation where phosphate groups are 
added to serine, threonine and tyrosine residues by kinases often marking 
enzymatic activation. Ubiquitylation is a much more complex modification 
than phosphorylation due to its chain linkage diversity. As kinases add 
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Figure 1.1. The variety of ubiquitylation types in cells. Ubiquitylation is the 
conjugation of a ubiquitin moiety to substrates. Substrates may be mono- or poly-
ubiquitylated. (A.) Monoubiquitylation involves the linkage of a single ubiquitin via
an isopeptide bond to the substrate. This can either be on a single lysine residue
(i.) or on multiple lysines (ii.). (B.) Polyubiquitylation is the build up of ubiquitins into
chains. Due to the variety of chain linkage types this can take the form of a chain 
made up of a single linkage type (i.), a single chain with multiple linkage types (ii.) 
or a branched chain with one ubiquitin residue acting as a bridge between two or
more linkage types (iii.).
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phosphate groups to substrates, so too are enzymes involved in the addition 
of ubiquitin to proteins. Again this is more complex in the case of 
ubiquitylation. Here, a sequence of enzymes, namely ubiquitin activating 
enzyme (E1), ubiquitin conjugating enzyme (E2) and ubiquitin ligase (E3), 
are the enzymes that add the ubiquitin to substrates (Clague, Heride et al. 
2015).  
 
1.1.2. Ubiquitin activation, conjugation, ligation 
Three types of enzymes cooperate to attach ubiquitin on to substrates. The 
number of distinct proteins for each family of enzymes is hierarchical – there 
are 2 E1s, 40 E2s and over 600 E3s. However the actual copy number of 
proteins in each class tips the balance in favour of the E2s with an 
approximate E1:E2:E3 ratio of 1:3:2 in HeLa cells (Kulak, Pichler et al. 2014, 
Clague, Heride et al. 2015).  
E1 conjugation enzymes rely on ATP to activate and bind ubiquitin. In 
vertebrates this group comprises UBA1 and UBA6 with the former 
outweighing the latter in abundance by 10:1 (Clague, Heride et al. 2015). E2s 
interact with both activated ubiquitin and the E1 enzyme to transfer the 
ubiquitin moiety to the active site cysteine of the E2. Different E2s play 
different roles; some determine chain specificity, whilst others are important 
for chain initiation or alternatively for conjugating ubiquitin to ubiquitin and 
therefore chain extension (Clague, Heride et al. 2015).  
Substrate specificity is bestowed by the E3 ubiquitin ligases. This group of 
enzymes can be split into three main subgroups; the HECT E3s, RING E3s 
and RING between RING (RBR) E3s. They differ in how they facilitate the 
conjugation of ubiquitin to substrates. The HECT and RBR E3 ligases take 
the ubiquitin chain onto their own active-site cysteine from the E2 conjugating 
enzymes before passing it on to the substrate. RING E3s, however, lack this 
active-site cysteine so must bring E2 and substrate into close proximity 
allowing transfer directly from one to the other (figure 1.2) (Rotin and Kumar 
2009, Heride, Urbe et al. 2014, Dove, Stieglitz et al. 2016). In addition to 
these families there are also complex multimeric ligases. An example of 
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Figure 1.2. The process of ubiquitylation. In an ATP driven process, an E1
activating enzyme picks up ubiquitin which is transferred to an E2 conjugating
enzyme. The E3 ligase then brings the E2 enzyme and substrate together. In
the case of HECT and RBR E3 ligases (left) the ubiquitin moiety is taken and 
transferred to the substrate. In the case of RING E3 ligases (right) the E3 acts
to bring the E2 enzyme bound to ubiquitin into close proximity of the substrate
facilitating the transfer of ubiquitin without ubiquitin first being passed to the E3
ligase. 
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these comes from the large family of Cullin-RING E3-ligases which are 
composed of one of five Cullin scaffold proteins, a RING protein and a variety 
of other adaptor proteins. The first of these to be described, and perhaps the 
best characterised, is the Skp, Cullin, F-box (SCF) complex which is made up 
of the Skp1 adaptor, an F-box protein, Cullin1 (Cul1) and the RING 
ROC1/RBX1/HRT1 (Petroski and Deshaies 2005, Heride, Urbe et al. 2014). 
Another of these Cullin-RING E3s, the Cul3-RING complex will be described 
in greater detail in section 1.5. Similarly, a subunit of the anaphase promoting 
complex/cyclosome (APC/C) contains a Cullin homology domain and the 
complex itself acts as an E3 ligase in the regulation of the cell cycle (Petroski 
and Deshaies 2005, Bochis, Fetica et al. 2015).  
 
1.1.3. Roles of ubiquitylation 
As discussed above, ubiquitylation was first identified as a way of marking 
proteins for non-lysosomal ATP-dependent degradation. Now we know that 
ubiquitylation is the key signal targeting proteins for degradation by the 26s 
proteasome. The 26S proteasome was first partially purified by Rechsteiner 
and colleagues when they discovered an ATP-dependent protease for the 
degradation of ubiquitin-tagged lysozyme in rabbit reticulocyte lysates 
(Hough, Pratt et al. 1986, Hough and Rechsteiner 1986). This protease was 
600kDa in mass. Later studies showed that, in fact, this multi-protein complex 
is comprised of a central catalytic 20S subunit between two 19S regulatory 
subunits as well as a number of associated accessory proteins including 
ubiquitin receptors (Hough, Pratt et al. 1987, Waxman, Fagan et al. 1987, 
Eytan, Ganoth et al. 1989, Driscoll and Goldberg 1990).  
Primarily, K48-linked ubiquitylation is the major signal for this type of 
degradation (Chau, Tobias et al. 1989, Finley, Sadis et al. 1994, Grice and 
Nathan 2016). In particular longer chains (four or more) of K48-linked 
ubiquitin or multiple short K48-linked chains are optimal (Thrower, Hoffman et 
al. 2000, Lu, Lee et al. 2015). The proteasome recognises ubiquitylated 
proteins through the presence of three ubiquitin receptors (Chen, Randles et 
al. 2016, Shi, Chen et al. 2016). Two of these receptors, Rpn10 and Rpn13 
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show similar specificity for both K48- and K63-linked ubiquitin in vitro; 
however K63-linked chains are not as readily degraded by the proteasome in 
cells. The reasons for this are not yet fully clear (Jacobson, Zhang et al. 
2009, Lu, Lee et al. 2015).  
Mixed chain linkage types might also target proteins for proteasomal 
degradation. For example, whilst K11-linked chains do not in themselves act 
as a signal for proteasome-mediated proteolysis, heterotypic K11/K48 chains 
do (Grice, Lobb et al. 2015). Additionally, there is some evidence that on 
occasion multi-monoubiquitylation can serve as the signal for proteasomal 
degradation as is the case for cyclin B1 (see figure 1.1) (Lu, Lee et al. 2015). 
In addition to proteasomal degradation, we now know that ubiquitylation, in 
particular via K63-linked poly-ubiquitin chains acts as a signal for lysosomal 
degradation. This will be discussed in detail in 1.2. Ubiquitylation might also 
act as a signal for the sequestration of misfolded proteins or damaged 
organelles into autophagosomes (see 1.2) (Stolz, Ernst et al. 2014). 
Ubiquitylation is not just a target for different types of degradation. Due to its 
complexity it is involved in a host of signalling events including the cell cycle, 
DNA damage repair and modulation of transcription. Ubiquitylation can also 
play a role in protein localisation and protein interactions, which can 
subsequently regulate signalling (Komander and Rape 2012).  
 
1.1.4. Deubiquitylases (DUBs) 
As with phosphorylation, ubiquitylation can be reversed by an enzyme. In this 
case, deubiquitylases (DUBs) perform this function. There are around 100 
DUBs encoded in the human genome of which 84 are proposed to be active 
(Komander, Clague et al. 2009, Clague, Barsukov et al. 2013). DUBs are 
split into five well-characterised families plus one newly identified family. The 
families are separated based on the structure of their catalytic domains. Five 
of the families are defined as cysteine proteases. These DUBs rely on the 
presence of a catalytic triad of conserved amino acids, which bear 
resemblance to other cysteine proteases such as papain. These five families 
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are the ubiquitin specific proteases (USPs), the ubiquitin C-terminal 
hydrolases (UCHs), the ovarian tumour proteases (OTU), the Josephins and 
the MINDY family. The sixth family are zinc metalloproteases 
JAB1/MPN/MOV34 (JAMMs) (Komander, Clague et al. 2009, Clague, 
Barsukov et al. 2013). The novel family of MINDY-DUBs comprises just four 
members, FAM63A, FAM63B, FAM188A and FAM188B (Abdul Rehman, 
Kristariyanto et al. 2016). These are cysteine proteases however they bear 
enough structural differences to the other cysteine protease families to be set 
within a unique group. These four novel DUBs have specificity for K48-linked 
poly-ubiquitin chains (Abdul Rehman, Kristariyanto et al. 2016). Rehman et 
al. showed that MINDY1 (FAM63A) has a preference for tetraubiquitin, a 
length specificity which may also apply to the other three members of the 
family (Abdul Rehman, Kristariyanto et al. 2016, Maurer and Wertz 2016).  
DUBs have a variety of domains, many of which are important for their 
interaction with substrates and/or ubiquitin itself. These ubiquitin binding 
domains (UBDs) can be split further into subcategories including ubiquitin 
interacting motifs (UIMs) or ubiquitin associated domains (UBAs).  Another 
common feature in DUBs are ubiquitin-like folds (UBL folds) which 
structurally look similar to ubiquitin but lack the di-Gly motif at the C-terminus 
and therefore cannot be cleaved by DUBs (Komander, Clague et al. 2009, 
Clague, Barsukov et al. 2013).  
The variety within the DUBs and their UBDs allows for a range of substrate 
specificities and chain-linkage specificities. This was first shown for AMSH 
(also known as STAMBP), a JAMM-domain containing deubiquitylase with a 
key role in the internalisation of receptors which will be discussed in much 
greater detail in section 1.2. AMSH shows exquisite specificity for K63-linked 
ubiquitin chains in in vitro DUB activity assays (McCullough, Clague et al. 
2004, McCullough, Row et al. 2006, Komander, Reyes-Turcu et al. 2009). A 
crystal structure of the highly related AMSH-like protein (AMSH-LP) in 
complex with K63-linked di-ubiquitin (diUb) has been solved (Sato, 
Yoshikawa et al. 2008). This structure shows how the enzyme binds to both 
the proximal and distal ubiquitin within the chain via the catalytic domain and 
two family specific insertions (Ins1 and Ins2). Understanding the molecular 
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structure of the interface between AMSH-LP and diUb provides a rationale 
for the linkage specificity of this DUB. The shared structure between AMSH 
and AMSH-LP suggests that the two share a common mechanism of action 
(Davies, Paul et al. 2011).  
At least two other members of the JAMM family (BRCC36 and 
POH/PSMD14) also show K63-linkage specificity, suggesting that this may 
be a common feature of this family (Cooper, Cutcliffe et al. 2009).  
In contrast, the USP family of DUBs show very little chain specificity (Faesen, 
Luna-Vargas et al. 2011). One exception is CYLD, which also shows a clear 
preference for K63- over K48-linked ubiquitin chains, but in contrast to AMSH 
also cleaves linear ubiquitin chains (Komander, Lord et al. 2008, Komander, 
Reyes-Turcu et al. 2009).  
The DUB family with the most defined linkage specificity is the OTU family. 
Mevissen and colleagues purified the 16 OTU deubiquitylases which have a 
complete catalytic triad and performed in vitro DUB activity assays using all 8 
types of diUb chains (Mevissen, Hospenthal et al. 2013). Cleavage of the 
isopeptide bond was assessed by separating diUb and monomeric ubiquitin 
by SDS-PAGE. Six of the DUBs they tested had a preference for a single 
chain linkage – these were Cezanne and Cezanne 2 which preferred K11-
linked chains, OTUD4 and OTUB1 which preferred K48-linked ubiquitin, 
OTUD1 which cleaved K63-linked chains and OTULIN which cleaved linear 
chains. They also identified an additional four DUBs that had linkage 
specificity for two chains: OTUD3 cleaved K6- and K11- linked chains, A20 
and VCPIP preferred K11- and K48-linked ubiquitin and phosphorylated 
OTUD5 cleaved K48- and K63-linked chains. Interestingly unphosphorylated 
OTUD5 was not active in their DUB assay (see below). Finally four OTU 
DUBs (OTUD2, OTUD6A, OTUB2 and TRABID) were able to cleave three or 
more chain linkages whereas the final two (ALG13 and OTUD6B) were 
inactive in their assay.  
MALDI-TOF mass spectrometry offers an alternative approach to assess 
chain linkage specificity (Ritorto, Ewan et al. 2014). The authors expressed, 
purified and then incubated 42 DUBs with diubiquitin topoisomers 
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representing each chain-linkage type in vitro. They then used MALDI-TOF 
mass spectrometry to quantitate the output of monoubiquitin by each DUB 
with each linkage type to interpret their chain-linkage specificity. From there, 
they separated the DUBs they characterised into high specificity, moderate 
specificity and low specificity categories. Within the high specificity group was 
OTULIN, which cleaves linear M1-linked chains, OTUB1 which is specific for 
K48 and AMSH and AMSH-LP, which prefer K63-linked chains. The 
moderate specificity group included A20, which cleaves K48 but at higher 
concentrations will cleave K11, Cezanne, which is specific for K11 but can 
also cleave K48 and K63, and TRABID, which prefers K29 or K33 but will 
also cleave K63 at higher concentrations. They also identified a large number 
of DUBs that displayed very little chain linkage type specificity such as USP1, 
USP7, USP8 and USP15. In fact all of the USPs they used in their assay 
displayed low specificity, which is in line with other work showing that USPs 
tend to be more promiscuous than other DUB-families (Faesen, Luna-Vargas 
et al. 2011). Finally, Ritorto et al. found a number of DUBs with little to no 
activity including OTU1, ATXN3L and JOSD1.  
DUBs themselves have three main roles. Firstly they are able to cleave the 
bonds between the linear chains of three or nine ubiquitins that make up two 
of the four gene products encoding ubiquitin. The other two genes encode a 
linear fusion between RPL40 and RPS27A (60s and 40s ribosomal subunits 
respectively) and ubiquitin and also require DUB activity to liberate one 
ubiquitin molecule. Thus DUBs generate a pool of free ubiquitin for the cell. 
Secondly, DUBs are important for terminating signalling events or rescuing 
proteins targeted for degradation. Once proteins are committed to the 
degradation pathway, DUBs also remove ubiquitin allowing it to be recycled 
by the cell. Finally DUBs are able to modulate signalling by trimming chains 
and allowing new branches to be built (figure 1.3) (Komander, Clague et al. 
2009).  
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1.1.4.1. Regulation of DUBs 
DUBs can be regulated in much the same way as many other enzymes. They 
can be regulated by post-translational modifications such as phosphorylation. 
For example, USP8 is phosphorylated at Ser680 triggering its interaction with 
and inhibition by 14-3-3 proteins. This phosphorylation is removed during the 
M-phase of the cell cycle when USP8 deubiquitylating activity is increased as 
cells divide (Mizuno, Kitamura et al. 2007). Conversely, evidence shows that 
phosphorylation of OTUD5 is sufficient and required for the enzymatic activity 
of this DUB. OTUD5 is phosphorylated at Ser177 which does not alter the 
structure of the apo (unbound) form (Huang, Ma et al. 2012). The crystal 
structure of OTUD5 in complex with ubiquitin highlights the importance of the 
phosphorylation at this residue. Once phosphorylated, OTUD5 is able to 
wrap around its substrate bringing the catalytic triad into an enzymatically 
competent configuration (Huang, Ma et al. 2012). 
Another DUB, that requires a conformational change for activation is USP7. 
USP7 switches between the active and inactive state and the active state can 
be stabilised by interaction with GMP synthase, which helps bring the 
catalytic triad into the correct confirmation (Faesen, Dirac et al. 2011) .   
In other cases, DUBs can be regulated by their localisation. USP19, for 
example, has a transmembrane domain inserting it into the endoplasmic 
reticulum membrane where it plays an important role in the endoplasmic 
reticulum associated degradation (ERAD) pathway and exit of newly 
synthesised and fully folded LRP6 from the ER (Hassink, Zhao et al. 2009, 
Perrody, Abrami et al. 2016).  
Similarly, DUBs can be recruited to other complexes. For example the K63-
ubiquitin specific JAMM deubiquitylase, AMSH, is brought to the early 
endosome due to its interaction with ESCRT-0 complex member STAM and 
multiple ESCRT-III components including CHMP3 and Clathrin (McCullough, 
Row et al. 2006). AMSH depletion enhances the degradation of the ESCRT-
cargo and EGFR downregulation presumably by enhancing ubiquityation 
dependent sorting of EGFR into the multivesicular bodies (McCullough, Row 
et al. 2006). AMSH activity is enhanced by its direct interaction with STAM 
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which is reliant on the UIM domain of STAM (see section 1.2 for detail) 
(McCullough, Row et al. 2006). Another example of DUB interactions with 
other complexes can be seen in USP28. This DUB binds to Fbw7, a 
substrate adapter of the Skp1-Cul1 E3 ligase complex. This interaction is 
required for the recognition of USP28 - substrates which include c-Myc. In 
this case the DUB and the E3 ligase complex counteract one another fine-
tuning c-Myc protein stability (Diefenbacher, Chakraborty et al. 2015).  
 
1.1.4.2. Measuring DUB activity 
There are a number of ways to assay the DUB activity of a protein. Some 
assays use fluorescence as an output, others use molecular weight shifts on 
a gel or rely on mass spectrometry (see above). One fluorescence-based 
technique monitors the cleavage of ubiquitin-amidomethylcoumarin (AMC) 
(Russell and Wilkinson 2005, Ovaa 2007). In this case, ubiquitin is fused to 
the fluorophore AMC and combined with a DUB in vitro. The fluorescence of 
this fluorogenic substrate increases when the DUB releases the AMC.  
More recently, active-site directed probes have become useful tools for 
studying the activity of DUBs (Ovaa 2007, Ekkebus, Flierman et al. 2014). 
The first of these had a ubiquitin moiety with a vinyl sulfone (UbVS) group 
attached. This VS group irreversibly modifies UCH and USP deubiquitylases 
allowing a shift of approximately 8.5kDa (the size of ubiquitin) to be 
detectable by SDS-PAGE. Subsequently, different chemical groups have 
been used to increase the sensitivity of the probes. An example of these – 
the Ub-VME probe – is used and described in chapter four (McGouran, 
Gaertner et al. 2013).  
Neither of the above two methods informs on linkage specificity. A simple 
assay for the chain-linkage specificity of DUBs is to combine diUb of different 
linkages and a DUB of interest in vitro and resolve the products on a gel, 
which can either be developed by silver stain or processed by western blot. 
DiUb runs differently on an SDS-PAGE gel and can be distinguished from 
monoubiquitin if the active DUB cleaves the bonds. Similarly, chain-length 
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specificity can be identified using increasing lengths of ubiquitin chains and 
monitoring the cleavage by SDS-PAGE.  
A similar type of assay makes use of Förster Resonance Energy Transfer 
(FRET) whereby the DUB activity separates two fluorophores attached to 
isopeptide-linked ubiquitin moieties triggering a shift in the wavelength 
(Horton, Strachan et al. 2007). Similarly the Progenra CHOP-assays can be 
used whereby cleavage of the isopeptide bond releases a reporter enzyme 
usually from a single ubiquitin and allows generation of fluorescence from the 
enzyme acting upon its substrate. 
Mass spectrometry has also been used to identify cleavages of di-ubiquitin 
as described above: Matthias Trost and colleagues recently generated diUb 
topoisomers of each chain linkage type using 15N-ubiquitin, which could then 
be measured by MALDI-TOF mass spectrometry after in vitro incubation with 
a number of deubiquitylases (Ritorto, Ewan et al. 2014).    
 
1.1.5. Ubiquitylation as a proteolysis signal 
I described above that ubiquitylation was first identified for its role in 
proteasomal degradation. In the next section I will discuss the role of 
ubiquitylation in the regulation of both lysosomal and autophagosomal 
degradation.   
 
1.2. Ubiquitin-dependent sorting in the endo-lysosomal 
pathway 
 
1.2.1. The lysosome 
Christian de Duve and colleagues first coined the term ‘lysosome’ in 1955 
(De Duve, Pressman et al. 1955). It was named such due to the organelle’s 
proposed digestive function, as the word is Greek for digestive (lysis) body 
(soma). The publication in 1955 was preceded by a number of biochemical 
studies that first described the organelle (Berthet, Berthet et al. 1951, Berthet 
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and De Duve 1951, Appelmans, Wattiaux et al. 1955). These studies 
employed the use of a novel fractionation technique developed by Albert 
Claude that involved centrifugation to separate four fractions – a nuclear 
fraction, a large-granule fraction comprised mostly of mitochondria, a small-
granule fraction referred to as microsomes and a final supernatant (Claude 
1946, Claude 1946). This led to the discovery of an additional fraction, which 
could be identified by the presence of an enzyme called acid phosphatase 
(De Duve, Pressman et al. 1955). The activity profile of the enzyme varied 
based on the level of decay in the samples, suggesting that this enzyme was 
enclosed within a membrane and required release in order to interact with its 
substrate. The team worked out a five-fractionation protocol and identified a 
fraction that lay between those of the mitochondria and of the microsomes in 
density. By 1955 an additional four enzymes had been characterised in this 
fraction, all of which behaved in a similar way to acid phosphatase. These 
were β-glucoronidase, Cathepsin (now known as Cathepsin D), 
Ribonuclease and Deoxyribonuclease (de, Berthet et al. 1951, De Duve, 
Pressman et al. 1955). They also identified a fifth enzyme, which behaved 
differently and was later shown to belong to another novel cytoplasmic 
particle, the peroxisome (De Duve and Baudhuin 1966). Following this 
biochemical identification of the organelle, the group went on to visualise the 
lysosome by electron microscopy (Novikoff, Beaufay et al. 1956). The 
presence of these degradative enzymes within the lysosomes, gave us our 
first glimpse at a mechanism for protein turnover (Simpson 1953, 
Ciechanover 2005). We now know that the lysosome has two key 
degradative functions. Firstly to degrade proteins internalised by endocytosis 
and secondly to fuse with autophagic vacuoles to allow the turnover of 
cellular organelles and cytosolic proteins (Kornfeld and Mellman 1989).  
The lysosome is comparable to the yeast vacuole, which serves as a key 
degradative organelle in yeast (Klionsky, Herman et al. 1990, de Marcos 
Lousa and Denecke 2016). Lysosomes and vacuoles differ in relative size 
and number: yeast cells contain one to five large 5µm vacuoles whereas 
mammalian cells contain 50-1000, small lysosomes between 0.1-1µm in size. 
However, like the lysosome, the yeast vacuole is an acidic compartment 
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containing pH-sensitive enzymes, which allow the breakdown of proteins 
delivered to this organelle (Klionsky, Herman et al. 1990).  
 
1.2.2. Endocytosis 
Endocytic processes can be categorised into macro-scale and micro-scale 
endocytosis. Macro-scale endocytosis includes phagocytosis and 
macropinocytosis, sometimes referred to as cell eating and drinking. In this 
type of endocytosis a cell can consume large particles or portions of 
extracellular liquid relative to the size of the cell itself. Micro-scale 
endocytosis is internalisation on a smaller scale of around 200nm (Kumari, 
Mg et al. 2010). This can be split further still into clathrin-mediated, caveolar 
and different types of clathrin- and dynamin-independent endocytosis. Here I 
will focus on clathrin-mediated endocytosis (CME), which is involved in 
delivering cell surface receptors to the lysosome for degradation.  
 
1.2.3. Clathrin-mediated endocytosis 
In 1964, Thomas Roth and Keith Porter published their study of the 
internalisation of yolk proteins by Aedes aegypti oocytes (Roth and Porter 
1964). Building on the idea that the process of internalisation was similar to 
micropinocytosis, they took sequential electron micrographs and showed 
invagination of the cell membrane. The pits, and subsequently pinched-off 
vesicles, had a 20µm bristle-like coat, which Kanaseki and Kadota later 
showed to be comprised of a polygon lattice that appeared to surround the 
vesicle like a basket (Kanaseki and Kadota 1969). Prior to this, at the end of 
the 19th century, Metchnikoff had shown that cells internalised litmus paper 
from outside of the cell into acidic compartments and in the 1930s, W. H. 
Lewis imaged macrophages internalising extracellular fluid (Roth 2006). 
However, it was the detailed electron micrographs from Roth and Porter that 
gave us our first visualisation of the coat itself. 
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In the 1970s, the major protein component of this lattice-like coat was 
isolated and named Clathrin by Barbara Pearse (Pearse 1975, Pearse 1976).  
 
1.2.4. The Clathrin coat  
The now iconic structure of the Clathrin-basket has, over the years, become 
well characterised. Clathrin is comprised of three heavy chains each with an 
associated light chain (Crowther and Pearse 1981, Kirchhausen and Harrison 
1981, Ungewickell and Branton 1981). These form a triskelion structure with 
the heavy chains providing three ‘legs’ each bent at the ‘knee’ and ‘ankle’ 
(Smith, Grigorieff et al. 1998, ter Haar, Musacchio et al. 1998, Musacchio, 
Smith et al. 1999). The light chains are believed to confer additional 
regulation in both yeast and mammalian cells (Nathke, Hill et al. 1990, Pley, 
Hill et al. 1995, Huang, Gullberg et al. 1997, Chu, Pishvaee et al. 1999). 
Pearse identified Clathrin as by far the most abundant protein of the Clathrin 
coat. However even in her first paper on this topic she identified the presence 
of other proteins which she suggested might “represent light impurities or 
minor proteins associated with vesicles” (Pearse 1975).  
We now know that Clathrin itself cannot interact with the lipid bilayer. It is 
recruited to the membrane via its interaction with adaptor protein (AP) 
complexes. AP complexes were first identified as approximately 100kDa 
‘assembly polypeptides’ (Zaremba and Keen 1983, Robinson 2015). When 
the fraction containing 100kDa proteins was combined with Clathrin itself, in 
vitro reassembly of  disrupted Clathrin coated vesicles (CCVs) was enhanced 
(Keen, Willingham et al. 1979). AP complexes are hetero-tetrameric protein 
complexes comprised of an α-type (α, γ, δ, ε or ζ), β, µ and σ chain 
(Kirchhausen 2000). In mammalian cells there are five known AP complexes: 
AP-1, AP-2, AP-3, AP-4 and AP-5. The former three of these have been 
shown to be capable of binding Clathrin (Kirchhausen 2000, Park and Guo 
2014). The most recent of these AP complexes to be identified, AP-5, has 
been shown to interact with the late endosome and plays a role in endosomal 
sorting but does not interact with Clathrin (Hirst, Barlow et al. 2011). Yeast 
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cells have three AP complexes of which only one has been shown to bind 
Clathrin (Huang, D'Hondt et al. 1999). 
In addition to AP complexes, Clathrin can also bind to other adaptor proteins 
called Golgi-localising, γ-adaptin ear homology domain, ARF-binding proteins 
(GGA proteins) (Nakayama and Wakatsuki 2003). These are monomeric 
adaptors, conserved from yeast to humans that are found at the Golgi. 
GGAs, together with AP-1, interact with cargos such as the Mannose 6 
Phosphate Receptor (M6PR) which binds to lysosomal hydrolases. GGAs 
therefore play a key role in transporting lysosomal hydrolases from the trans-
Golgi network (TGN) to the endosome via CCVs (Braulke and Bonifacino 
2009). Endosomal maturation and subsequent fusion with the lysosome 
allows the delivery of these enzymes to the lysosome. The M6PR dissociates 
from the hydrolases at the low pH of the endosome and is retrieved by 
retrograde trafficking facilitated by the retromer (Trousdale and Kim 2015).  
AP complexes allow the recruitment of Clathrin to cargo, and cargo to 
Clathrin by acting as a bridge between the two (Keen, Willingham et al. 1979, 
Pearse and Bretscher 1981, Pearse and Robinson 1990, Brodsky, Hill et al. 
1991, Kirchhausen, Bonifacino et al. 1997, Kirchhausen 2000). The AP 
complex required for Clathrin-mediated endocytosis is AP-2. AP-2 contains 
an α chain, a β2 chain, a µ2 chain and an σ2 chain (Robinson and Pearse 
1986, Ahle, Mann et al. 1988, Hirst and Robinson 1998). The N-terminal 
region targets AP-2 to the plasma membrane whereas other AP complexes 
are targeted elsewhere and therefore play different roles in trafficking. For 
example AP-1 is targeted to the TGN via the small G protein Arf-1 and is 
important for Golgi to endosome trafficking alongside GGAs (Gaidarov, Chen 
et al. 1996, Gaidarov and Keen 1999, Zhu, Traub et al. 1999).  
The flexibility of Clathrin itself allows curvature of the membrane. This is 
especially evident at the knee region of each heavy chain where the protein 
is not constrained by contacts with the light chain or adaptor complexes. This 
curvature is reliant on the structure of the combined Clathrin molecules of the 
coated pit (Musacchio, Smith et al. 1999). Clathrin assembles into a mixture 
of both hexagonal and pentagonal polygons and the diversity of these 
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shapes is fundamental to the curvature of the membrane in a similar way to 
the structure of a football (Kanaseki and Kadota 1969, Heuser 1980).  
The exact method of Clathrin-coated pit (CCP) initiation is not yet fully 
understood. Historically it was believed that AP-2 recruitment to the plasma 
membrane was the first step, however in some cases CCPs form in the 
absence of AP-2 (Motley, Bright et al. 2003). A collection of other factors 
might be involved in the nucleation step, including cell surface phospholipids, 
the recruitment of other adaptor proteins such as Eps15 and the presence of 
cargo (Merrifield and Kaksonen 2014). The initiation process may also 
engage SNARE protein complexes, small Rab proteins and Epsin. The latter 
is involved in inducing membrane curvature and links Clathrin to cargo as 
well as binding ubiquitin as will be discussed below (Kirchhausen 2000). 
 
1.2.5. Clathrin coated vesicle (CCV) propagation and scission  
A number of proteins are involved in the growing CCV, including Bin 
Amphiphysin Rvs (BAR) domain-containing proteins and amphiphysin. These 
recognise and regulate membrane curvature. Curvature of the membrane is 
also dependent on the proportion and layout of pentagonal Clathrin polygons 
within the pentagonal/hexagonal complement. In addition, the brain protein 
AP-180 and its ubiquitous mammalian equivalent CALM are involved in 
regulating the size of CCVs (Kirchhausen 2000).  
Amphiphysin recruits the membrane scission protein, dynamin, to the 
budding vesicle. The helix of this corkscrew-shaped protein pinches off the 
vesicle allowing its release into the cytosol. The Clathrin coat is rapidly 
removed once the vesicle is released into the cell (Kirchhausen 2000). 
 
1.2.6. Receptor-mediated endocytosis 
A particular subtype of Clathrin-mediated endocytosis is the internalisation of 
cell surface receptors (figure 1.3.). Anderson, Brown and Goldstein described 
ligand-induced receptor-mediated endocytosis of LDL and its receptor, which 
they first identified in 1974 (Brown and Goldstein 1974, Anderson, Brown et 
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Figure 1.3. A simplified schematic of ligand-induced RTK internalisation and
trafficking to the multivesicular body and recycling back to the cell surface. 
1. Ligand binding triggers receptor dimerisation and activation by phosphorylation.
2. The activated receptor is ubiquitylated and internalised. 3. The receptor is traff-
icked to the early endosome where it is sorted into multivesicular bodies facilitated
by ESCRT proteins and the endocytic DUBs, USP8 and AMSH (see figure 1.4.). 4.
Receptors can be recycled to the plasma membrane or degraded upon endosome
fusion wit the lysosome (5.).
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al. 1977, Anderson, Goldstein et al. 1977, Goldstein, Anderson et al. 1979). 
Using human fibroblasts incubated for two hours at 4°C with Ferritin-labelled 
LDL, then fixed and imaged by electron microscopy, the authors showed that 
60-70% of Ferritin labelling occurred at indented, coated regions, which 
comprised less than 2% of the cell surface area. When these cells were 
warmed up to 37°C it took only one minute for Ferritin to appear in coated 
endocytic vesicles. By ten minutes nearly all of the membrane-bound Ferritin-
LDL had been internalised. These imaging studies allowed the visualisation 
of sequential internalisation steps and the uncoating of internalised vesicles. 
Tracking Ferritin-tagged LDL revealed its incorporation into structures that 
were morphologically similar to lysosomes, indicating a potential fusion of the 
endocytic carriers with lysosomes.  Thus Anderson, Brown and Goldstein 
were fundamental in describing the process of receptor-mediated 
endocytosis. This was later confirmed by studies on insulin, EGF and α2-
macroglobulin using similar experiments, whereby fluorescent derivatives of 
these ligands were imaged after initial binding at 4°C and subsequent 
internalisation at 37°C in Swiss 3T3 cells (Maxfield, Schlessinger et al. 1978). 
Over time, our understanding of receptor mediated endocytosis and some of 
the signals involved in its regulation have grown.  
 
1.2.7. Ubiquitylation as a signal for receptor-mediated endocytosis 
Ligand-activated receptor tyrosine kinases (RTKs) such as the epidermal 
growth factor receptor (EGFR) become autophosphorylated and these 
phosphorylation sites recruit downstream signalling molecules (discussed in 
1.4). In addition to the recruitment of signalling effectors, the phosphorylation 
sites can recruit E3 ligases such as c-Cbl (Joazeiro, Wing et al. 1999, 
Levkowitz, Waterman et al. 1999, Waterman, Levkowitz et al. 1999, 
Yokouchi, Kondo et al. 1999, Klapper, Waterman et al. 2000, Peschard, 
Fournier et al. 2001). Recruitment of Cbl can be direct via its tyrosine kinase-
binding (TKB) domain, which interacts with Y1045 of EGFR, Y1003 of Met 
and Y1112 of ERBB2 (Levkowitz, Waterman et al. 1999, Klapper, Waterman 
et al. 2000, Peschard, Fournier et al. 2001). Cbl can also be indirectly 
recruited via adaptors such as Grb2 (which binds to Y1068 and Y1086 of 
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EGFR), APS (recruited to Y1021 of PDGFR) or a complex of Grb2 and FRS2 
(in the case of FGFR) (Yokouchi, Wakioka et al. 1999, Waterman, Katz et al. 
2002, Wong, Lamothe et al. 2002, Jiang, Huang et al. 2003).  
Cbl then recruits an E2, UBCH7, via its RING domain facilitating the linkage 
of single ubiquitin molecules on to the receptor (Yokouchi, Kondo et al. 1999, 
Zheng, Wang et al. 2000). Cbl also interacts with the adaptor protein CIN85 
which allows the coupling of Cbl to endophilins. This complex might induce 
the negative membrane curvature required for successful endocytosis 
(Soubeyran, Kowanetz et al. 2002). Other E3 ligases may also be involved in 
the endocytosis of cell surface receptors such as Nedd4 and the Cbl-like 
ligase Hakai which regulate the levels of insulin-like growth factor receptor 
and E-cadherin respectively (Vecchione, Marchese et al. 2003) (Fujita, 
Krause et al. 2002, Huang, Choi et al. 2015).  
At the early stage of CCV formation, there are a number of proteins that are 
able to bind to ubiquitin. For example, tandem ubiquitin interacting motifs 
have been found in Epsin 1 and Epsin 2 as well as the yeast Epsin 
homologues Ent1p and Ent2p and human Eps15 (Hofmann and Falquet 
2001, Klapisz, Sorokina et al. 2002, Shih, Katzmann et al. 2002). In yeast, 
the homologue of Eps15, Ede1p, contains a ubiquitin-associated (UBA) 
domain (Shih, Katzmann et al. 2002). Research in yeast has been 
fundamental in understanding this pathway. Initial studies in Saccharomyces 
cerevisiae showed that a GPCR (Ste2p) and two transporters, uracil 
permease and Ste6p, are mono- and/or poly-ubiquitylated (Kolling and 
Hollenberg 1994, Hicke and Riezman 1996, Galan and Haguenauer-Tsapis 
1997). A ubiquitylated form of the ABC-transporter family member, Ste6p, 
accumulates at the plasma membrane in endocytic mutants of S. cerevisiae 
as evidenced by immunofluorescence and cell fractionation. In endocytic 
mutants, Ste6p is mostly localised to intracellular membranes with only a 
small portion found at the plasma membrane (Kolling and Hollenberg 1994). 
This redistribution of Ste6p gave an indication that this protein might be 
internalised into the endocytic pathway. Immunoprecipitation of Ste6p from 
cells expressing myc-tagged ubiquitin and western blotting with anti-myc 
antibodies confirmed its ubiquitylation. Additionally, Ste6p is stabilised in cells 
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defective in ubiquitin conjugation, and this is reversed by the re-expression of 
an E2 ligase, UBC5.  
Just two years later Hicke and Riezman published their work on the yeast 
GPCR Ste2p (Hicke and Riezman 1996). Ste2p is mono-ubiquitylated and 
internalised in response to ligand binding and subsequently trafficked to the 
vacuole for degradation. Double ubiquitin E2 enzyme mutants (ubc1ubc4 and 
ubc4ubc5) internalise the ligand-bound receptor 5- and 15-times slower than 
wild-type, and a K337R mutant Ste2p is no longer ubiquitylated or 
internalised. Meanwhile Galan and Haguenauer-Tsapsis showed that uracil 
permease is ubiquitylated in yeast and that this is ablated by mutation of the 
ubiquitin ligase Npi1p (Galan and Haguenauer-Tsapis 1997). Npi1p mutant 
cells also have an increase in plasma membrane localised uracil permease. 
Likewise, ubiquitin-conjugated uracil permease accumulates at the cell 
surface of cells in which internalisation is blocked due to a temperature 
sensitive actin (act1) mutation (Galan, Moreau et al. 1996). The authors went 
on to show that in fact, K63-linked ubiquitylation is important in enhancing 
endocytosis of this protein and that endocytosis is impaired in cells lacking 
the deubiquitylase Doa4p (Galan and Haguenauer-Tsapis 1997).   
Prior to these findings in yeast, receptors had been shown to be ubiquitylated 
in mammalian cells. In 1992, Mori et al. showed that PDGF binding to the 
PDGFβ receptor induces its polyubiquitylation (Mori, Heldin et al. 1992). 
Mutation of K63 to an alanine in the receptor prevented its ubiquitylation and 
ligand-induced degradation. Meanwhile in 1994, two groups showed that the 
c-Kit receptor was subjected to ligand-induced polyubiquitylation, which 
enhanced its internalisation and turnover, and reduced its cell surface levels 
(Miyazawa, Toyama et al. 1994, Yee, Hsiau et al. 1994). Thus the link 
between ubiquitylation and receptor degradation was evident, however that 
this process required endocytosis in mammalian cells was not shown until 
studies by Strous et al. in 1996 made use of Chinese hamster ovary (CHO) 
cells with a temperature sensitive defect in ubiquitin conjugation (CHO-ts20) 
(Strous, van Kerkhof et al. 1996). The authors transfected these cells as well 
as the wild-type (CHO-E36) cells with growth hormone receptor (GHR) and 
stimulated them with the growth hormone (GH) ligand. Using this method 
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they showed that GHR ubiquitylation is ligand dependent, ligand induces 
internalisation and that internalisation is ubiquitin dependent. At 42°C the 
CHO-ts20 cells are unable to undergo ubiquitin conjugation. Cells treated 
with GH at this temperature failed to internalise the fluorescently labelled 
receptor. Endo-lysosomal degradation inhibitors NH4Cl and bafilomycin A1 
blocked the ligand-induced downregulation  of GHR at the permissive 
temperature. We now know that ubiquitylation acts as an internalisation 
signal for a number of receptors in mammalian cells. In addition ubiquitylation 
accelerates the slow, ligand-independent, constitutive internalisation of RTKs 
such as EGFR family members, MET, and PDGFR (Levkowitz, Waterman et 
al. 1998, Miyake, Lupher et al. 1998, Marmor and Yarden 2004).  
In 1998 a further link between ubiquitylation and receptor-mediated 
endocytosis was reported. Levkowitz et al. showed that the E3 ligase c-Cbl 
increases the rate of EGFR degradation and that it does so by interacting 
with the receptor itself (see above). Upon stimulation, EGFR was shown to 
be ubiquitylated by Cbl and is subsequentally degraded in the lysosome 
(Levkowitz, Waterman et al. 1998). Conversely, overexpression of inactive 
oncogenic viral Cbl (v-Cbl) interfered with the ability of c-Cbl to sort 
receptors, which were subsequently recycled instead of degraded – pointing 
to a role for ubiquitylation in the targeting of receptors to the lysosome.  
Experiments in yeast linked the deubiquitylase Doa4 to sorting of Ste6p-GFP 
to the vacuolar lumen. Mutant Doa4 led to the entrapment of Ste6p-GFP at 
the vacuolar membrane, indicating that the protein was successfully 
internalised but unable to cross into the vacuole (Losko, Kopp et al. 2001). 
This led to the proposition that reversible ubiquitylation is required for sorting 
into multivesicular bodies.  
Mono-ubiquitylation on one or several lysines is sufficient for internalisation of 
a number of RTKs. For example EGFR- or PDGFR-ubiquitin chimeric 
proteins were internalised although the ubiquitin in these chimeras was 
mutated such that it could not be conjugated to additional ubiquitin moieties 
(Haglund, Sigismund et al. 2003, Mosesson, Shtiegman et al. 2003). These 
receptors as well as the MET receptor were shown to crossreact with 
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antibodies that recognise mono-ubiquitylated proteins, but not with antibodies 
specific for polyubiquitin (Carter, Urbe et al. 2004, Marmor and Yarden 2004). 
These observations are in line with some of the earlier findings in yeast 
outlined above, in which Ste2p was mono-ubiquitylated, subsequently 
internalised and degraded (Hicke and Riezman 1996).  
There is evidence, however, that also in mammalian cells, short K63-linked 
chains might be more efficient signals for endocytosis at least in some cases. 
One such example of this comes from mass spectrometry analysis of 
ubiquitylated EGFR (Huang, Zeng et al. 2013). Huang and colleagues found 
that the majority of ubiquitin associated with EGFR was found in the form of 
poly-ubiquitin chains, mostly linked through K63 moieties. Additionally, EGFR 
expressed as a fusion protein with the K63 specific deubiquitylase AMSH 
reduced polyubiquitylation, increased mono-ubiquitylation and delayed 
degradation of EGFR. However these mono-ubiquitylated receptors still 
underwent the initial internalisation step suggesting that K63-linked chains 
may be important for a downstream sorting pathway (Huang, Zeng et al. 
2013). Incidentally, Cbl may remain associated with activated EGFR beyond 
the initial internalisation of the receptor as it is seen to colocalise with EGFR 
in endosomes (Levkowitz, Waterman et al. 1998).  
Studies in yeast already hinted at a role for K63-linked chains. Firstly, Galan 
et al. showed that uracil permease requires K63-linked chains for its 
degradation as described above (Galan and Haguenauer-Tsapis 1997). 
Additionally, the S. cerevisiae HECT E3 ligase, RSP5, which ubiquitylates a 
number of cell surface receptors including Ste2p and Gap1 permease, 
produces K63-linked ubiquitin chains (Kim and Huibregtse 2009). Finally, 
Lauwers et al. showed that K63-linked ubiquitylation is required for MVB 
sorting of Gap1 permease in yeast, although monoubiquitylation was 
sufficient for the protein’s initial internalisation (Lauwers, Jacob et al. 2009).   
 
1.2.8. The ESCRT machinery  
Initial studies in yeast identified 46 vacuolar protein sorting (vps) mutants that 
were involved in the transport of cargo to the vacuole, the yeast equivalent to 
24
the mammalian lysosome (Bryant and Stevens 1998). Thirteen of these 
mutants produced an exaggerated, aberrant ‘class E’ compartment, which is 
equivalent to an aberrant endosome. Later work, pioneered by the Emr lab, 
characterised three ESCRT complexes – ESCRT I, II and III – which in 
combination with the already-characterised Vps4 complex and the upstream-
acting ESCRT-0 complex comprise the 5-step pathway required for the 
biogenesis of multivesicular bodies (figure 1.4.) (Katzmann, Babst et al. 
2001, Babst, Katzmann et al. 2002, Babst, Katzmann et al. 2002, Bilodeau, 
Urbanowski et al. 2002, Katzmann, Stefan et al. 2003). Equivalent ESCRT 
complexes were characterised in mammalian cells (table 1.1.) (Williams and 
Urbe 2007, Raiborg and Stenmark 2009, Hurley 2010). 
The initial step in MVB biogenesis is the recognition of ubiquitylated proteins 
by ESCRT-0. The mammalian ESCRT-0 complex is made up of HRS and 
STAM1/2 (Vps27 and Hse1 respectively in yeast). These two proteins 
constitutively interact with one another via anti-parallel coiled-coil and GAT 
domains which bring the ubiquitin binding regions of the two proteins into 
close proximity (Prag, Watson et al. 2007, Ren, Kloer et al. 2009). HRS 
possesses a FYVE domain which interacts with phosphatidylinositol-3-
phosphate (PI3P), a lipid that is enriched on early endosomes (Burd and Emr 
1998, Gaullier, Simonsen et al. 1998, Kutateladze, Ogburn et al. 1999, Misra 
and Hurley 1999, Urbe, Mills et al. 2000). This interaction between HRS and 
PI3P recruits the ESCRT-0 complex as a whole to the endosome (Raiborg, 
Bache et al. 2001, Raiborg, Bremnes et al. 2001). The ESCRT-0 complex is 
involved in the initial sorting of cargo. It recognises ubiquitylated cargo via the 
VHS domains of both HRS and STAM, alongside the multiple UIMs 
possessed by the two proteins (Mizuno, Kawahata et al. 2003, Hong, Ahn et 
al. 2009, Ren, Kloer et al. 2009, Ren and Hurley 2010). Both mammalian 
HRS and yeast Vps27 are capable of binding three ubiquitin moieties. In 
addition to the ubiquitin interacting N-terminal VHS domain HRS carries a 
double-sided UIM and Vps27 has two tandem UIMs (Urbe, Sachse et al. 
2003, Hirano, Kawasaki et al. 2006). STAM contains both the N-terminal 
VHS domain and a traditional UIM (Mizuno, Kawahata et al. 2003). 
Therefore, in total, ESCRT-0 can interact with up to five ubiquitin moieties or 
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Figure 1.4. MVB biogenesis at the early endosome. The MVB biogenesis path-
way is composed of four ESCRT complexes - ESCRT-0, ESCRT-I, ESCRT-II and 
ESCRT-III. Ubiquitylated receptors are first recognised by the ESCRT-0 complex.
The ESCRT complexes act together to sort cargo into multivesicular bodies at the 
early endosome. Finally the VPS4 complex dissociates the ESCRT machinery.
USP8 and AMSH are recruited to both the ESCRT-0 and ESCRT-III complex and
are involved in cargo deubiquitylation. 
Table 1.1. Componenets of the ESCRT complexes in yeast and mammals. 
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multiple ubiquitin moieties on a poly-ubiquitylated protein. In mammalian 
cells, HRS and STAM also interact with Clathrin via the Clathrin-binding 
domain present in HRS (Raiborg, Bache et al. 2001). The early endosome is 
associated, through HRS, with a flattened Clathrin coat comprised of both the 
Clathrin heavy and light chains but lacking adaptor protein (AP) complexes 
(Clague 2002, Sachse, Urbe et al. 2002, Hurley 2010). Invagination of the 
membrane into intralumenal vesicles (ILVs) of the endosome during MVB 
biogenesis was seen adjacently rather than directly below Clathrin coated 
regions (Sachse, Urbe et al. 2002). It has been proposed that this coat might 
favour membrane remodelling to occur consistently in the correct direction – 
internalising vesicles into the MVB rather than vesicles budding outwards 
(Clague 2002, Sachse, Urbe et al. 2002).  
In addition to interaction with PI3P, Clathrin and ubiquitylated receptors, 
ESCRT-0 is able to recruit the next complex in the sequence, ESCRT-I. This 
is in part via interactions between P(S/T)XP motifs within Vps27/HRS and the 
ubiquitin E2 variant (UEV) domain within the ESCRT-I complex member 
Vps23/TSG101. Finally, ESCRT-0 also recruits a pair of endocytic DUBs, 
which will be described in greater detail below (Clague and Urbe 2006).  
ESCRT-I is comprised of TSG101 (Vps23 in yeast), Vps28, Vps37 and 
Mvb12/UBAP1. As described above, the complex is recruited by the direct 
interaction of TSG101 with HRS. Together with ESCRT-II, this complex is 
believed to be involved in initiation and stabilisation of vesicle budding. 
Additionally, ESCRT-I encodes multiple UBDs, which allow it to interact with 
and contribute to the sorting of ubiquitylated cargo. One such UBD is the 
Ubiquitin E2 Variant (UEV) domain within the N-terminus of yeast Vps23 and 
human TSG101 (Williams and Urbe 2007, Hurley 2010). The mammalian 
proteins that fulfil the function of yeast Mvb12 (although without sequence 
conservation) are MVB12A, MVB12B and UBAP1. UBAP1 is endosome-
specific, regulates ubiquitin-dependent EGFR sorting and is not required for 
the other known functions of the ESCRT machinery – cytokinesis or viral 
packaging (Stefani, Zhang et al. 2011, Agromayor, Soler et al. 2012, 
Wunderley, Brownhill et al. 2014). UBAP1 contains a solenoid of overlapping 
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UBA (SOUBA) domain comprised of three rigid UBA regions (Agromayor, 
Soler et al. 2012).  
ESCRT-II is made up of Vps36/Eap45, Vps22/Eap22 and two Vps25/Eap20 
molecules. Vps36/Eap45 and each Vps22/Eap22 interact with one another 
and one of the two Vps25/Eap20 proteins giving the complex a ‘Y’ shape. 
Vps36/Eap45 also interacts with Vsp28 of ESCRT-I, PI3P of the endosome 
and the ubiquitin moieties of sorted cargo via a GLUE domain which carries a 
plekstrin homology (PH) lipid binding region at its core (Gill, Teo et al. 2007, 
Williams and Urbe 2007, Hurley 2010).  
Whilst the ESCRT machinery may pass off cargo step-wise from one 
complex to the next, it seems more plausible that these complexes work in 
concert with one another. As mentioned, some of the complexes have 
overlapping functions – such as ESCRT-I and ESCRT-II – and many share 
interaction partners.  
The complicated role of the ESCRT-III complex is not fully elucidated yet. It is 
comprised of a number of proteins: Vps20/CHMP6, Snf7/CHMP4, 
Vps24/CHMP3, Vps2/CHMP2 and the accessory components Did2/CHMP1, 
Vps60/CHMP5 and Ist1 (Williams and Urbe 2007, Hurley 2010, Schmidt and 
Teis 2012, Christ, Raiborg et al. 2016). Each of the proteins are brought to 
the membrane and activated from their monomeric auto-inhibition by 
conformational changes in a step-wise fashion. They form two sub-
complexes made up of Vps2/CHMP2-Vps24/CHMP3 and Vps20/CHMP6-
Snf7/CHMP4 (Christ, Raiborg et al. 2016). The complete role of ESCRT-III is 
not fully understood but it is known to play a key part in the membrane 
remodelling required for the completion of budding and scission of internal 
vesicles into the lumen of the nascent MVB. A key component of this might 
be the filaments comprised predominantly of CHMP4 (and to a lesser extent 
CHMP2 and CHMP3) which recruit another ESCRT associated protein ALIX 
(Bro1 in yeast) (Saksena, Wahlman et al. 2009, Christ, Raiborg et al. 2016). 
It has been proposed that these curved filaments might be involved in the 
membrane remodelling and typically associate with membrane neck regions 
(Christ, Raiborg et al. 2016). They also confer additional links between 
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ESCRT-I and ESCRT-III since ALIX interacts with the ESCRT-I complex 
member TSG101 via a P(S/T)XP motif (Raiborg, Bache et al. 2001, Bilodeau, 
Urbanowski et al. 2002, Katzmann, Stefan et al. 2003). Other subunits of the 
ESCRT-I and ESCRT-II complexes can help bring ESCRT-III components to 
the endosomal membrane. For example Eap20 of ESCRT-II and Vps28 of 
ESCRT-I can interact with CHMP6 (Yorikawa, Shibata et al. 2005). 
Additionally both CHMP6 (through myristoylation) and CHMP4 (through an 
amphipathic helix) can interact with the endosomal membrane (Yorikawa, 
Shibata et al. 2005, Buchkovich, Henne et al. 2013). 
Another key ESCRT-III binding protein is HD-PTP (Doyotte, Mironov et al. 
2008). This protein switches between binding to ESCRT-0 complex member 
STAM and binding to CHMP4 (Christ, Raiborg et al. 2016). Its role as an 
ESCRT-III interactor is not fully understood; however the switch between 
each ESCRT complex is regulated by the recruitment of the deubiquitylase 
USP8 (also known as UBPY) to STAM (Ali, Zhang et al. 2013). Its interaction 
with ESCRT-0 is known to modulate cargo sorting into ILVs. Additionally, HD-
PTP interacts with the ESCRT-I complex member UBAP1 (Stefani, Zhang et 
al. 2011).  
The Vps4 complex is made up of Vps4 and a co-factor, Vta1. Vps4 belongs 
to the AAA-ATPase family of which the membrane fusion protein NSF is also 
a member. NSF is involved in synaptic vesicle fusion, a pathway modulated 
by SNARE complexes. Vps4 is recruited to ESCRT-III both via its 
microtubule interacting and transport (MIT) domain and the two MIT domains 
within its co-factor Vta1. In particular, Vta1 binds very well to VPS60/CHMP5 
which is a late acting, ESCRT-III associated protein (Hurley 2010, Christ, 
Raiborg et al. 2016). The recruitment of the Vps4 complex promotes 
disassembly of ESCRT-III in an ATP-dependent manner thus promoting the 
dissociation and recycling of upstream ESCRT complexes. 
 
1.2.9. Endocytic DUBs 
The mammalian ESCRT-III components also recruit the endocytic DUBs 
AMSH and USP8, while yeast Doa4 may be recruited to both the proteasome 
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and endosomes (Papa, Amerik et al. 1999, Amerik, Nowak et al. 2000, 
Clague and Urbe 2006, McCullough, Row et al. 2006). At this stage, it is 
believed that deubiquitylation of the cargo is required to a) release the earlier 
ESCRT complexes that bind ubiquitin moieties and b) allow recycling of 
ubiquitin whilst permitting cargo targeted for lysosomal degradation to be fully 
ensconced within MVBs (Clague and Urbe 2006). The cargo is then 
committed for degradation as the maturing endosome fuses with the 
lysosome (Futter, Pearse et al. 1996).  
The yeast deubiquitylase Doa4 plays a role in proteasomal degradation 
through its interaction with the 26S proteasome (Papa, Amerik et al. 1999). It 
is also recruited to the endosome via direct interactions with Snf7 (of the 
ESCRT-III complex) and the ESCRT associated protein Bro1 (ALIX in 
mammalian cells) both of which are described above (Amerik, Nowak et al. 
2000, Bowers, Lottridge et al. 2004, Luhtala and Odorizzi 2004). The role of 
Doa4 in yeast appears to be related to the recycling of ubiquitin since Doa4-
deleted strains have reduced ubiquitin levels in the stationary phase 
(Swaminathan, Amerik et al. 1999, Amerik, Nowak et al. 2000, Losko, Kopp 
et al. 2001). This can be partially recovered by the blockade of the MVB 
pathway by preventing MVB fusion with the vacuole (Amerik, Nowak et al. 
2000). These Doa4Δ cells also had proteolytic defects and less efficient 
protein sorting to the vacuole, which could be rescued by the addition of free 
ubiquitin again lending weight to the argument that Doa4 is important in the 
recycling of ubiquitin at the late stage of the MVB sorting pathway 
(Swaminathan, Amerik et al. 1999, Losko, Kopp et al. 2001). However 
deubiquitylation of cargo is not essential for MVB sorting in yeast as Doa4-
deleted cells still had cargo present on the vacuolar membrane (Reggiori and 
Pelham 2001).  In addition to this role in recycling ubiquitin, Doa4 has been 
linked to internalisation of surface proteins in yeast. One study showed that 
Doa4Δ cells are no longer able to degrade the Gap1 permease in response 
to ammonia treatment and instead the protein remains active on the cell 
surface. Nikko and André suggested that this was due to a failure of the cells 
to sort and target Gap1 for degradation. They proposed that Gap1 was still 
endocytosed but recycled back to the plasma membrane since additional 
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deletion of a gene important in recycling results in partially internalised GAP1 
(Nikko and Andre 2007).  
There are two endocytic DUBs recruited to the ESCRT machinery during 
cargo sorting and MVB biogenesis in mammalian cells. AMSH is a JAMM 
metalloprotease with specificity for K63-linked ubiquitin chains, whereas 
USP8 is a USP with relatively little chain linkage specificity (see section 1.1) 
(McCullough, Clague et al. 2004, Mizuno, Iura et al. 2005, McCullough, Row 
et al. 2006). Both USP8 and AMSH are able to interact with the ESCRT-0 
member STAM through their single (AMSH) or three (USP8) SH3 domains 
which bind to a non-canonical SH3 binding motif PX(V/I)(D/N)RXXKP within 
STAM (Tanaka, Kaneko et al. 1999, Kato, Miyazawa et al. 2000, Kaneko, 
Kumasaka et al. 2003). Both DUBs also interact with several ESCRT-III 
components via their MIT domains (McCullough, Row et al. 2006, Row, Liu et 
al. 2007). In particular AMSH is able to interact with CHMPs1, 2, 3 and 4, 
whereas USP8 interacts with CHMP1, CHMP2 and CHMP4 (Agromayor and 
Martin-Serrano 2006, Tsang, Connell et al. 2006, Ma, Boucrot et al. 2007, 
Row, Liu et al. 2007).  
AMSH is also localised to endosomes via its binding to Clathrin (McCullough, 
Row et al. 2006, Nakamura, Tanaka et al. 2006). The activity of AMSH is 
positively regulated by its direct interaction with STAM (McCullough, Row et 
al. 2006). This relies on the ability of STAM to bind ubiquitin as mutation of 
the UIM prevents its regulation of AMSH activity. This might be due to the 
additional binding of ubiquitylated cargo facilitating cleavage of K63-linked 
ubiquitin as the chain is held in a favourable orientation (Clague and Urbe 
2006, McCullough, Row et al. 2006, Davies, Paul et al. 2013).  
Expression of a catalytically-inactive mutant form of AMSH leads to an 
accumulation of endosomal ubiquitin in HeLa cells and its siRNA-mediated 
depletion leads to the acceleration of EGFR degradation (McCullough, 
Clague et al. 2004, Bowers, Piper et al. 2006). In addition, a recent siRNA 
screen for DUBs involved in the regulation of EGFR levels confirmed that 
AMSH depletion accelerated EGFR degradation (Savio, Wollscheid et al. 
2016). Based on these findings it has been proposed that AMSH 
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deubiquitylation of cargo early in the MVB pathway might rescue cargo from 
lysosomal degradation and contribute to its recycling back to the plasma 
membrane (McCullough, Clague et al. 2004, Clague and Urbe 2006, Liu, 
Urbe et al. 2012). In principle, USP8 may also contribute to this function. As a 
K63-linkage specific DUB, AMSH may be unable to remove the last ubiquitin 
from polyubiquitylated cargo, but USP8 has less specificity and therefore 
might work cooperatively with AMSH. Further support for ubiquitin as a 
lysosomal sorting signal at the endosome comes from the observation that 
the transferrin receptor, which normally recycles constitutively, can be forced 
down the lysosomal degradation pathway through tagging or fusing ubiquitin 
onto its C-terminus (Raiborg, Bache et al. 2002). Finally, as mentioned 
above, fusion of AMSH onto EGFR leads to delayed degradation of the 
receptor despite its successful internalisation into early endosomes (Huang, 
Zeng et al. 2013).  
Conversely, some studies report that AMSH depletion reduces the 
degradation of EGFR and other receptors such as CXCR4 (Ma, Boucrot et al. 
2007, Sierra, Wright et al. 2010). In particular, the G-protein coupled receptor 
CXCR4 is internalised when AMSH is depleted but the overall levels of the 
receptor were reported to increase (Sierra, Wright et al. 2010).  
 
1.2.10. USP8 
Ubiquitin specific protease 8 (USP8), also called UBPY, was first identified in 
1998 as a growth regulated deubiquitylase with similarities to the yeast DUB 
Doa4 (Naviglio, Mattecucci et al. 1998). Naviglio and colleagues showed that 
this protein had DUB activity using ubiquitylated proteins extracted from 
rabbit reticulocyte lysate. Having first treated the lysate with NEM to block 
endogenous cysteine DUB activity the authors treated with GST-USP8 with 
or without additional NEM and separated the lysates by SDS-PAGE. Western 
blot analysis using an anti-ubiquitin antibody showed that USP8 was able to 
remove high molecular weight bands which corresponded to ubiquitylated 
forms of proteins (Naviglio, Mattecucci et al. 1998).  
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USP8 was first described from its cDNA sequence, which predicted a 1118 
amino acid protein (Naviglio, Mattecucci et al. 1998). Today, data from 
Ensembl describes three protein-coding transcripts accounting for two known 
isoforms. The first isoform, annotated by NCBI as isoform a is coded for by 
transcripts USP8_001 and USP8_003, CCCDS10137. This protein has a 
UniProt reference of 40818-1. Isoform a is the full length, 1118 amino acid 
protein with a predicted molecular weight (mW) of 128kDa. Isoform b is 
coded for by transcript USP8_002, CCCDS561632. The UniProt reference 
for isoform b is 40818-2. This protein misses amino acids 35-111 
corresponding to exons 2 and 3 in addition to amino acids 601-629 coded for 
by exon 11. This protein is 1012 amino acid in size with a predicted mW of 
115kDa. The second isoform was identified following an effort to better 
characterise human cDNA from tissue, primary cell cultures and cell lines 
(Ota, Suzuki et al. 2004). To date, no isoform specific functions have been 
reported for either of these however isoform b lacks a key domain involved in 
the recruitment of the protein to ESCRT machinery, the MIT domain an 
interaction fundamental to the function of USP8 in particular contributing to its 
role in regulating the stability of STAM (see below for detail). This might hint 
at an alternative localisation of the smaller protein, which retains the full 
catalytic domain and could allude to an additional, ESCRT machinery 
independent function of USP8. In addition to these two reported isoforms 
there are three isoforms predicted by computational analysis according to 
NCBI. These are USP8_X1, USP8_X2 and USP8_X3. The first corresponds 
in protein sequence to the full-length protein whereas isoforms X2 and X3 are 
predicted to comprise 1089 and 928 amino acids respectively.  Predicted 
isoform X2 would differ to the full length protein only in its loss of amino acids 
601 to 629 corresponding to exon 11 whilst retaining exons 2 and 3 in 
contrast to isoform a.  
By far the best characterised role for USP8 is its interaction with ESCRT 
machinery proteins and regulation of receptor degradation by the lysosome. 
Only two years after USP8 was first described in the literature, Kato et al. 
identified an interaction between USP8 and an HRS binding protein Hbp, the 
mouse orthologue of STAM2 (Kato, Miyazawa et al. 2000). Then, in the mid-
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2000s a spate of papers linked USP8 to the downregulation of EGFR, Met 
and ERBB3 as well as to the regulation of global ubiquitylated protein levels 
and endosomal morphology. First, Mizuno et al. reported in 2005 that 
overexpression of USP8 led to a decrease in EGF-stimulated ubiquitylation of 
EGFR and a delay in its degradation, whereas RNAi depletion of the DUB led 
to an increase in EGF-stimulated ubiquitylation and accelerated degradation 
of EGFR (Mizuno, Iura et al. 2005). Conversely, in 2006, Row et al. showed 
that RNAi depletion of USP8 led to the increase in global ubiquitylated 
proteins and delayed ligand-induced EGFR degradation. In the same year, 
Mizuno et al. also showed that lysosomal trafficking of endocytosed EGF was 
blocked in USP8-depleted cells, a finding apparently incongruent with their 
initial finding that USP8-depletion accelerated the degradation of EGFR 
(Mizuno, Kobayashi et al. 2006). Row and colleagues showed that over-
expressed wild-type USP8 was recruited to early endosomes upon EGF 
stimulation, whereas a pool of the catalytically-inactive mutant was 
permanently associated with endosomes (Row, Prior et al. 2006). The same 
study also reported an accumulation of enlarged aberrant endosomes and an 
increase in the number and size of MVBs, which clustered in the perinuclear 
area. STAM, and to a lesser extent HRS, protein levels were severely 
reduced, and residual HRS was associated with these perinuclear structures 
while its cytoplasmic pool was depleted. Importantly, STAM stability was 
shown to depend not only on the presence of USP8 but also the DUB’s 
recruitment to ESCRT-III components via its MIT domain: the expression of 
an siRNA resistant form of USP8 could partially rescue HRS and STAM 
levels, and this was dependent on USP8 catalytic activity and its MIT domain 
(Row, Liu et al. 2007). This suggests that deubiquitylation of STAM by USP8 
might rescue the protein from proteasomal degradation. In agreement with 
this, ubiquitylated STAM could be stabilised by proteasome inhibitors in 
USP8 depleted cells. In the absence of USP8, AMSH would be unable to 
compensate due to its specificity for K63 chains leaving the proteasomal 
targeting K48-linked ubiquitin untouched. Although USP8 is able to interact 
with ESCRT-0 via binding to STAM, this is not required for its recruitment to 
the endosome. Just as for AMSH, the group showed that USP8 activity is 
regulated by STAM (Row, Liu et al. 2007). 
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USP8 knockout in mice is embryonically lethal and conditional knockout of 
USP8 in adult mice eventually leads to severe liver failure (identified by 
apoptotic hepatocytes) and death (Niendorf, Oksche et al. 2007). Niendorf 
and colleagues showed that in USP8 knockout mice there is a reduction in 
the overall protein levels of EGFR. In hepatocytes, where a small amount of 
EGFR does remain, the protein is found within the cell rather than at the cell 
surface which might point towards enhanced internalisation and lysosomal 
degradation of the protein. The authors also reported a reduction in ERBB3 
and c-MET levels. The knockout mice show a reduction in HRS and STAM 
levels and immortalised mouse embryonic fibroblasts derived from these 
mice present with enlarged aberrant endosomes and an accumulation of 
MVBs, much like that seen in siRNA depleted HeLa cells described above 
(Niendorf, Oksche et al. 2007).  
As mentioned above, USP8 interacts with a number of components of the 
ESCRT machinery. Through its SH3 domains, it is able to interact with the 
ESCRT-0 component, STAM, an interaction that also increases its DUB 
activity (Row, Prior et al. 2006, Row, Liu et al. 2007). Through its MIT 
domain, USP8 is able to interact with several ESCRT-III associated CHMPs 
(Row, Liu et al. 2007). Additionally, Ali et al. showed that USP8 interacts with 
HD-PTP, an ESCRT accessory protein which cycles between ESCRT-0 and 
ESCRT-III (Ali, Zhang et al. 2013). Their work suggested a complicated 
interaction between HD-PTP, CHMP4, STAM and USP8 in which USP8 
competed with HD-PTP for STAM binding. Based on their findings, the 
authors proposed a mechanism whereby USP8 is recruited to HD-PTP first 
via CHMP4 which both proteins interact with. From here USP8 would 
displace HD-PTP from ESCRT-0, allowing it to cycle towards ESCRT-III. 
Meanwhile, USP8 deubiquitylation of STAM-associated cargo would allow 
the passage of that cargo through the ESCRT pathway. In fact, the authors 
showed that HD-PTP did recruit USP8 to ubiquitylated EGFR, and depletion 
of HD-PTP phenocopied depletion of USP8 (Ali, Zhang et al. 2013).  
As well as the impact on EGFR degradation, Row et al. found that HGF-
induced Met degradation was also delayed upon USP8 depletion (Row, Prior 
et al. 2006).  In agreement with this, Alwan and van Leeuwen reported that 
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expression of a dominant negative, catalytically inactive form of USP8 
resulted in delayed EGFR degradation (Alwan and van Leeuwen 2007). 
Interestingly, this study also showed that USP8 is phosphorylated in 
response to EGFR activation and that this might be due to Src kinase activity 
(Alwan and van Leeuwen 2007). Prior studies have shown that HRS is 
phosphorylated downstream of EGFR, and that this phosphorylation can be 
prevented by a Src-family kinase inhibitor (PP1) (Bache, Raiborg et al. 2002, 
Row, Clague et al. 2005).  
USP8 also indirectly regulates ERBB3 receptor levels, albeit by an alternative 
mechanism (Wu, Yen et al. 2004, Cao, Wu et al. 2007). The degradation of 
ERBB3 follows a different pathway to EGFR, PDGFR and MET, which are 
ubiquitylated by the E3 ligase c-Cbl and targeted to the lysosome (Levkowitz, 
Klapper et al. 1996). Instead, the ubiquitin E3 ligase Nrdp1 regulates basal 
levels of ERBB3. Nrdp1 is in turn stabilised by USP8 in a ligand dependent 
manner, which the authors propose relies on USP8 phosphorylation by AKT 
(Wu, Yen et al. 2004, Cao, Wu et al. 2007). Neuregulin (NRG1) stimulation 
caused the accumulation of Nrdp1 in cells expressing catalytically-active but 
not catalytically-inactive USP8. Conversely, USP8 depletion correlated with 
reduced ERBB3 ubiquitylation and degradation (Cao, Wu et al. 2007). 
At this stage, it became clear that USP8 plays an important role in the 
regulation of a number of RTKs. This has since been extended to other 
membrane proteins including GPCRs and even some ion channels. For 
example the GPCR, Chemokine Receptor 4 (CXCR4) is stabilised upon 
USP8 depletion (Berlin, Higginbotham et al. 2010). USP8 also regulates the 
ubiquitylation status of the E3 ligase for activated CXCR4, Itch (also known 
as AIP4) (Bhandari, Trejo et al. 2007, Panner, Crane et al. 2010). Balut et al. 
reported that USP8 depletion also led to accumulation of the potassium 
channel KCa3.1 in a ubiquitylated form and inhibits its degradation (Balut, 
Gao et al. 2010, Balut, Loch et al. 2011). 
USP8 has become well established as a regulator of cell surface protein 
stability however it is possible that some of the observed effects on trafficking 
are due to general pleiotropic effects on the MVB pathway, since USP8 
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depletion also severely reduces ESCRT-0 levels and has major effects on 
the morphology of endosomes. The current list of proposed USP8 substrates 
is summarised in table 1.2.  
As mentioned above, ESCRT complexes are also involved in the regulation 
of cytokinesis. It is then of interest that USP8, and in fact, AMSH have been 
observed at the mid-body of cells undergoing cytokinesis (Mukai, Mizuno et 
al. 2008). The two DUBs localise in overlapping but distinct regions of the 
mid-body.  The ESCRT-0 component and USP8 binding protein HRS is 
localised to this region but with a different pattern. ESCRT-III complexes 
have a similar double-banded staining pattern at this region as USP8 
suggesting their potential relevance in recruiting the DUB (Morita, Sandrin et 
al. 2007). Furthermore, cells depleted of USP8 or AMSH had impaired 
cytokinesis as detected by an increase in multi-nucleated cells.   
 
1.2.12. Other DUBs associated with endocytic trafficking  
While AMSH and USP8 are well established as DUBs important for trafficking 
and downregulation of cell surface receptors, there are a number of other 
DUBs that may play a role in this process. A study from Polo and colleagues 
sought to identify all of the DUBs involved in the ligand-induced degradation 
of EGFR (Savio, Wollscheid et al. 2016). They used an siRNA library to 
transiently deplete each active DUB in HeLa cells that they then stimulated 
with EGF. Using immunoblotting and an ELISA-based assay they measured 
EGFR degradation and categorised each knockdown into one of three 
groups – no change, delayed EGFR degradation or accelerated EGFR 
degradation. As described above they found AMSH or USP8 depletion to 
accelerate and delay EGFR degradation respectively. They also confirmed a 
study implicating USP2a in the downregulation of EGFR (Liu, Zanata et al. 
2013). In total they identified 15 DUBs that affect EGFR degradation kinetics. 
In particular the group focused on the depletion of USP9X. Depletion of this 
DUB led to a severe delay in ligand-induced EGFR degradation and 
accumulation of the ubiquitylated receptor on endosomes (Savio, Wollscheid 
et al. 2016). In addition, Savio et al. showed that ubiquitylation of the 
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Table 1.2. Proposed USP8 substrates compiled from data in the 
literature. OE: data from USP8 overexpression. RNAi: data from USP8
depletion by RNA interference. 
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endocytic adaptor protein Eps15 was increased upon USP9X depletion and 
that Eps15 was a substrate of this DUB. They postulated that the regulation 
of EGFR degradation by USP9X might hinge on this adaptor since depletion 
of the two combined did not have an additive effect on receptor 
internalisation (Savio, Wollscheid et al. 2016).  
Another DUB siRNA library screen identified the Otubain Cezanne/OTUD7B 
as a DUB involved in the regulation of EGFR. Pareja et al. showed that 
simultaneous depletion of Cezanne 1 and Cezanne 2 led to enhanced 
degradation of EGFR. Overexpression of Cezanne 1 led to a reduction in 
EGFR ubiquitylation and subsequent stabilisation of the receptor. Cezanne 1 
binds to and deubiquitylates EGFR and receptor downregulation was reliant 
on Cezanne 1 catalytic activity in HeLa cells (Pareja, Ferraro et al. 2012).  
 
1.3. Autophagy 
Autophagy is a mechanism by which the cell can degrade organelles and 
other cytosolic material in response to starvation or damage. It relies on 
ultimate degradation by the lysosome and makes use of some of the 
machinery outlined above. During autophagy, membrane is acquired from 
other intracellular organelles to form the phagophore or isolation membrane. 
As this membrane grows it begins to surround and sequester material, 
including proteins and organelles, which eventually become engulfed by a 
double membrane which closes to become the autophagosome. The 
autophagosome subsequently fuses with the lysosome, allowing hydrolases 
from this digestive organelle to break-down the contents, including the inner 
membrane of the autophagosome. The amino acids acquired from this 
digestion are then released back into the cytosol. 
As with our understanding of the MVB biogenesis pathway, much of what we 
know about the process of autophagy began with genetic research in S. 
cerevisiae. To date, 37 autophagy-related genes (ATG) have been identified, 
and many of these are conserved beyond yeast in multicellular eukaryotes 
(Ohsumi 2014, Stanley, Ragusa et al. 2014). The initial work came from a 
number of groups who defined autophagy mutants. Firstly, the Ohsumi lab 
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identified a yeast mutant that failed to accumulate autophagic bodies when 
starved of nitrogen. This autophagy defective mutant, apg1, was able to grow 
and survive normally in full media conditions, but under starvation conditions 
the cells failed to degrade proteins and eventually died. The group used this 
viability defect to screen for other Apg mutants which they confirmed using 
light microscopy to verify their inability to accumulate autophagic bodies. 
They identified another 99 autophagy defective mutants which could be split 
into fifteen complementation groups (Tsukada and Ohsumi 1993). This 
screen formed the basis of the work for which Ohsumi was awared a Nobel 
Prize in Physiology or Medicine in 2016. Meanwhile, Thumm and colleagues 
studied S. cerevisiae that were unable to produce vacuolar autophagic 
bodies under starvation conditions and identified six so-called Aut mutants 
(Thumm, Egner et al. 1994). The Klionsky lab studied the cytosol to vacuole 
targeting (Cvt) pathway which shares the same membrane dynamics as 
autophagy. Following α-aminopeptidase I from the cytosol to the vacuole, 
they identified Cvt mutants which were unable to transport this enzyme into 
the vacuole, and which were later shown to be largely the same as the Apg 
mutants described above (Harding, Morano et al. 1995, Baba, Osumi et al. 
1997). Later these mutants, combined with others from groups working on 
specific types of selective autophagy, were unified into one gene 
nomenclature system, re-naming all the genes associated with autophagy as 
ATG genes.  
 
1.3.1. Atg complexes 
The protein (Atg) products of ATG genes are assembled into six complexes 
that are involved in the biogenesis of the autophagosome (Ohsumi 2014, 
Stanley, Ragusa et al. 2014). Upon induction of autophagy, these complexes 
are recruited to the pre-autophagosomal structure (PAS) (figure 1.5.) (Suzuki, 
Kirisako et al. 2001, Suzuki and Ohsumi 2010). In yeast the presence of the 
PAS is constitutive as it is involved in Cvt (Suzuki and Ohsumi 2010, Stanley, 
Ragusa et al. 2014). However mammalian cells lack this constitutive Cvt 
pathway and the ATG complexes are recruited to the Omegasome, a PI3P-
rich subdomain of the endoplasmic reticulum (ER) (Mizushima, Yoshimori et 
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al. 2011). To date we do not fully understand all of the roles each complex 
plays in the biogenesis of the autophagosome, however we do know that the 
recruitment of these complexes of Atg proteins is hierarchical (Stanley, 
Ragusa et al. 2014) .  
 
1.3.2. The Atg1 kinase complex 
The first Atg protein described was the protein kinase Atg1. Yeast Atg1 is 
able to bind to Atg13, which under normal conditions is phosphorylated by 
TORC1 kinase. Under starvation conditions, Atg13 is dephosphorylated, 
increasing its affinity for Atg1 (Kamada, Funakoshi et al. 2000). In addition, 
the binding of Atg13 to Atg1 enhances the kinase activity of Atg1. The Atg1-
Atg13 complex is then able to interact with a stable trimer of Atg17-Atg29-
Atg31, forming a pentameric complex (Kabeya, Noda et al. 2009, Ragusa, 
Stanley et al. 2012). In yeast, Atg17-Atg29-Atg31 is associated with the PAS 
regardless of nutritional status (Suzuki, Kubota et al. 2007, Kabeya, Noda et 
al. 2009).  
In mammalian cells the equivalent complex is formed by ULK1 and ULK2, 
which have homology to Atg1, alongside the mammalian ATG13, ATG101, 
and a scaffold protein FIP200 which is orthologous to ATG17 (Hara, 
Takamura et al. 2008, Ganley, Lam du et al. 2009, Mercer, Kaliappan et al. 
2009, Cheong, Lindsten et al. 2011, McAlpine, Williamson et al. 2013). 
Mammalian TORC1 (mTORC1) forms part of the complex under normal 
conditions but dissociates during starvation resulting in dephosphorylation of 
ULK1, ULK2 and ATG13, ultimately releasing ULK1 from the inhibitory effect 
of phosphorylation (Hosokawa, Hara et al. 2009, Wirth, Joachim et al. 2013).  
1.3.4. Atg9 
ATG9 is a transmembrane protein expressed in both yeast and mammals. In 
yeast, Atg9 is found within the membranes of small vesicles that contribute 
the membrane required for the phagophore (Noda, Kim et al. 2000, 
Yamamoto, Kakuta et al. 2012). In mammalian cells, ATG9 is found in the 
trans-Golgi network and late endosomes, however, upon starvation parts of 
the ATG9-positive membranes from these organelles are donated to the 
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Figure 1.5. Mammalian autophagy. (adapted from Helgason, Karvela et al. 2011)
A. Shows the hierarchy of ATG proteins at each stage of autophagy. B. Two 
ubiquitin-like conjugation systems are involved in autophagy. In the first (left), 
ubiquitin-like ATG12 is conjugated to ATG5 facilitated by ATG16. This complex can 
act as an E3 for lipidation of phosphatidylethanolamine (PE) with LC3-II. LC3-I is 
processed to LC3-II by ATG4 cleavage which is activated by the E1 ATG7 and tran-
sferred to the E2 ATG3 (right). LC3-II is conjugated to PE facilitated by the ATG5-
ATG12-ATG16 complex.
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phagophore (Tooze 2010, Yang and Klionsky 2010). This serves as a 
nucleation site for membrane biogenesis (Ohsumi 2014). As these small 
vesicles accumulate, their membranes fuse assisted by soluble N-
ethylmaleimide sensitive factor (NSF) attachment protein receptors 
(SNAREs) (Stanley, Ragusa et al. 2014).  
 
1.3.5. PI3K complex 
The phosphoinositide 3 kinases (PI3Ks) are a family of lipid kinases that, in 
yeast, comprise only one member – Vps34. This kinase forms a component 
of two complexes; complex II is important for vacuolar protein sorting, 
whereas complex I is required for autophagy (Ohsumi 2014). Complex I 
comprises Vps34, Vps15, Vps30/Atg6, Atg14 and the recently described 
Atg38 (Ohashi, Soler et al. 2016). Vps34 generates phosphatidylinositol 3 
phosphate (PI3P) which resides on the inner membrane of the 
autophagosome and is believed to recruit other proteins required for 
autophagosome formation, such as Atg18 (described below).  
In mammalian cells VPS34 is a class III PI3K (the classes are described in 
greater detail in section 1.3) and the complex as described above is 
composed of VPS34, Beclin1 (the mammalian orthologue of Atg6), VPS15 
and the human ATG38 – NRBF2 (Yang and Klionsky 2010). In addition 
Beclin1 interacts with a number of regulatory proteins such as UV radiation 
resistance associated genes (UVRAG), activating molecule in Beclin1 
regulated autophagy (AMBRA1) and autophagy related protein 14-like 
protein (Atg14L) (Fimia, Stoykova et al. 2007, Itakura, Kishi et al. 2008, Yang 
and Klionsky 2010). Other mammalian regulatory components of this 
complex include the positive regulator BAX-interacting factor 1 (BIF-1) and its 
inhibitory partner run domain Beclin1-interacting and cysteine-rich containing 
protein (RUBICON) which are brought to the complex via Beclin1’s 
interaction with UVRAG (Takahashi, Coppola et al. 2007, Zhong, Wang et al. 
2009). Additionally, the anti-apoptotic protein B-cell lymphoma 2 (BCL-2) 
interacts directly with the BH3 domain of Beclin1 and acts in an inhibitory way 
on the complex (Abrahamsen, Stenmark et al. 2012).  
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 1.3.6. Atg18 
Atg18 forms a complex with Atg2 and binds both the Vps34 generated PI3P 
and phosphatidylinositol 3,5 bisphosphate (PI(3,5)P2) (Ohsumi 2014). 
PI(3,5)P2 is generated from PI3P by the PI3P 5-kinase Fab1 (PIKfyve in 
mammalian cells) (Jin, Lang et al. 2016). Whilst PI(3,5)P2 functions mostly in 
the regulation of vacuolar size it is also involved at some level in autophagy 
since mutation in PI(3,5)P2 results in a defect in the degradation of 
autophagosomes that are directed to the vacuole in yeast (Jin, Lang et al. 
2016).  Atg18 appears to have roles in autophagy, vacuolar size and possibly 
endocytosis. Although its function still requires full elucidation, we do know 
that its regulation of autophagosome formation is PI3P dependent 
(Stromhaug, Reggiori et al. 2004, Krick, Henke et al. 2008). In humans the 
WIPI proteins share sequence homology with Atg18. WIPI1 and WIPI2 have 
both been shown to be recruited to the autophagosomal membrane through 
a preferred interaction with PI3P (Proikas-Cezanne, Ruckerbauer et al. 2007, 
Polson, de Lartigue et al. 2010, Dooley, Razi et al. 2014, Proikas-Cezanne, 
Takacs et al. 2015).  
 
1.3.7. Atg12 conjugation 
Atg12 is a ubiquitin-like protein which is activated by the E1 enzyme Atg7. 
Following transfer to the E2 enzyme Atg10, Atg12 is conjugated by 
isopeptide bond to K149 of Atg5 (Mizushima, Noda et al. 1998). Atg12-Atg5 
dimerisation is facilitated by Atg16 homodimers (Mizushima, Noda et al. 
1999, Kuma, Mizushima et al. 2002). The Atg12-Atg5 conjugate can function 
as an E3-like enzyme to enhance Atg8 lipidation (figure 1.5.B.) (Hanada, 
Noda et al. 2007). 
 
1.3.8. Atg8 lipidation 
Like Atg12, Atg8 is a ubiquitin-like protein. During starvation conditions the 
expression of Atg8 is increased and it is partially localised to the 
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autophagosome and the membranes of autophagic bodies (Kirisako, Baba et 
al. 1999). Atg8 is synthesised as a precursor, processed by the cysteine 
protease Atg4 and activated by Atg7 (Ichimura, Kirisako et al. 2000, Kirisako, 
Ichimura et al. 2000). Through the E2 enzyme Atg3 and with facilitation from 
the Atg12-Atg5 conjugate, Atg8 can be passed onto the head group of 
phosphatidylethanolamine (PE) (Ichimura, Kirisako et al. 2000). The amount 
of Atg8 on the growing isolation membrane regulates the final size of the 
autophagosome (Xie, Nair et al. 2008).  
In mammalian cells the homologue for Atg8 is LC3 which is converted to 
LC3-I by ATG4 cleavage and subsequent lipidation to LC3-II at both faces of 
the phagophore (figure 1.5.B.). Its removal from the outer membrane 
precedes fusion of the autophagosome with the lysosome (Yang and 
Klionsky 2010).  
 
1.3.9. Selective autophagy and ubiquitylation 
Selective autophagy is reliant on different autophagy receptors which are 
brought to autophagosomes through their interaction with Atg8/LC3 (Stolz, 
Ernst et al. 2014). Many of these receptors contain LC3-interacting regions 
(LIR) with a consensus sequence W/F/YxxL/I/V (Pankiv, Clausen et al. 2007, 
Khaminets, Behl et al. 2016).  
Whilst the role for ubiquitylation in autophagy is mostly understood through 
ubiquitin-dependent cargo recognition in selective autophagy (as will be 
exemplified below), there is some evidence that ubiquitylation is also 
involved, to some degree, in the regulation of core autophagy components. 
For example, free p85b subunits of the Vps34 PI3K complex are targeted for 
degradation by the Skp, Cullin, F-box-containing complex (SCP) E3 ligase 
which prevents formation of the PI3K complex (Kuchay, Duan et al. 2013). 
SUMOylation is the addition of small ubiquitin-like modifiers (SUMOs) to 
proteins. Vps34 can be SUMOylated by the E3 SUMO ligase KRAB-
associated protein 1 (KAP1) which enhances its interaction with Beclin1, 
Atg14L and UVRAG complexes (Yang, Fiskus et al. 2013).  
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A recent study has linked the DUB USP8 to the regulation of autophagy in 
Drosophila melanogaster (Jacomin, Bescond et al. 2015). The authors 
coexpressed dsRNA targeting 25 DUBs of USP and UCH families, together 
with the autophagy marker GFP-LC3B, in the larval fat body (Jacomin, 
Bescond et al. 2015). Under normal conditions GFP-LC3B is cytosolic, but 
upon induction of autophagy it is recruited to the membranes of 
autophagosomes. Using larvae with low basal levels of autophagy, the 
authors identified four DUBs out of 25 for which depletion increased the 
accumulation of LC3B positive dots in a minimum of 50% of cells. The 
phenotype for two of these DUBs, USP8 and USP12, could be further 
confirmed using an alternative RNAi system.  
For their follow up experiments the authors made use of transgenic 
Drosophila lines expressing GFP and mCherry double tagged Atg8a, the 
Drosophila paralogue of LC3B. GFP is quenched in the acidic environment of 
the autolysosome resulting in a switch from green and red autophagosomes 
to uniquely red autolysosomes.  Using this method they showed that USP8 
depletion increased basal autophagy as the number of GFP-mCherry positive 
punctate structures increased. They also suggested that there was a block in 
autophagic flux since there was no accumulation of autolysosomes despite 
the activation of autophagy. Similar results were obtained with expression of 
catalytically inactive USP8. Electron-microscopy based analysis of these 
USP8-depleted cells showed double membrane bound autophagosomes with 
undigested content and significantly smaller lysosomes. Likewise GFP-
LAMP1 staining was redistributed from large perinuclear structures to smaller 
vesicles that were distributed throughout the cytosol. The authors suggested 
that these might correspond to vesicles transporting enzymes from the 
biosynthetic secretory pathway (i.e. the trans-Golgi network) to the endo-
lysosomal pathway. 
Interestingly, USP8 has been implicated in this pathway once before. A key 
protein in lysosomal enzyme delivery from the biosynthetic pathway is the 
Mannose-6 phosphate receptor (M6PR) which is both involved in delivering 
newly synthesised hydrolases from the TGN to the lysosomes and also 
scavenging secreted enzymes from the plasma membrane. In 2014, 
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MacDonald et al. reported that USP8 depletion leads to M6PR accumulation 
in endosomes due to a failure to recycle back to the TGN (MacDonald, Urbe 
et al. 2014). The receptor was thus unable to pick up new lysosomal 
enzymes from the TGN which prevented the delivery of these degradative 
enzymes to the lysosome. As a result the hydrolase, Cathepsin D, was found 
to be constitutively secreted rather than delivered to the lysosome. 
Based on the data from these two papers it seems possible that depletion of 
USP8 affects autophagy by dysregulating lysosome biogenesis thus 
preventing autophagosome fusion with the lysosome. This would prevent the 
generation of, and degradation by the autolysosome. In addition, components 
of the autophagy machinery described above have been linked to 
components of the ESCRT machinery. For example, Atg12 has recently been 
shown to form a conjugate with Atg3 which is then able to interact with the 
ESCRT-III associated protein ALIX. It is proposed that this interaction might 
play a role in late endosome distribution and basal autophagy but not 
starvation-induced autophagy (Murrow, Malhotra et al. 2015).  
More recently a study has implicated another DUB in autophagy. Xu et al. 
showed that AKT phosphorylates and activates the proteasome associated 
DUB USP14. USP14 activation promotes the removal of K63-linked ubiquitin 
chains from Beclin1 whilst its depletion leads to an increase in autophagy 
(Xu, Shan et al. 2016).  
 
1.3.10. Mitophagy  
The best example for the role of ubiquitin in selective autophagy is its role in 
mitophagy. Two E3 ligases, Parkin and Glycoprotein 78, have been 
implicated in this mechanism which serves to degrade damaged 
mitochondria (Geisler, Holmstrom et al. 2010, Fu, St-Pierre et al. 2013, 
Khaminets, Behl et al. 2016). Most famously, the RING between RING (RBR) 
ligase Parkin and its activating kinase PINK1 play a key role in this pathway. 
Loss of function of Parkin and PINK1 in the substantia nigra have been 
associated with Parkinson’s disease (Durcan and Fon 2015).  Under normal 
conditions the PTEN induced putative kinase 1 (PINK1) is constitutively 
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imported into the mitochondrial inner membrane where it is cleaved by 
presenilin-associated rhomboid-like protein (PARL) and then subsequently 
degraded by the proteasome in the cytosol (Jin, Lazarou et al. 2010, Bingol 
and Sheng 2016). When mitochondria become damaged, PINK1 is stabilised 
at the mitochondrial outer membrane due to impairment of the translocase of 
the outer membrane (TOM) complex which can be blocked by a change in 
membrane potential (Hamacher-Brady and Brady 2016). At the outer 
mitochondrial membrane, PINK1 phosphorylates Mitofusin 2 (Mfn2) at 
Ser442 and Thr111 and other mitochondrial outer membrane proteins and 
accumulates at the TOM complex (Bingol and Sheng 2016). This recruits 
Parkin to the outer membrane (Chen and Dorn 2013). PINK1 then 
phosphorylates the ubiquitin-like (UBL) domain of Parkin at Ser65 as well as 
ubiquitin itself at the topologically equivalent residue (Shiba-Fukushima, Imai 
et al. 2012, Kane, Lazarou et al. 2014, Koyano, Okatsu et al. 2014). This 
triggers a conformational change in the E3 ligase causing its activation. 
Activated Parkin ubiquitylates a number of outer mitochondrial membrane 
proteins including both Mitofusin 1 and Mitofusin 2 (Sarraf, Raman et al. 
2013). Following Parkin activation, there is an increase in K48-, K63-, K6- 
and K11- linked ubiquitylation on mitochondria. Some of the mitochondrial 
outer membrane proteins are degraded by the proteasome, which is 
essential for mitophagy (Chan, Salazar et al. 2011, Ordureau, Sarraf et al. 
2014, Bingol and Sheng 2016). In addition, autophagy receptors are recruited 
by ubiquitylation which then bridge the target mitochondria to the autophagy 
machinery as described above (Hamacher-Brady and Brady 2016). These 
receptors include the ubiquitin-binding domain containing proteins 
p62/SQSTM1, NBR1 and Optineurin (Hamacher-Brady and Brady 2016). In 
addition, the Beclin1-interacting protein AMBRA1 also interacts with Parkin at 
the outer mitochondrial membrane, providing another link between the 
autophagy machinery and damaged mitochondria (Fimia, Stoykova et al. 
2007).  
Recently, USP8 has been linked to the regulation of mitophagy through its 
purported DUB activity against Parkin. Using an unbiased siRNA screen, 
Durcan et al. depleted DUBs in U2OS cells stably expressing GFP-Parkin 
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and looked for defects in the recruitment of Parkin to depolarised 
mitochondria in cells treated with carbonyl cyanide m-chlorophenylhydrazone 
(CCCP) (Durcan, Tang et al. 2014). USP8 depletion delayed the recruitment 
of GFP-Parkin and increased the levels of steady-state Parkin. 
Overexpression of USP8 reduced Parkin steady-state levels and rescued the 
defect in Parkin recruitment caused by USP8 depletion. In addition, USP8 
depletion delayed successful autophagy since the cells retained 
mitochondrial protein TOM20 for longer than cells treated with non-targeting 
siRNA. An in vitro DUB activity assay confirmed activity of USP8 against K6-
linked auto-ubiquitylation of Parkin. Other DUBs have been linked to 
mitophagy. Depletion of both USP15 and USP30 promotes mitophagy 
however neither of these USPs deubiquitylate Parkin directly.  Instead they 
are thought to act downstream of this E3 ligase (Bingol, Tea et al. 2014, 
Cornelissen, Haddad et al. 2014, Durcan, Tang et al. 2014, Liang, Martinez 
et al. 2015) . 
 
1.3.11. p62/Sequestosome 1  
The scaffold protein p62/Sequestosome 1 (p62/SQSTM1) is an autophagy 
receptor that possesses a ubiquitin associated (UBA) domain, a LC3-
interacting region (LIR) and a PB1 domain permitting its self-oligomerisation. 
In addition, p62 contains a KEAP1-interacting region (see 1.5. for detail) 
(Katsuragi, Ichimura et al. 2015). There is disagreement in the literature as to 
whether p62 is essential for mitophagy, however it is known to promote 
aggregation of damaged mitochondria and link the autophagy machinery to 
these aggregates (Hamacher-Brady and Brady 2016). Optineurin, another 
ubiquitin adapter, is recruited to ubiquitylated proteins at the mitochondria by 
its LIR and brings TANK-binding kinase (TBK1) into proximity of p62. This 
results in the phosphorylation of p62 within its UBA domain at Ser403 which 
increases its binding affinity for ubiquitin chains, acting as a positive feedback 
mechanism (Matsumoto, Wada et al. 2011, Richter, Sliter et al. 2016). 
On top of the involvement of p62 in the regulation of mitophagy, it has also 
been implicated both in the autophagosomal degradation of protein 
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aggregates (aggrephagy) and bacteria (xenophagy), again due to its ability to 
interact with ubiquitin (Katsuragi, Ichimura et al. 2015, Hamacher-Brady and 
Brady 2016). For example, misfolding of Tau is associated with the formation 
of p62 positive protein aggregates and neurodegeneration (Kuusisto, 
Salminen et al. 2001). K63-linked ubiquitylation of mutant Tau has been 
shown to correlate with its degradation by autophagy (Tan, Wong et al. 
2008). 
Interestingly, studies investigating the degradation of p62-positive protein 
aggregates by autophagy have also highlighted a potential role for the 
ESCRT machinery in this process. Depletion of the ESCRT-0 component 
HRS, was shown to result in the accumulation of both ubiquitylated proteins 
and p62 (Oshima, Hasegawa et al. 2016). The accumulation of p62 is 
typically a marker of a block in autophagy since the protein in itself is 
targeted for degradation by this pathway. Since we already know that DUBs 
interact so closely with the ESCRT-machinery, this might hint at another link 
between ubiquitylation and autophagy. Indeed the endocytic DUB, USP8 has 
been linked to the clearance of α-synuclein aggregates in Lewy body 
disease. Lewy body accumulation is a feature of Parkinson’s disease. A 
recent study showed strong staining for K63-linked ubiquitin in α-synuclein 
positive Lewy bodies in neurons with pathological inclusions (Alexopoulou, 
Lang et al. 2016). This K63-ubiquitin immunostaining was reduced in the 
substantia nigra whereas USP8 levels were increased in the same tissue.  
The authors showed that USP8 interacts with α-synuclein and its 
overexpression stabilised total α-synuclein levels while reducing the K63-
linked pool. 
Conversely USP8 depletion enhanced lysosomal degradation of α-synuclein. 
Hence the authors propose that USP8 is required for K63-linked 
deubiquitylation of this protein, rescuing it from degradation. Importantly, 
USP8 depletion protected dopaminergic neurons in Drosophila from α-
synuclein induced locomotor deficits and cell loss suggesting that USP8 
might be an interesting therapeutic target in Parkinson’s disease. 
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 1.4. Signal transduction pathways 
 
1.4.1. Signalling 
While individual cells have all the genes they need for their own survival, as 
part of a complicated multi-cellular organism they are reliant on external 
signals from other cells or changes in the environment around them such as 
availability of nutrients. This is why the signalling receptors on the cell 
surface are fundamentally important in order for cells to respond to these 
changes via activation of signalling pathways that allow for a change in gene 
expression. Unicellular organisms such as yeast also possess cell surface 
receptors as they must also engage with their external environment in a 
similar way.  
There are a number of different types of receptor on the surface of our cells. 
Broadly speaking these can be split into three groups; ion channel-linked 
receptors, enzyme-linked receptors and G-protein-coupled receptors. 
Here I will focus on a subset of the enzyme-linked receptors, receptor 
tyrosine kinases (RTKs). 
 
1.4.2. Receptor tyrosine kinases 
The human genome comprises genes for 90 tyrosine kinases. Of these, 58 
are transmembrane receptors. These 58 are classed into 20 families 
including the growth factor receptor families, such as epidermal growth factor 
receptor (EGFR), PDGFR, MET and the vascular endothelial growth factor 
receptor (VEGFR); the collagen receptor family known as the discoidin 
domain receptors (DDRs); and the ephrin receptors which bind a membrane 
bound ligand, ephrin (Robinson, Wu et al. 2000).  
Receptor tyrosine kinases share the same basic structural layout. The 
extracellular domain contains a ligand-binding region whilst the intracellular 
domain comprises the tyrosine kinase domain and additional regulatory 
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features; a single transmembrane region links the two (Lemmon and 
Schlessinger 2010). Upon ligand binding, the majority of RTKs homo- or 
hetero-dimerise prior to their transactivation. This leads to the 
transphosphorylation of the activation loop within one receptor monomer by 
its partner and vice versa thus creating an active receptor dimer (Stamos, 
Sliwkowski et al. 2002). Activation of the receptor dimer allows 
autophosphorylation of a number of other tyrosine residues. In the case of 
EGFR these are Y992, Y1045, Y1068, Y1086, Y1148 and Y1173 
(Downward, Parker et al. 1984, Hsuan, Totty et al. 1989, Margolis, Lax et al. 
1989, Walton, Chen et al. 1990, Levkowitz, Waterman et al. 1999). 
Phosphorylation of tyrosine residues within the intracellular domain allows for 
the recruitment of a number of downstream effectors triggering the signalling 
output of that particular receptor. This is exemplified below for the epidermal 
growth factor receptor (EGFR) family. 
 
1.4.3. Epidermal growth factor receptor family 
In the 1950s and 1960s, Rita Levi-Montalcini and Stanley Cohen published 
their study on the identification of two growth factors, ultimately winning a 
Nobel Prize for their discoveries (Weltman 1987). Rita Levi-Montalcini had 
initially identified a tumour-derived agent which altered the development of 
the sympathetic nervous system when tumours from mice were implanted 
into chicken embryos (Levi-Montalcini 1952). Working together with Stanley 
Cohen, they purified this factor which was later dubbed ‘nerve growth factor’ 
(NGF). The epidermal growth factor (EGF) was also identified by Cohen 
injecting salivary gland extracts into new-born mice, an intervention that 
triggered accelerated growth of the mice (Cohen and Levi-Montalcini 1957, 
Levi-Montalcini and Cohen 1960, Cohen 1962).  
Soon after their work was published, the first RTK, EGFR, was discovered 
(O'Keefe, Hollenberg et al. 1974, Carpenter, Lembach et al. 1975). Carpenter 
and colleagues showed that 125I-labelled EGF specifically binds to human 
fibroblasts and that the growth factor is subsequently degraded. This was a 
process that could reach saturation point dependent on time and temperature 
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(Carpenter, Lembach et al. 1975). Later in vitro work showed that EGF binds 
to membrane proteins and triggers phosphorylation of endogenous proteins 
in A-431 tumour cells (Carpenter, King et al. 1978). The authors proposed 
that the mechanism for increased phosphorylation of endogenous proteins 
indicates that the receptor might be a protein kinase. The full amino acid 
sequence was reported in 1984 (Ullrich, Coussens et al. 1984). 
Subsequently, three additional members of the EGFR family have been 
described, ERBB2, ERBB3 and ERBB4 with EGFR (ERBB1) completing the 
set (figure 1.6.A.) (Stern D.F. 1986, Bargmann and Weinberg 1988, 
Plowman, Whitney et al. 1990, Plowman, Culouscou et al. 1993) 
 
1.4.3.1. EGFR family activation 
A number of ligands associate with the different EGFR family members. 
EGFR itself is the best characterised member within this family and to date 
seven ligands are known for this receptor (Singh, Carpenter et al. 2016). As 
yet, no ligand has been found for ERBB2. This orphan receptor does, 
however, activate signalling pathways through its dimersation and 
cooperative activation with other EGFR family members (Citri, Skaria et al. 
2003). Due to its conformation, ERBB2 is the preferred dimerisation partner 
of all the other EGFR family members (Tzahar, Waterman et al. 1996, Graus-
Porta, Beerli et al. 1997, Citri, Skaria et al. 2003). In particular, ERBB2 
heterodimerises very well with ERBB3, and this pairing is especially 
beneficial since ERBB3 does not have an active kinase domain but does bind 
ligands, the neuregulins (Tzahar, Waterman et al. 1996, Citri, Skaria et al. 
2003). ERBB4 also binds to and is activated by neuregulins. This receptor is 
subsequently cleaved and the intracellular domain makes its way into the cell 
to activate its downstream effectors (Schlessinger 2002, Arasada and 
Carpenter 2005, Lemmon 2009).  
Whilst there is some evidence for pre-existing dimers of these receptors on 
the cell surface, the conformation of these receptors prevents both ligand 
binding and dimerisation in the basal state. The receptors possess a tether 
within their extracellular region that obstructs the binding of ligands and the 
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Figure 1.6. A simplified schematic of EGFR family signalling. (A) EGFR family
potential dimers , ligands and whether or not they can signal (indicated by a tick or 
cross). (B) A simplified outline of the MAPK and PI3K signalling pathways. The 
MAPK pathway is activated by the recruitment of adapter proteins to phosphorylated 
RTKs triggering activation of downstream effectors. PI3K recruitment and active 
RTKs allows lipidphosphorylation and recruitment of AKT and one of its two 
activating kinases PDK1. Following mTORC2 phosphorylation active AKT can act 
on downstream effectors promoting cell survival.
EGF
NRG1
EGF/NRG1 EGFR ErbB2 ErbB3 ErbB4
54
dimerisation domain (Holbro and Hynes 2004, Hynes and Lane 2005, 
Lemmon and Schlessinger 2010). EGF-like ligands are bivalent but instead 
of bridging two receptors as is the case for other RTKs, the ligand binds in 
two places within the same monomer. This breaks the tether and allows 
dimerisation and subsequent activation of the receptor. Different 
subpopulations of the EGFR family have different ligand binding affinities, 
both high and low. Those dimeric forms described above may account for the 
high-affinity subpopulation (Schlessinger 2002, Lemmon 2009).  
Ligand induced hetero- and/or homo-dimerisation of EGFR family members 
triggers their activation and autophosphorylation (figure 1.6.). These 
receptors transactivate by phosphorylation of tyrosines within the C-terminus. 
This phosphorylation recruits SH2 domain containing proteins to the cell 
surface allowing the activation of downstream pathways (figure 1.6.B.).  
 
1.4.3.2. MEK/ERK signalling 
One of the proteins, activated EGFR recruits to the cell surface, is the 
adaptor protein GRB2. This protein contains both SH2 and SH3 domains. 
The SH3 domain allows GRB2 to recruit another protein, Son of sevenless 
(SOS). SOS is a guanine nucleotide exchange factor (GEF) for the small 
GTPase superfamily, RAS. Activated GTP-bound RAS can in turn activate 
the MAP kinase kinase kinase (MAPKKK) protein, RAF that subsequently 
activates downstream kinase MEK (figure 1.6.B) (Katz, Amit et al. 2007). 
MEK phosphorylates and activates the MAPK ERK, which in its activated 
form can phosphorylate cytosolic and cytoskeletal proteins or other kinases. 
Alternatively it translocates to the nucleus where it can activate transcription 
factors such as FOS and JUN (Murphy and Blenis 2006, Katz, Amit et al. 
2007). Activation of this pathway stimulates cell proliferation through 
regulation of cell cycle proteins and migration through transcriptional 
regulation or phosphorylation of proteases that alter focal adhesions and 
other cytoskeletal components (Murphy and Blenis 2006, Katz, Amit et al. 
2007).  
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1.4.3.3. PI3K pathway signalling 
The other main canonical pathway activated by EGFR family members is the 
phosphatidyl inositide 3-kinase (PI3K)-AKT signalling pathway. In a similar 
way to the MEK/ERK signalling pathway, it all begins with the recruitment of 
a protein. In this case, PI3K is recruited to phosphorylated tyrosines within 
the C-terminus of the receptor. There are several classes of PI3K. In the 
case of RTK activation, it is the heterodimeric class I kinases that are 
recruited and activated (Vanhaesebroeck, Stephens et al. 2012). The Class I 
family of PI3Ks comprises four kinases within two subgroups. The class IA 
subgroup is made up of 3 enzymes each containing the p110α, p110β or 
p110δ catalytic subunit paired with the p85 regulatory subunit. Class IB is 
made up of the p110γ catalytic subunit paired with either p101 or p84/p87 
regulatory subunits (Vanhaesebroeck, Stephens et al. 2012). Class IB PI3Ks 
are activated by G-protein-coupled receptors (Andrews, Stephens et al. 
2007). Activated RTKs recruit the p85 subunit of class IA PI3K via its SH2 
domain. This is something that the ERBB2/ERBB3 heterodimer does 
particularly well due to the presence of a large number of p85 recruiting 
domains on the intracellular region of ERBB3. As described, ERBB3 has 
ligand binding potential but no kinase activity and typically heterodimerises 
with the orphan receptor ERBB2 for its activation (Citri, Skaria et al. 2003).  
Once recruited to the activated receptor, PI3K can be phosphorylated and 
activated. Then it phosphorylates phosphatidyl inositol 4,5 bisphosphate 
(PIP2) to phosphatidyl inositol 3,4,5 trisphosphate (PIP3), a process which 
can be reversed by the phosphatase PTEN. This acts as a docking site for 
PH domain containing proteins (figure 1.6.B.). In this way PIP3 recruits PDK1 
and AKT and triggers a conformational change in AKT, which allows PDK1 to 
phosphorylate Thr308 within its activation loop. AKT activation requires the 
phosphorylation by a second kinase, mTORC2 at Ser473 within the 
hydrophobic pocket of the kinase. 
Activated AKT has a wide variety of outputs as it is able to phosphorylate a 
large number of substrates, including pro-apoptotic BAD and FOXO proteins. 
Perhaps most importantly, AKT has pro-survival functions which will be 
discussed below.  
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 1.4.3.4. AKT and cell survival 
AKT plays a very complex role in cell survival. It both promotes normal cell 
cycle progression and inhibits pro-apoptotic pathways in a direct and indirect 
way. One of the best-characterised pathways that AKT regulates is that of 
the forkhead family of transcription factors. This superfamily consists of 
FOXO1 (FKHR), FOXO3 (FKHRL1), FOXO4 (AFX) and FOXO6 which 
contain two (FOXO6) or three (FOXO1, FOXO3 and FOXO4) AKT 
phosphorylation sites within their structure (Tzivion, Dobson et al. 2011). 
These transcription factors stimulate the transcription of a number of genes 
that promote apoptosis and cell cycle arrest such as p130, p27 and TRAIL. 
Activated AKT phosphorylates FOXO proteins precluding them from the 
nucleus. Once trapped in the cytosol, FOXOs are bound and sequestered by 
14-3-3 proteins ultimately leading to their proteasomal degradation. 
Additionally, AKT can regulate the cell cycle directly by regulating p21 and 
p27 (Shin, Yakes et al. 2002, Viglietto, Motti et al. 2002). It also regulates the 
levels of p53 through phosphorylation of its E3 ligase, MDM2 promoting the 
degradation of p53 (Zhou, Liao et al. 2001, Ogawara, Kishishita et al. 2002). 
AKT also activates IKKα leading to the phosphorylation and proteasomal 
degradation of IκB (Bai, Ueno et al. 2009). This releases NFκB from its 
inhibition allowing its translocation to the nucleus where it activates 
transcription of pro-survival genes. Finally, AKT phosphorylates the pro-
apoptotic BH3-only protein BAD resulting in its dissociation from the 
BAD/BCL-XL complex (del Peso, Gonzalez-Garcia et al. 1997). This prevents 
BAD from activating the pro-apoptotic Bcl2-family members BAX and BAK, 
which are normally held in check by anti-apoptotic members of the family 
including BCLXL, BCL2 and MCL1. Activation of BAX and BAK leads to the 
permeabilisation of the outer mitochondrial membrane, release of 
Cytochrome C and activation of apoptotic caspases (Elmore 2007).  
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1.5. The ROS signalling pathway 
In this introduction I have described the role for ubiquitylation in lysosomal 
degradation of RTKs and depicted the link between one of those RTK 
signalling pathways and cell survival. Thus ubiquitylation can play a role in 
cell survival in an indirect way through modulating the signalling output of this 
pathway. 
Another way in which ubiquitylation contributes to the regulation of cell 
survival and response to stress is in the management of reactive oxygen 
species (ROS). Endogenous ROS are generated by the mitochondria during 
normal cellular metabolism. Under oxidative phosphorylation the generation 
of ATP causes the production of ROS such as superoxide and hydrogen 
peroxide. This can lead to the production of free radicals, which can damage 
the cell, cause DNA damage, and ultimately requires the cell to undergo 
apoptosis. It follows that ROS levels must be carefully regulated. There is 
evidence that ROS may also have beneficial effects for the cell. In particular, 
ROS are involved in propagation of cell growth and survival pathways such 
as the MAPK and PI3K pathways. In the case of the PI3K pathway, there is 
evidence that ROS can modify the phosphatase for PIP3, PTEN, thus 
inhibiting it and allowing sustained PI3K pathway activation (Ray, Huang et 
al. 2012).  
 
1.5.1. Identification of NRF2 
NRF2 was isolated from a screen for DNA-binding proteins that recognise the 
NFE2 motif present in the β-globin locus (Moi, Chan et al. 1994). Whereas 
NFE2 is an erythroid-specific transcription factor involved in erythropoiesis 
and platelet development, NRF2 is expressed ubiquitously. Like NFE2, NRF2 
belongs to a subset of the basic region leucine zipper (bZip) transcription 
factors; the cap ‘n’ collar (CNC) family (Moi, Chan et al. 1994). NRF2 was 
later implicated in the regulation of drug mediated enzymes (DMEs) such as 
glutathione S-transferase (GST) and NAD(P)H:quinine oxidoreductase 1 
(NQO1) that are upregulated in response to antioxidants and electrophiles 
(Venugopal and Jaiswal 1996, Itoh, Chiba et al. 1997). These genes had in 
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common an antioxidant response element (ARE), which had been identified 
in the early 1990s as a region that was important in expression of the 
Glutathione S-transferase Ya subunit induced by tert-butylhydroquinone 
(tBHQ) (Rushmore and Pickett 1990). This ARE showed homology to the 
NFE2 motif described above. An investigation into the binding of CNC-bZip 
transcription factors subsequently linked NRF2 to genes under ARE control 
and showed an increase in the expression of genes bearing the ARE motif 
with NRF2 overexpression (Venugopal and Jaiswal 1996).  
Meanwhile, work on NRF2 knockout mice showed that whilst these mice 
survived and grew normally, they were prone to pathologies with oxidative 
elements such as lupus-like nephritis (Yoh, Itoh et al. 2001, Itoh, Mimura et 
al. 2010). Itoh et al. reported that the induction of ARE regulated genes, GST 
and NQO1, was reduced in the livers and intestines of NRF2 knockout mice 
(Itoh, Chiba et al. 1997). The same study also identified a binding partner for 
NRF2 in small Maf proteins. 
 
1.5.2. NRF2 binding and transcriptional activation 
The basic region of NRF2 facilitates its interaction with DNA whereas its bZip 
domain is important for its heterodimerisation with small musculo-aponeurotic 
fibrosarcoma proteins (Mafs). Mafs are capable of binding to ARE motifs but 
do not possess a transactivation domain required to facilitate transcriptional 
activation (Nguyen, Huang et al. 2000, Nioi, McMahon et al. 2003, Hayes, 
McMahon et al. 2010). NRF2 has six Nrf2-ECH homology domains two of 
which (Neh4 and Neh5) allow its binding to cAMP response element-binding 
protein (CREB)-binding protein (CBP) (Katoh, Itoh et al. 2001). CBP has 
histone acetyl-transferase activity and may act as a co-activator for NRF2 by 
allowing the DNA into a more ‘open’ configuration and giving accessibility for 
the recruitment of the transcription machinery (Hayes, McMahon et al. 2010).  
NRF2 itself is involved in the transcriptional regulation of over 100 genes 
which orchestrate a number of different pathways (Sporn and Liby 2012). As 
well as modulating the levels of NQO1 and GSTs described above, NRF2 
can regulate the expression of antioxidant proteins such as glutathione 
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peroxidase and drug-metabolising enzymes (Jaramillo and Zhang 2013). 
NRF2 also regulates the synthesis and metabolism of glutathione which 
serves as a ROS neutralising agent in its reduced state. This can be through 
control of enzymes such as glutamate-cysteine ligase catalytic subunit which 
is rate limiting in the glutathione synthesis process (Jaramillo and Zhang 
2013).  
Since NRF2 plays such a key role in the stress response it makes sense that 
it would be involved in the cancer response. In fact, NRF2 can both act as a 
tumour suppressor and an oncogene (Sporn and Liby 2012, Jaramillo and 
Zhang 2013). NRF2 knockout mice are more prone to tumour formation 
triggered by exposure to carcinogens and this is correlated with a reduction 
in the expression of ARE controlled genes (Ramos-Gomez, Kwak et al. 2001, 
Sporn and Liby 2012, Jaramillo and Zhang 2013). However other studies 
show that NRF2 is elevated in a number of cancers and prognosis with 
elevated NRF2 is poor (Jaramillo and Zhang 2013).  
 
1.5.3. Identification of KEAP1 
The Neh4 and Neh5 domains of NRF2 each confer transcriptional activation 
activity to the protein whereas Neh2 is, in fact, inhibitory (Itoh, Wakabayashi 
et al. 1999). In HD3 erythroblasts, the expression of wild-type NRF2 leads to 
only mild gene activation however mutation of the Neh2 domain enhances 
the ability of NRF2 to activate transcription. Additionally the mild 
transcriptional activation upon wild-type NRF2 expression in HD3 cells was 
enhanced by increasing amounts of co-expressed isolated Neh2 domain 
suggesting that an inhibitory protein might interact with this domain in a 
competitive way. Using this domain as bait in a yeast two-hybrid screen, the 
authors identified a novel protein, which due to sequence homology with an 
actin binding protein in Drosophila, was named Kelch-like ECH associated 
protein 1 (KEAP1).  
Soon after the identification of KEAP1 in HD3 cells, Dhakshinamoorthy and 
Jaiswal cloned a cytosolic inhibitor of NRF2 from rat livers which they named 
Inhibitor of Nrf2 (INrf2). They characterised this protein as a 624 amino acid, 
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cysteine-rich polypeptide of approximately 70kDa that contains a bric-à-brac, 
tramtrack and broad complex (BTB) domain and a KELCH domain which Itoh 
et al. had also described in KEAP1 (Itoh, Wakabayashi et al. 1999, 
Dhakshinamoorthy and Jaiswal 2001). We now know the two proteins to be 
the same.  
KEAP1 has two protein binding domains. The Kelch repeat or double glycine 
repeat (DGR) domain allows for its interaction with NRF2’s Neh2 domain (Li, 
Zhang et al. 2004, Lo, Li et al. 2006). The bric-à-brac, tramtrack and broad 
complex (BTB) domain recruits the scaffold protein and E3 ligase, Cullin3 
(Cul3) (Cullinan, Gordan et al. 2004, Kobayashi, Kang et al. 2004, Furukawa 
and Xiong 2005). Thus KEAP1 is a substrate adapter for the Cullin3-RING 
E3 ligases. The BTB domain also permits KEAP1 dimerisation, which is 
important for its interaction with NRF2 (Zipper and Mulcahy 2002).  
 
1.5.4. NRF2 binding to KEAP1 
There are two independent binding sites for KEAP1 in the Neh2 domain of 
NRF2 (figure 1.7.). The low-affinity DLG motif and the high-affinity ETGE 
motif bind one each of the two β-propeller protein-docking sites presented by 
the KEAP1 dimer (see figure 1.4) (McMahon, Thomas et al. 2006, Tong, 
Kobayashi et al. 2006). This creates what is described as a hinge and latch 
mechanism wherein newly synthesised NRF2 is picked up by dimeric KEAP1 
at the high-affinity ETGE motif thus promoting DLG motif binding (figure 1.7.). 
Through its binding to NRF2, KEAP1 performs two roles. Firstly, it retains 
NRF2 in the cytosol, preventing its nuclear import. Immunofluorescence 
experiments showed that expression of NRF2 and KEAP1 together retained 
the transcription factor in the cytosol whereas NRF2 expressed alone was 
nuclear (Itoh, Wakabayashi et al. 1999). In the early 2000s several studies 
showed that the stability of NRF2 is regulated by proteasomal degradation 
and that this is dependent on KEAP1 (Itoh, Wakabayashi et al. 2003, 
McMahon, Itoh et al. 2003, Nguyen, Sherratt et al. 2003, Stewart, Killeen et 
al. 2003, Zhang and Hannink 2003).  
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Figure 1.7. A simplified schematic of NRF2-KEAP1 binding. The two binding
regions in NRF2 are the high affinity ETGE motif and the low affinity DLG which
each bind to one of the two DGRs in the KEAP1 homodimer. 
Figure 1.8. A simplified schematic of NRF2 regulation by KEAP1. The KEAP1
homodimer binds to NRF2 and recruits the Cul3-RING complex (1). This promotes
NRF2 ubiquitylation (2) and degradation by the proteasome (3). ROS modifies reac-
tive cysteines in KEAP1 and block its binding with NRF2 (4). Released NRF2 trans-
locates to the nucleus where it heterodimerises with small MAFs and binds ARE
promoters (5). NRF2 activates genes involved in ROS regulation (6).
1.
2. 3.
4.
5.
6.
KEAP1
NRF2
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 1.5.4. Ubiquitin-mediated degradation of NRF2 
Coincidentally, work in C. elegans had identified a link between the E3 ligase 
scaffold protein Cullin3 (Cul3) and the BTB domain of MEL-26 (Furukawa, He 
et al. 2003, Pintard, Willis et al. 2003, Xu, Wei et al. 2003). At the time, the 
role of Cullin3 had not fully been understood, however it was proposed that it 
might form a similar complex to the SCF E3 ligase complex comprised of 
Cullin1 (Cul1), Skp1, an F box protein and the E3 ligase RBX1/ROC1/HRT1 
(Deshaies 1999). The finding in C. elegans lent weight to this argument since 
not only did Cul3 interact with the BTB domain containing protein MEL-26, it 
also promoted the ubiquitylation and subsequent degradation of the meiotic 
protein, MEI-1.  
Mass spectrometry to identify Cul3 binding proteins first reported two proteins 
that both had BTB domains (KIAA1309 and KIAA1354). This was later 
extended to a total of four proteins with the addition of BTBD1 and MEL-26 
which were identified by yeast two-hybrid (Furukawa, He et al. 2003). In 
addition the authors expressed the BTB domains from a select number of 
proteins showing that, at least in vitro, Cul3 bound to 13 distinct BTB domain. 
Meanwhile, Xu et al. identified 11 proteins that bound to a Cul3 bait in a yeast 
two-hybrid screen all of which contained BTB domains which they confirmed 
by biochemistry (Xu, Wei et al. 2003).  
This, plus a number of other studies have allowed us to understand the 
formation of the Cul3-BTB E3 ligase complex (reviewed in (Pintard, Willems 
et al. 2004). In the case of NRF2 regulation, KEAP1 recruits NRF2 to the 
Cul3-RING box protein 1 (Rbx1) complex (figure 1.8.). NRF2 is 
polyubiquitylated at several lysine residues within the Neh2 domain and 
between the two KEAP1 binding motifs (Cullinan, Gordan et al. 2004, 
Kobayashi, Kang et al. 2004, Furukawa and Xiong 2005). This targets NRF2 
to the proteasome for degradation and keeps its half-life to less than 20 
minutes (figure 1.8.) (Kobayashi, Kang et al. 2004). The level of reactive 
oxygen species in the cell regulates this process: the conformation of KEAP1 
can be altered by modification at several reactive cysteine residues which 
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weakens its association with NRF2. This in turn, reduces NRF2 ubiquitylation 
and allows its translocation to the nucleus (figure 1.8.) (Kobayashi, Kang et 
al. 2004, Hayes, McMahon et al. 2010). In particular cysteine residues in the 
intervening region of KEAP1 between the BTB and DGR domains are 
modified by ROS and this may block the association with NRF2 (Dinkova-
Kostova, Holtzclaw et al. 2002, Tong, Kobayashi et al. 2006). 
 
1.5.5. Disruption of the KEAP1-NRF2 interaction 
Other proteins can disrupt the binding of the Neh2 domain to KEAP1 and 
thereby regulate NRF2 activity. This occurs when proteins competitively bind 
to either NRF2 or KEAP1. For example, the cyclin-dependent kinase p21 
knockout mouse also has reduced NRF2 levels (Chen, Sun et al. 2009). This 
p53-regulated protein, p21, can interact with the DLG motif of NRF2 via a 
basic tripeptide KRR region. By stabilising NRF2, increased p21 levels might 
therefore increase transcription of anti-apoptotic genes that are under ARE 
regulation (Chen, Sun et al. 2009). Moreover, p53 itself can be activated by 
oxidative stress thus potentially feeding in to this pathway (Han, Muller et al. 
2008). 
There are a number of important proteins that can interact with KEAP1. 
Phosphoglycerate mutase family member PGAM5 is a mitochondrial 
phosphatase, which interacts with KEAP1 via an ESGE motif that looks 
similar to the EGTE motif of NRF2 (Lo and Hannink 2006). Similarly 
p62/Sequestosome 1 (p62/SQSTM1) possesses an STGE motif, which 
facilitates its interaction with KEAP1 (Komatsu, Kurokawa et al. 2010). The 
potential role of KEAP1 interaction with these two proteins is discussed 
below however at the very least they might release NRF2 from its inhibition 
by KEAP1 allowing its translocation to the nucleus. Evidence for this comes 
from Atg7 knockout mice. Atg7 negatively regulates p62 and in the Atg7 
knockout mice the levels of NRF2 activity are increased (Komatsu, Kurokawa 
et al. 2010). In itself, p62 is an NRF2 target gene and this might play a role in 
a positive feedback of this pathway (Jain, Lamark et al. 2010). 
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 1.5.6. KEAP1 and autophagy 
As described above, macroautophagy is a pathway controlling the 
degradation of long-lived proteins, damaged organelles and proteins that 
tend to form aggregates.  
P62/SQSTM1 is able to act as a specific autophagy receptor through its 
interaction with both ubiquitylated proteins and LC3-II of the growing 
phagophore. In this way it triggers selective autophagy by bringing cargo to 
the autophagy machinery.  
Under treatment with the oxidative stressor sodium arsenite, p62 forms 
aggregates. Following its aggregation, phosphorylation of p62 at Ser351 by 
mTORC1 increases the binding affinity of p62 for KEAP1 (Ichimura, Waguri 
et al. 2013). Over time Ichimura and colleagues saw a reduction in KEAP1 
protein levels suggesting that the protein was first sequestered and then 
degraded by selective autophagy. This led to the persistent activation of 
NRF2. The authors identified this when they expressed a phospho-mimetic 
p62 mutant in human hepatocellular carcinoma cells and saw increased 
tumourigenesis in mouse xenografts. This effect was ablated by NRF2 
depletion (Ichimura, Waguri et al. 2013).  
In addition Taguchi et al. showed that KEAP1 accumulates in the livers of 
autophagy deficient mice (either p62 or Atg7 deficient) again suggesting that 
KEAP1 protein levels might be regulated by autophagy (Taguchi, Fujikawa et 
al. 2012).  
 
1.5.7. KEAP1 and cell death 
As already mentioned above, KEAP1 has been proposed to also bind to 
PGAM5 (Lo and Hannink 2006). PGAM5 is an outer mitochondrial membrane 
protein with phosphatase activity that binds the anti-apoptotic BCL-2 family 
member BCL-XL (Stepkowski and Kruszewski 2011).  In addition to this, 
PGAM5 regulates the activity of apoptosis signal-regulated kinase 1 (ASK1) 
through its dephosphorylation of this protein (Takeda, Komuro et al. 2009). In 
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this way, PGAM5 is important in preventing apoptosis triggered by sustained 
activation of the JNK and p38 pathways, which activate ASK1 (Takeda, 
Komuro et al. 2009, Stepkowski and Kruszewski 2011). 
Interestingly, it has been shown that KEAP1-deficient mouse embryonic 
fibroblasts (MEFs) are resistant to apoptosis induced by the ROS-inducer 
paraquat (Stepkowski and Kruszewski 2011). This was shown to be due to a 
failure to activate ASK1 in KEAP1-deficient MEFs (Niso-Santano, Gonzalez-
Polo et al. 2010). A subsequent study has shown that PGAM5 stability is in 
fact regulated by its interaction with KEAP1 (Xu, Fang et al. 2013). KEAP1 
can be recruited to mitochondrial membranes by PGAM5. It has been 
proposed that KEAP1 in turn can recuit the Cul3-Rbx1 complex and promote 
the polyubiquitylation and subsequent proteasomal degradation of PGAM5 
(Lo and Hannink 2006).  
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Chapter two: Materials and methods 
 
2.1. Mammalian cell culture 
 
2.1.1. Cell culture inhibitors, reagents and antibodies 
Unless otherwise stated, cell culture reagents, plasticware and chemicals 
were from Gibco (Invitrogen, UK), Corning Inc (New York, USA) and Sigma-
Aldrich (Pool, UK) respectively. Inhibitors were obtained from the companies 
indicated in table 2.1. Inhibitors were diluted in dimethyl sulphoxide (DMSO) 
(Sigma-Aldrich) and stored at -20°C in aliquots.  Prior to use the inhibitors 
were thawed and diluted in warm media at the concentrations indicated in 
table 2.1. Recombinant growth factors neuregulin (NRG1) and epidermal 
growth factor (EGF) were obtained from Peprotech (London, UK). 
Supplements for the growth of MCF10A cells were from Sigma-Aldrich.  
Antibodies for western blotting and immunofluorescence were purchased 
from the companies detailed in tables 2.2, 2.3, 2.4, 2.5 and 2.6 and used at 
the concentrations indicated. Tert-butyl hydroperoxide was purchased from 
Sigma Aldrich. 
 
Table 2.1. Inhibitors used. 
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2.1.2. Cell culture 
HeLa, MCF7, U2OS and HEK293T cells were cultured in 5% CO2 at 37°C. 
Culture medium was Dulbecco’s modified Eagle’s medium (DMEM) 
+GlutaMAX supplemented with 10% fetal bovine serum (FBS) and 0.1mM 
minimum essential medium (MEM) non-essential amino acids (NEAA). The 
split ratio was 1:5-1:7, 1:3-1:5, 1:4-1:5 and 1:9-1:12 every 2-3 days for HeLa, 
MCF7, U2OS and HEK293T cells respectively. NCI-H1650 and NCI-H1975 
cells (ATCC, LGC Standards Ltd, Middlesex, UK) were cultured in RPMI-
1640 media plus L-Glutamine supplemented with 10% FBS. These cells were 
split 1:2-1:4 every 2-3 days.  MCF10A parental and isogenic cell lines 
(Horizon Discovery, Cambridge, UK) were cultured in DMEM/F12 GlutaMAX 
supplemented with 5% horse serum (HS), EGF (20ng/ml), hydrocortisone 
(500ng/ml), insulin (0.01mg/ml) and cholera toxin (100ng/ml).  The MCF10A 
cells were split at a ratio of 1:5-1:8 every 2-3 days. FKHRL1-U2OS cells 
(Thermo Scientific, Bioimage products, Lafayette, USA) stably expressing 
FKHRL1 (FOXO3) fused to the N-terminus of enhanced green fluorescent 
protein (EGFP) under a CMV promotor were cultured in DMEM +GlutaMAX 
supplemented with 0.5mg/ml Geneticin (G418). These cells were split at a 
ratio of 1:3-1:4 every 2-3 days. For maintenance, cells were dissociated from 
flasks or dishes with 0.05% trypsin with EDTA. 
 
2.1.3. SiRNA transfection 
SiRNA transfection used the siRNA oligomers in table 2.4. All siRNA was 
purchased from either Qiagen (Crawley, UK) or GE Dharmacon (Lafeyette, 
USA) as indicated. Transfection of cells either followed a forward, fast-
forward or reverse protocol using Lipofectamine® RNAiMAX transfection 
reagent (Thermo Fisher Scientific, Massachusetts, USA). For the forward 
protocol, cells were seeded in 6 well plates, 6cm or 10cm dishes and 
transfected the following day following the RNAiMAX protocol. For 6 well 
plates siRNA to a final concentration of 10 or 40nM was combined with opti-
MEM in a final volume of 180µl. Separately; 2µl RNAiMAX was combined 
with 18µl opti-MEM. Both mixtures were incubated at room temperature for 5-
7min before they were mixed, incubated together for a further 20min and 
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added to the cells in a final volume of 1ml. This was scaled-up according to 
plate size.  
 
For the fast-forward protocol, the cells were seeded 4-8 hours prior to 
transfection following the above protocol later that day. For the reverse 
protocol, cells were seeded directly on to a transfection reagent mixture. 
SiRNA was diluted in 200µl opti-MEM to a final concentration of 10 or 40nM. 
2µl RNAiMAX was added to the mixture and the mixture incubated in the 6 
well plate for 10-20 minutes at room temperature. Cells were seeded directly 
on to this mixture making a final volume of 1ml and a final siRNA 
concentration of 10 or 40nM.  
 
2.1.4. DNA transfection 
For transient DNA transfections, 1µg DNA was diluted in 150µl opti-MEM and 
mixed. 3µl of GeneJuice (Merck-Millipore, Nottingham, UK) was added to this 
mixture, mixed and incubated for 20 minutes at room temperature. This was 
added, dropwise, to cells that had been seeded up to 24 hours earlier. Cells 
were incubated with the transfection mixture for 24 to 72 hours. 
 
2.1.5. Crystal violet staining 
For staining of cells with crystal violet, cells in a 6 well plate were washed 
once with room temperature PBS and fixed with ice cold methanol for 10 
minutes at -20°C. The cells were washed once more with PBS and stained 
with 1mg/ml crystal violet in methanol (Sigma-Aldrich, Poole, UK) for 30 
minutes at room temperature. The cells were washed 4-5 times with ddH2O 
and left to air-dry overnight before scanning on an Epson scanner.  
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 Table 2. 2. SiRNA oligos used for RNA interference 
 
2.1.6. Scepter cell count 
Where indicated, cell counts were taken using a Scepter 2.0 (Merck-Millipore, 
Wisconsin, USA). For this cells were dissociated with trypsin and 
resuspended in full media as usual. 100µl of singularised cells were added to 
900µl PBS and a cell count taken using 60µm tips (Merck-Millipore). To count 
only live cells the Scepter was set to count cells with a minimum of 12 and 
maximum of 30µm diameter. 
Entrez 
gene ID
NCBI 
gene 
symbol
Name Company Type
Catalogue 
number
Sequence
9101 USP8 HS_USP8
_1 (QI1)
QIAGEN Flextube 
siRNA
S1000073014 CAGGGTCAATT
CAATCTACA
9101 USP8 HS_USP8
_2 (QI2)
QIAGEN Flextube 
siRNA
S1000073024 AAGGCTCGTAT
TCATGCAGAA
9101 USP8 HS_USP8
_3 (QI3)
QIAGEN Flextube 
siRNA
S1000073031 CAGGTTCAGGC
AAGCCATTTA
9101 USP8 HS_USP8
_5 (QI4)
QIAGEN Flextube 
siRNA
S103103604 GAGGATACAGA
CGATACCGAA
9101 USP8 Oligo 1 
(Dh1)
Dharmacon siGENOME D-005203-02 TGAAATACGTG
ACTGTTTATT
9101 USP8 Oligo 2 
(Dh2)
Dharmacon siGENOME D-005203-03 GGACAGGACAG
TATAGATATT
23032 USP33
Oligo 6 
(USP33) Dharmacon
ON 
TARGET 
plus
J006081-06
GGGCATGTCTG
GAGAATAGTT
N/A N/A
Non-
targeting 1 
(NT1)
Dharmacon
ON 
TARGET 
plus
D-001810-01
TGGTTTACATG
TGTTTTCTGA
N/A N/A
Non-
targeting 3 
(NT3)
Dharmacon
ON 
TARGET 
plus
D-001810-03
TGGTTTACATG
TCGACTAA
N/A N/A
AllStars 
Negative 
Control 
(SiC)
QIAGEN
AllStars 
negative 
control
1027280 Not provided
GACCAAGGTGA
ATCTTC, 
GAAGTACGCTT
GCTGAATC, 
CAACAAGCAGC
AAAGTGTA, 
AGACCTAGTGG
AACAATTA
TRABID/ 
ZRANB1 
(TBD)
54764 ZRANB1 Dharmacon
ON 
TARGET 
plus
LQ-009270-00
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 2.2. Microscopy 
 
2.2.1. Immunofluorescence staining 
For immunofluorescence, cells were grown on glass coverslips. At the end of 
the experiment the coverslips were washed twice with PBS at room 
temperature and fixed with 4% paraformaldehyde in PBS for 15 minutes. 
Cells were washed twice more with PBS and the fixation quenched with 
50mM ammonium chloride in PBS for 10 minutes followed by another two 
PBS washes. The cells were permeabilised with 0.2% Triton-X-100 in PBS 
for 4 minutes and blocked with 10% goat serum or 3% BSA depending on the 
antibody (table 2.5) for 30 minutes. The primary antibody was incubated with 
the coverslips for 20 minutes or 1 hour (table 2.5) and the coverslips washed 
three times with PBS. The secondary antibody was incubated with the 
coverslips for 20 minutes (table 2.6) and the coverslips washed three times 
with PBS, rinsed once with ddH2O and mounted on slides with Mowiol plus 
4’,6-diamidino-2-phenylindole (DAPI) stain (Molecular Probes, Thermo Fisher 
Scientific, Massachusetts, USA). Where indicated DRAQ7 (0.3µM) and 
annexin V-AF350 (5µl per 1ml) (Molecular Probes and Thermo Fisher 
Scientific respectively) were used to visualize dead cells and apoptotic cells, 
respectively. 
 
Table 2.3. Primary antibodies used for immunofluorescence. 
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 Table 2.4. Secondary antibodies used for immunofluorescence 
2.2.3. Time-lapse microscopy 
For time-lapse microscopy, cells in 6 well plates were kept in the presence of 
5% CO2 at 37°C for the duration of the experiment. Cells were imaged using 
a fully motorised NikonTi-E eclipse microscope (CFI Super Plan Fluor 
20x/0.45 NA) at intervals as indicated per experiment.  Movies were 
processed using NIS-Elements software (Nikon, Amsterdam, Netherlands) 
and FijiIsJustImageJ 1.48 or ImageJ 1.47v (NIH).  
 
2.3. Protein biochemistry 
 
2.3.1. Cell lysis 
Cells were lysed as indicated with either RIPA (10mM Tris-HCl pH 7.5, 
150mM NaCl, 1% w/v Triton X-100, 0.1% SDS, 1% sodium deoxycholate) or 
NP40 (0.5% NP40, 25mM Tris-HCl pH 7.5, 100mM NaCl, 50mM NaF) lysis 
buffer. In both cases the lysis buffers were supplemented with PhosSTOP 
phosphatase inhibitor cocktail tablets (Roche, Basel, Switzerland) and 
mammalian protease inhibitors (Sigma Aldrich, Poole, UK). Cells were rinsed 
twice with ice cold PBS on ice then incubated with 150µl (per 6 well plate 
well), 250µl (6cm dish) or 500µl (10cm dish) lysis buffer for 10minutes on ice. 
The lysate was centrifugated at 14,000rpm for 5 minutes at 4°C and the 
supernatant collected for protein assay.  
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2.3.2. Protein assay 
Protein concentration was assessed using the Bio-Rad bicinchroninic acid 
(BCA) assay kit (#23225 Pierce, UK) according to the manufacturer’s 
instructions using IgG as a standard.  
 
2.3.4. SDS polyacrylamide electrophoresis (SDS-PAGE) 
Concentration adjusted protein lysates were combined with a 1x final 
concentration sample buffer (3% w/v SDS, 62.5mM Tris-HCl pH 6.8. 10% 
glycerol, 3.2% β-mercaptoethanol stained with bromophenol blue), boiled for 
5 minutes at 98°C and separated by SDS-PAGE. Samples were either 
loaded onto 4-12% precast Bis-Tris gradient gels (NuPAGE, Invitrogen, 
Paisley, UK) or 8% mini-gels poured using a Bio-Rad mini-protean® 3 system 
(BioRad, California, USA) (resolving gel (2 gels): 5.3ml protogel, 5.2ml 
protogel resolving, 9.2ml water, 15µl tetramethylethylenediamene (TEMED) 
(VWR, Lutterworth, UK), 150µl 10% APS (Sigma-Aldrich, Poole, UK); 
stacking gel (2 gels): 1.3ml protogel, 2.5ml protogel stacking, 6.1ml water, 
50µl TEMED, 10µl 10% APS). Separation typically took place either at a 
constant voltage of 200V for 60min (NuPAGE) or 90V for 15min followed by 
180V for 45min (BioRad). Samples were run alongside Broad Range marker 
(New England BioLabs, Herts, UK) and Rainbow Marker (GE Healthcare, 
Amersham, UK).  
 
2.3.5. Western blotting 
Separated proteins were transferred on to 0.45µm Protran nitrocellulose 
membrane (Geneflow, Lichfield, UK). The transfer was performed using the 
GenieBlotter system (Idea Scientific, Minneapolis, USA) at a constant current 
of 08-09A for one hour. Transferred proteins were visualised with Ponceau S 
(Sigma-Aldrich, Poole, UK) staining which was subsequently removed with 
PBS.  The membrane was blocked with 0.5% Marvel TBS-T (20mM Tris, 
137mM NaCl, pH 7.6, 0.1% Tween-20) or 0.5% Marvel PBS-T (1x PBS, 0.1% 
Tween-20) for one hour at room temperature or overnight at 4°C. Membranes 
were incubated with primary antibody as indicated below. Prior to the addition 
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of the secondary antibody (see table 2.3) membranes were washed three 
times with TBS-T or PBS-T for 15 minutes in total. The secondary antibody 
was added to the membrane for one hour and the membrane washed again 
two times with TBS-T/PBS-T and one time with TBS/PBS. Protein bands 
were visualised using the LI-COR Odyssey Classic scanner (LI-COR, 
Nebraska, USA).  
 
Table 2.5. Secondary antibodies used for western blotting 
 
2.4. Quantitative real-time polymersase chain reaction (qRT-
PCR) 
 
2.4.1. Reverse Transcription 
mRNA was prepared from cell lysates harvested using the Qiagen RNeasy 
Kit following the manufacturer’s guidelines. The RNA concentration was 
determined using a NanoDrop Spectrophotometer ND1000 at 260nm. 1µg 
RNA was diluted in sterile water to a final volume of 10µl. Poly(A) tails of the 
mRNA were primed by incubation of the solution with 1µl oligo dT primers at 
70°C for 5 minutes. 8µl reaction buffer (4µl 5x reverse transcription buffer, 
2µl PCR nucleotide mix, 0.5µl RNasin, 1.5µl nuclease free deionised water) 
was combined with the mRNA and oligo dT primer mix. The mixture was 
incubated for 5 minutes at 37°C before the addition of 1µl MuLV reverse 
transcriptase. The reaction was carried out at 42°C for 1 hour then 70°C for 
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10 minutes. The final reaction mixture was made up to 100µl with sterile 
water. 
 
2.4.2. qRT-PCR 
Reaction buffer (per single reaction: 5µl 2x SYBR Mastermix, 1.66µl water, 
0.17µl 20µM forward primer, 0.17µl 20µM reverse primer) was prepared 
using iTaqTM Universal SYBR® Green Supermix (Bio-Rad) according to the 
manufacturer’s protocol. KEAP1 forward primer (5’-CAG ATT GGC TGT 
GTG GAG TT-3’) and reverse primer (5’-GCT-GTT-CGC-AGT-CGT-ACT-TG-
3’) were gifts from Prof. Ian Copple (Universit of Liverpool). cDNA from 2.4.1. 
was diluted 3-fold before 3µl was added to the reaction buffer. qRT-PCR was 
performed using the CFX ConnectTM Real-Time PCR detection system (Bio-
Rad). Denaturation took place at 95°C for 3 minutes. A two-step amplification 
protocol consisted of incubation at 95°C for 10 seconds followed by 60°C for 
30 seconds for 40 cycles. The melt curve was analysed after 40 cycles. The 
Ct values for test genes were normalised to actin and relative expression 
represented as 2-[ΔΔCt]. 
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 Table 2.6. Primary antibodies used for western blotting 
Target 
protein
Species
Source 
(catalogue 
number)
Blocking 
buffer
Incubation 
buffer
Dilution 
(temperature, 
time)
Actin mouse Abcam (ab6276) 5% Milk TBS-
T/PBS-T
5% Milk TBS-
T/PBS-T
1:10,000 (RT, 1h)
AKT rabbit Cell Signaling 
(#9272)
5% Milk TBS-
T/PBS-T
5% BSA TBS-
T/PBS-T
1:1000 (4°C, o/n)
p-AKT rabbit Cell Signaling 
(#4060)
5% Milk TBS-
T/PBS-T
5% BSA TBS-
T/PBS-T
1:2000 (4°C, o/n)
EGFR goat Santa Cruz (SC03-
1005)
5% Milk TBS-
T/PBS-T
5% Milk TBS-
T/PBS-T
1:200 (4°C, o/n)
ErbB3 rabbit Cell Signaling 
(#12708)
5% Milk TBS-
T/PBS-T
5% Milk TBS-
T/PBS-T
1:1000 (4°C, o/n)
HRS goat Everest Biotech 
(EB07211)
5% Milk TBS-
T/PBS-T
5% Milk TBS-
T/PBS-T
1:2000 (4°C, o/n)
HRS rabbit
Home-made (864) 
(Sasche, Urbé et 
al. 2002)
5% Milk TBS-
T/PBS-T
5% Milk TBS-
T/PBS-T 1:1000 (4°C, o/n)
HRS rabbit Bethyl (A300-989A) 5% Milk TBS-
T/PBS-T
5% Milk TBS-
T/PBS-T
1:1000 (4°C, o/n)
MET mouse Cell Signaling 
(#3127)
5% Milk TBS-
T/PBS-T
5% BSA TBS-
T/PBS-T
1:1000 (4°C, o/n)
PARP p85 mouse Cell Signaling 
(#9546)
5% Milk TBS-
T/PBS-T
5% BSA TBS-
T/PBS-T
1:2000 (4°C, o/n)
USP33 mouse Sigma-Aldrich 
(WHO002032M1)
5% Milk TBS-
T/PBS-T
5% Milk TBS-
T/PBS-T
1:1000 (4°C, o/n)
USP8 rabbit Sigma-Aldrich 
(HPA004869)
5% Milk TBS-
T/PBS-T
5% Milk TBS-
T/PBS-T
1:1000 (4°C, o/n)
USP8 rabbit Bethyl (A300-929A) 5% Milk TBS-
T/PBS-T
5% Milk TBS-
T/PBS-T
1:2000 (4°C, o/n)
USP8 sheep R&D Systems 
(AF7735)
5% Milk TBS-
T/PBS-T
5% Milk TBS-
T/PBS-T
1:500 (RT, 2h)
STAM2 rabbit
Home-made (198) 
(Row, Clague et al. 
2005)
5% Milk TBS-
T/PBS-T
5% Milk TBS-
T/PBS-T 1:1000 (RT, 1h)
ERK rabbit Cell Signaling 
(#4695)
5% Milk TBS-
T/PBS-T
5% BSA TBS-
T/PBS-T
1:1000 (4°C, o/n)
p-ERK rabbit Cell Signaling 
(#4370)
5% Milk TBS-
T/PBS-T
5% BSA TBS-
T/PBS-T
1:2000 (4°C, o/n)
p-MEK rabbit Cell Signaling 
(#9154)
5% Milk TBS-
T/PBS-T
5% BSA TBS-
T/PBS-T
1:1000 (4°C, o/n)
p-MEK1/2 rabbit Cell Signaling 
(#9121)
5% Milk TBS-
T/PBS-T
5% BSA TBS-
T/PBS-T
1:1000 (4°C, o/n)
NRF2 rabbit Abcam (ab62352) 5% Milk TBS-
T/PBS-T
5% Milk TBS-
T/PBS-T
1:500 (4°C, o/n)
KEAP1 mouse Abcam (ab119403) 5% Milk TBS-
T/PBS-T
5% Milk TBS-
T/PBS-T
1:400 (4°C, o/n)
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2.5. FACs analysis 
The media from adherent cells was collected and cells were dissociated from 
dishes with 0.05% trypsin EDTA. All media and trypsin was retained. The 
collected cells, media and trypsin were were centrifugated at 2000rpm for 3 
minutes. The cell pellet was resuspended in 1ml Annexin V buffer 
(Ca2+/Mg2+ rich) with Annexin-V-FITC (1:20,000 dilution) and incubated for 
5-8 minutes. 5µl propidium iodide (50µg/ml) was added and incubated for 2 
minutes. The FITC and PI staining was measured using an Attune® NxT 
Acoustic Focusing Cytometer. All reagents were gifts from Prof. Gerald 
Cohen and Dr Shankar Varadarajan (University of Liverpool). 
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Chapter three: The role of the PI3K 
pathway in regulating USP8 
USP8 is well characterised as an important DUB that regulates the trafficking 
of growth factor receptors to the lysosome (Clague and Urbe 2006). Thus by 
regulating the levels of these receptors this DUB also influences the 
subsequent outputs of these important signalling molecules. Endocytic 
trafficking of growth factor receptors does not only promote their 
downregulation, there is also evidence that internalised receptors might 
signal en route through the trafficking system (Villasenor, Kalaidzidis et al. 
2016).  
In addition to this indirect effect on signalling, there is increasing evidence 
that USP8 may also interact with downstream effectors of these growth factor 
receptors adding an extra layer of regulation. 
Interestingly, a number of studies report direct or indirect interactions 
between the PtdIns-3 kinase (PI3K) -AKT signalling pathway and USP8 with 
a particular focus on a purported interaction between USP8 and p-AKT (Cao, 
Wu et al. 2007, Cai, Crotty et al. 2010, Panner, Crane et al. 2010). In 
particular, these studies show that changes in p-AKT levels correlate with 
changes in USP8 levels. It has been suggested that USP8 is, in fact, a direct 
substrate of activated AKT and that USP8 phosphorylation (either by AKT, or 
other kinases) regulates the stability, subcellular localisation and activity of 
this DUB (Ballif, Cao et al. 2006, Cao, Wu et al. 2007, Mizuno, Kitamura et al. 
2007, Cai, Crotty et al. 2010, Panner, Crane et al. 2010, Meijer, Kerperien et 
al. 2013). However, currently the data linking USP8 to the PI3K-AKT 
signalling pathway are contradictory. In 2007 Cao and colleagues reported 
that stimulation of the PI3K pathway using NRG1 correlated with an increase 
in USP8 stability (Cao, Wu et al. 2007). This was complemented by data 
using PI3K pathway inhibition, which showed a decrease in AKT was 
associated with a decrease in USP8 (Cai, Crotty et al. 2010). However a 
study in transformed mouse astrocytes and human glioblastoma xenografts 
indicated an inverse correlation between AKT activation and USP8 levels 
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(Panner, Crane et al. 2010). In this chapter, my aim was to investigate this 
discrepancy in the literature and to understand the role, if any, for the PI3K 
pathway in regulating USP8.  
In order to further investigate this proposed interaction between USP8 and 
the PI3K pathway I assembled a toolkit of reagents and cell lines to use in 
this chapter.  First I used EGF and neuregulin to activate EGFR and ERBB3 
in two cell lines. HeLa cells had been used in a previous investigation in our 
lab assessing the role of USP8 in EGFR degradation and these MCF7 cells, 
together with HeLa cells had been employed in some of the studies 
mentioned above (Row, Prior et al. 2006, Cao, Wu et al. 2007). Neuregulin is 
a particularly potent activator of the PI3K pathway by activating the ERBB3-
ERBB2 heterodimer. ERBB2 is an orphan receptor but can heterodimerise 
with ERBB3 which has a particular propensity for recruiting PI3K due to a 
large number of PI3K recognition sites within its intracellular domain (Citri, 
Skaria et al. 2003).  
In order to examine the role of PI3K specifically I made use of a panel of 
isogenic MCF10A cell lines from Horizon Discovery, comparing parental cells 
to their PI3K mutant counterparts. Additionally, my toolkit comprised 
inhibitors of the PI3K pathway (LY294002, Wortmannin, PI-103 and GDC-
0491) as well as the AKT inhibitor MK-2206.  
 
3.1. Objective 
The objective of this chapter was to investigate whether the PI3K pathway 
exerts an influence on USP8 levels, distribution or activity.  
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 3.2. Results 
 
3.2.1. USP8 levels do not change in response to RTK activation 
Following on from previous reports suggesting that activation of AKT leads to 
an increase in the levels of USP8, I investigated the activation response of 
both HeLa and MCF7 cells to EGF or NRG1 stimulation, both of which 
activate AKT. I first stimulated serum-starved HeLa cells with EGF and 
observed a characteristic peak in p-Ser473-AKT levels following 5 minutes of 
stimulation, which drops down to basal levels by 180 minutes (figure 3.1.A). 
A similar AKT activation profile is evident in NRG1-stimulated cells (figure 
3.1.A). Despite the clear activation of AKT, the levels of USP8 remain 
unchanged with either growth factor throughout the time-course.  
In MCF7 cells the AKT activation profile in response to EGF looks very 
similar to that observed in the HeLa cells (figure 3.1.B). Interestingly, with 
NRG1 stimulation the AKT activation is more sustained in these cells, 
peaking at 5 minutes as for EGF but retaining activation for the remainder of 
the 6 hour time-course. Importantly, neither the EGF nor the sustained NRG1 
activation of this pathway triggers a change in USP8 levels (figure 3.1.B).  
 
3.2.2. USP8 levels do not change with constitutive PI3K activation with 
or without EGFR activation 
I next looked for a different way to activate AKT that would be independent of 
growth factor receptor activation. Mutation of histidine 1047 to an arginine 
renders the PI3K enzyme constitutively active (Chakrabarty, Rexer et al. 
2010). I used isogenic MCF10A cell lines in which this H1047R mutation has 
been introduced in one allele of the endogenous gene and compared their p-
Ser473-AKT and USP8 levels with those of parental MCF10A cells. The 
standard growth medium for MCF10A cells contains a large number of 
supplements including cholera toxin, hydrocortisone, insulin, and importantly 
EGF.  Parental cells show decreased p-Ser473-AKT levels when EGF is 
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Figure 3.1. USP8 levels do not change with RTK activation. (A) HeLa cells
were starved for 18h before stimulation with 20ng/ml EGF or 50nM NRG1 over
a 6h time course followed by RIPA lysis at the indicated time points (n=1). Lysates 
were separated by SDS-PAGE and western blots probed with the indicated 
antibodies. (B) MCF7 cells were starved for 18h then stimulated with EGF or 
NRG1 for up to 6h (n=1). RIPA lysates were separated by SDS-PAGE and 
western blots probedwith the indicated antibodies. Dotted lines separate 
individual western blots.
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Figure 3.2. USP8 levels do not change in response to constitutive PI3K 
activation with or without RTK activation. Parental (PAR) or PI3K mutant 
(H1047R) isogenic MCF10A cells were grown to confluence in media with or 
without EGF. Cells were lysed in RIPA buffer, samples separated by SDS-PAGE 
and probed with the indicated antibodies. PAR and H1047R samples were run 
on the same gels (n=1).
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withdrawn from their culture medium for 6 hours.  In contrast to the parental 
cells, PI3K mutant cells retain high levels of p-Ser473-AKT independently of 
the presence of EGF in the medium. There is no change in USP8 level when 
comparing the two cell lines to one another, nor is there a change in USP8 
level when comparing plus or minus EGF conditions within each cell line. 
 
3.2.3. USP8 levels are not affected by inhibitors of the PI3K pathway 
Inhibition of the PI3K pathway or AKT directly should likewise be informative 
on the potential regulation of USP8 by this pathway. Acute inhibition (30 
minutes) of the PI3K pathway with LY294002, PI-103 or Wortmannin should 
result in reduced AKT activitation. I used these inhibitors plus an allosteric 
inhibitor of AKT (figure 3.3.A). The LY294002 inhibitor is a reversible, ATP 
competitive inhibitor of a number of kinases (McNamara and Degterev 2011). 
As well as PI3K family members, at doses of over 10µM, it also inhibits 
mTOR, one of the two activating kinases of AKT, DNA-PK and other, 
unrelated proteins including a number of channels. Following 24 hour 
treatment the LY294002 clearly decreased p-Ser473-AKT levels in HeLa 
cells, whilst Wortmannin only had a very small effect. The AKT inhibitor MK-
2206 most strikingly abolishes AKT activation. However USP8 levels were 
not affected by either PI3K or AKT inhibition (figure 3.3.B). 
I next conducted a time-course experiment in both HeLa (left) and MCF7 
(right) cells (figure 3.3.C). The cells were treated for up to 24 hours with 
LY294002 the only PI3K inhibitor that markedly affected AKT levels in panel 
B. Strong inhibition of AKT activity is obvious up to 8 hours in HeLa cells and 
24 hours in MCF7 cells. In HeLa cells, basal p-Ser473-AKT levels appear 
unaffected in the 24 hour treatment sample although this is unlikely due to 
instability of the drug given the successful p-Ser473-AKT reduction in MCF7 
cells.  
In neither HeLa cells nor MCF7 cells does prolonged inhibition of PI3K 
decrease the levels of USP8. 
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Figure 3.3. USP8 levels do not change with PI3K pathway inhibition.  (A)
PI3K pathway inhibitors used. (B) HeLa cells were treated with the PI3K inhibitors
PI-103 (100nM), LY294002 (20µM) or Wortmannin (100nM) or the AKT inhibitor
MK-2206 (1µM) or DMSO for 24h prior to RIPA lysis. Lysates were separated 
by SDS-PAGE and western blots probed for the indicated proteins (n=1). Tublin 
acts as a loading control for each separate western blot. (C) HeLa
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(8, 12 and 65nM respectively)
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 3.2.4. USP8 distribution does not change upon PI3K pathway inhibition 
My data suggest that USP8 levels do not change upon PI3K pathway 
manipulation. However, it is possible that the distribution of this DUB is 
affected by the PI3K pathway. Following activation, EGFR is internalised to 
endosomes where it co-localises with USP8. Co-localisation of 
overexpressed GFP-USP8 with EGFR can be seen in HeLa cells stimulated 
for 10 minutes with EGF (figure 3.4). Pre-treating cells for 10 minutes prior to 
addition of EGF (total treatment with inhibitors: 20 minutes) with PI3K or AKT 
inhibitors, LY294002 or MK-2206 respectively, did not alter this distribution 
and USP8 remained co-localised with EGFR at punctate structures within the 
stimulated cells.  
 
3.2.5. The availability of the USP8 catalytic site is not affected by EGF 
stimulation 
In order to assess activity changes in USP8 with EGF stimulation I used a 
DUB-activity or suicide inhibitor probe, ubiquitin-VME (Ub-VME) which binds 
irreversibly to the active site in DUBs that have a catalytic cysteine 
(McGouran, Gaertner et al. 2013). MCF7 cells were pre-treated with EGF for 
10 minutes, then lysed and extracted proteins were incubated with increasing 
concentrations of the probe for 15 minutes at 37°C (figure 3.5). Binding of the 
probe to the active site of the DUB results in an approximate 8kDa shift in the 
apparent molecular weight of that DUB (figure 3.5.A). Probing samples 
separated by SDS-PAGE with a USP8 antibody thus allowed me to compare 
any changes in the ability of USP8 to react with this probe with and without 
EGF stimulation. Incubation with 10 and 20ng/ml Ub-VME results in an 
upshift of approximately 20 and 55% respectively of the USP8 band (figure 
3.5.B) Pre-treatment of cells with EGF does not appear to alter the proportion 
of USP8 that is able to interact with the probe. Thus I was unable to detect 
any changes in USP8 activity upon EGF stimulation.  
The ubiquitin-VME probe is conjugated to a small HA tag which allows for 
identification of global changes in reactive proteins by western blot analysis. 
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Figure 3.4. USP8 punctate co-localisation does not change with PI3K pathway
inhibition. HeLa cells grown on coverslips were transfected with GFP-USP8 and
starved for 18h, 24h after transfection. Cells were pre-treated with the PI3K inhibitor
LY294002 (20µM), the AKT inhibitor MK-2206 (1µM) or DMSO for 30min prior to 
stimulation with EGF (100ng/ml) for 10min. Cells were fixed with 4% PFA in PBS,
stained with EGFR antibody and AlexaFluor 594 coupled secondary antibody and 
imaged on a Nikon Eclipse TiE microscope (n=1). 
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Figure 3.5. The availability of the USP8 active site does not change with EGF
stimulation. (A) Ubiquitin active site probe consists of a vinyl methyl ester (VME)
warhead and HA tag. The irreversible reaction of Ubiquitin-VME with a DUB results
in a covalently linked complex that is detectable by an 8.5kDa upshift in a western 
blot. (B) MCF7 cells were stimulated with EGF at a concentration of 20ng/ml for 
10min prior to their lysis and incubation at 37°C for 15min. Samples were separated 
by SDS-PAGE and western blots probed with HA or USP8 antibodies (n=1).
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This would not include all DUBs, only those with a reactive cysteine as 
described above. In addition to deubiquitylases the Ub-VME probe also binds 
to a number of ubiquitin conjugating enzymes as E1, E2 and some E3 
proteins also possess reactive cysteines and ubiquitin binding domains. 
Based on the banding pattern seen in the HA blot, I did not detect any major 
changes in global Ub-VME probe binding upon 10 minutes of EGF 
stimulation (figure 3.5.B). 
 
3.2.6. Synthetic lethality of PI3K inhibition and USP8 depletion  
Joe Sacco, a previous student in our lab, showed that USP8-depleted U2OS 
cells expressing GFP-tagged FOXO3 (referred to hereafter as FKHRL1-
U2OS cells) die when they are treated with the PI3K inhibitor PI-103 (Sacco 
2012). My data did not support an effect on USP8 levels, distribution or 
activity by the PI3K pathway, however Joe’s finding alludes to some 
functional interplay between USP8 and this pathway.  
In order to revisit this finding, I first depleted FKHRL1-U2OS cells of USP8 
and treated the cells with the more specific PI3K inhibitor, GDC-0491, for 6 
hours. Two out of the three USP8 siRNA oligos showed an increase in cell 
death as identified by morphological changes in the cells when combined 
with PI3K inhibition (figure 3.6). 
Examining this further, I used PARP cleavage (PARP p85) as a marker for 
apoptosis by western blotting. In addition to the FKHRL1-U2OS cells I also 
analysed wild-type U2OS cells. FKHRL1, also called FOXO3, is a pro-
apoptotic transcription factor that regulates expression of proteins involved in 
apoptosis and the cell cycle including p130, p21 and TRAIL. Under basal 
conditions FOXO3 shuttles between the cytosol and the nucleus however 
PI3K pathway inhibition promotes the translocation of this transcription factor 
to the nucleus. Here it can trigger the expression of genes important in 
apoptosis. The overexpression of this pro-apoptotic protein in the FKHRL1-
U2OS cells might sensitise them to cell death. To account for this I analysed 
the wild-type U2OS cells.  
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Figure 3.6. USP8 depleted cells die when subjected to PI3K inhibition. 
U2OS cells stably expressing GFP-FOXO3 cells were transfected with USP8 
siRNA (Dh1, Qi1 or Qi3), non-targeting controls (NT1 or SiC) or an siRNA 
targeting the unrelated DUB USP33 (33). The cells were seeded onto coverslips. 
48 hours post-transfection the cells were treated with 1µM GDC-0491 or DMSO 
for 6h, fixed with PFA and imaged with brightfield using a Nikon TiEclipse 
microscope (20x objective) (n=1). Scale bar is 400µm in width.
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Both FKHRL1-U2OS and U2OS cells exhibited increased cell death when 
depleted of USP8 for 48 hours followed by 6-8 hour treatment with 1µM 
GDC-0491 compared to DMSO (figure 3.7.A and 3.7.B respectively).  
Data from Cai et al suggest that the non-small cell lung cancer cell line NCI-
H1650 (H1650) may be sensitive to changes in USP8 levels (Cai, Crotty et 
al. 2010). In their study considering the role of DGKδ in regulating USP8 
stability (described in more detail below), the authors found that a reduction 
of USP8 levels as a result of DGKδ depletion caused a decrease in cell 
viability of this cell line. Therefore I also examined H1650 cells and another 
NSCLC cell line NCI-H1975 (H1975).  Both H1650 and H1975 cell lines 
showed increased PARP p85 upon 48 hour USP8 depletion combined with 6-
8 hour PI3K pathway inhibition by GDC-0491 treatment at a concentration of 
1µM (figure 3.7.B). In the H1975, and indeed in both the FKHRL1-U2OS and 
U2OS cells, this effect was most evident with the Qi2 and Qi3 siRNA oligos 
whereas the H1650 cells only exhibited increased PARP p85 upon treatment 
with Qi3 siUSP8. The Dh1 oligo had little to no effect and was not used with 
the FKHRL1-U2OS cells in figure 3.7.A.  
3.3. Summary of results 
 USP8 levels are stable in HeLa and MCF7 with an activated or 
inhibited PI3K pathway 
 Constitutive activation of PI3K in MCF10A isogenic cells does not 
affect USP8 protein stability 
 Overexpressed wild-type USP8 is not redistributed upon inhibition of 
the PI3K pathway 
 The availability of the USP8 active site is not altered by activation of 
the PI3K pathway through EGF stimulation 
 USP8-depleted U2OS, FKHRL1-U2OS and H1975 cells undergo 
apoptotic cell death with PI3K pathway inhibition  
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Figure 3.7. USP8 depleted cells die by apoptosis when treated with the PI3K
pathway inhibitor GDC-0491. (A) FKHRL1-U2OS cells were depleted of USP8
for 48h prior to treatment with 1µM GDC-0491 or DMSO for 6-8h. NP40 lysates 
were separated by SDS-PAGE and western blots probed with the antibodies 
indicated (n=1). Actin is representative for each of the above blots. (B) U2OS, 
H1650 or H1975 cells were depleted of USP8 for 48h prior to treatment with 1µM 
GDC-0491 or DMSO for 6-8h. NP40 lysates were separated by SDS-PAGE and 
western blots probed as indicated (n=1). The same images were relevelled at a 
higher intensity (inc. level) where indicated. mPARP: mature PARP, cPARP: cleaved 
PARP. Actin is representative for each of the above blots.
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 3.4. Discussion 
The aim of this chapter was to investigate the relationship between USP8 
and the PI3K-AKT signalling pathway. A number of studies described below 
report changes in USP8 levels linked to AKT activation (Cao, Wu et al. 2007, 
Cai, Crotty et al. 2010, Panner, Crane et al. 2010).  One study focused on the 
role of DGKδ in regulating p-AKT levels and the subsequent effect on USP8 
(Cai, Crotty et al. 2010). DGKδ metabolises diacylglycerol (DAG), a second 
messenger generated by phospholipase C enzymes, which can be activated 
by EGFR activation (Crotty, Nakano et al. 2013). DAG recruits and activates 
PKC, which in turn increases activated AKT levels.  
The authors found that DGKδ deficiency in HeLa cells led to increased 
ubiquitylation of EGFR, which in turn led to decreased steady state levels 
and increased ligand-induced EGFR degradation. This was not due to 
changes in levels or activity of the EGFR E3 ligase Cbl. Nor was it due to 
changes in the interaction between Cbl and EGFR. Instead the authors 
reported that USP8 levels were reduced both by DGKδ depletion and PI3K 
pathway inhibition using the LY294002 inhibitor. This correlated with reduced 
p-Ser473-AKT levels and reduced threonine phosphorylated USP8 levels. 
Conversely, Panner et al. found an inverse correlation between AKT 
activation and USP8 levels in transformed mouse astrocytes and human 
glioblastoma xenografts (Panner, Crane et al. 2010). They reported that 
knock-out of PTEN, which led to increased activated AKT levels, results in a 
decrease in USP8 levels. They also showed that AKT inhibition increased 
USP8 levels.  
Whilst both papers described above considered USP8 regulation in the 
context of EGFR signalling, Cao et al. looked at its regulation upon activation 
of other EGFR family receptors which do not rely on Cbl ubiquitylation for 
their ligand-induced degradation (Cao, Wu et al. 2007). Using MCF7 cells the 
authors report that ERBB3 activation by NRG1 leads to increased levels of 
activated AKT, which results in phosphorylation of USP8 and its subsequent 
stabilisation.   
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Here we thus have contradictory studies, reporting either a positive or a 
negative correlation between AKT activation and USP8 levels respectively. 
These papers used a variety of ways to activate or inhibit the PI3K pathway 
or, indeed, inhibit AKT directly. In my experiments I found no evidence for 
changes in USP8 levels in response to EGF or NRG1 stimulation, nor upon 
PI3K nor AKT inhibition in HeLa or MCF7 cells, nor upon stable expression of 
constitutively active PI3K in MCF10A cells. I did not observe any obvious 
changes in USP8 distribution or co-localisation with EGFR, nor did I find any 
evidence for changes in USP8 activity, based on its ability to bind DUB-
activity probes.  
However, the ubiquitin-VME probe assay may not be suitable to pick up 
subtle changes in DUB activity. The probe relies on the availability of the 
active site, which in many but not all DUBs is readily accessible. One 
exception is USP7, which requires a ubiquitin binding mediated 
conformational change for its activation, which can be further stabilised by 
interaction with GMP-synthase. The conformational change brings the 
catalytic triad of USP7 into an organisation that allows its enzymatic activity 
(Faesen, Dirac et al. 2011).  
The crystal structure of an apo-form of USP8 has been solved which shows 
that this DUB has the correctly aligned organisation of the catalytic triad 
however there is a subdomain which seems to block access to this active site 
(Avvakumov, Walker et al. 2006). Thus in principle, it would be possible that 
phosphorylation for example by AKT could in principle assist the binding of 
ubiquitin to USP8. A ubiquitin bound form of the DUB is yet to be crystallised.  
However not all DUBs require conformational changes for their activity and 
therefore bind the probe with or without additional modifications (McGouran, 
Gaertner et al. 2013). As such this probe may be better able to detect DUB 
abundance rather than activity.  
Other assays that may be more informative are direct in vitro activity 
measurements using, for example, ubiquitin-AMC. Here a ubiquitin peptide is 
conjugated to a fluorophore which only fluoresces once the ubiquitin moiety 
has been cleaved off. Similarly mass spectrometry quantitation of conversion 
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of di-ubiquitin to mono-ubiquitin can be used to monitor DUB activity (Ritorto, 
Ewan et al. 2014).   
There is only one paper, which suggests USP8 is phosphorylated by AKT. 
Cao and colleagues found phosphorylation of mouse USP8 at Thr907, which 
fits within the AKT recognition sequence RXRXXS/T (although this is not the 
case for the equivalent residue in human USP8). This phosphorylation was 
seen upon NRG1 stimulation when both proteins were overexpressed in 
HEK293Ts. The levels of pThr on immunoprecipitated USP8 were increased 
in cells depleted of DGKδ (which leads to increased AKT activation) (Cao, 
Wu et al. 2007). 
In addition to the studies described above, a yeast two-hybrid screen from 
Hybrigenics suggests a direct interaction between USP8 and AKT (Daviet 
and Colland 2008). In addition to this, the same Cao et al. study described 
above showed co-immunoprecipitation of overexpressed USP8 and AKT in 
HEK293T cells.  I therefore undertook preliminary co-immunoprecipitation 
experiments using overexpressed GFP-USP8 and myc-AKT, which did not 
provide evidence for an interaction between USP8 and AKT.  
There are known ubiquitylation sites within the AKT protein. For example the 
E3 ligase TRAF-6 is believed to ubiquitylate AKT within its PH domain which 
is important for its subsequent activation and potentially its recruitment to the 
cell surface (Yang, Wang et al. 2009). Ubiquitylation of AKT by TRAF6 has 
been shown to be via K63-linked chains and its deubiquitylation has been 
assigned to the linear- and K63-chain specific CYLD (Lim, Jono et al. 2012). 
It is nevertheless conceivable that USP8 also contributes to AKT regulation 
rather than AKT modulating USP8 levels as proposed by the studies 
described above. 
In contrast to the negative results concerning effects of PI3K and AKT 
modulation on USP8 protein levels, I did find evidence for synthetic lethality 
combining PI3K pathway inhibition and USP8 depletion. Additionally, Cai et 
al. found that the NSCLC cell line H1650 has reduced cell viability when both 
USP8 and p-AKT levels are reduced by DGKδ depletion. Elsewhere in the 
literature there is evidence that USP8 depletion sensitises some cancer cell 
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lines to cell death (Byun, Lee et al. 2013). This will be discussed further in 
both chapters four and five. 
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Chapter four: The role of USP8 in non-
small cell lung cancer (NSCLC) cell 
viability 
In chapter three I discussed my work on the potential role for USP8 in EGFR 
family signalling through the PI3K pathway in cervical HeLa and breast MCF7 
cancer cells. In the meantime, a new study reported a role for USP8 
depletion or inhibition in controlling cell viability in gefitinib resistant EGFR 
mutant non-small cell lung cancer (NSCLC) cell lines (Byun, Lee et al. 2013).  
The cells under study were the NSCLC cell lines NCI-H1650 and NCI-H1975 
(hereafter referred to as H1650 and H1975 respectively) and they were 
compared to normal human bronchial cells and human lung fibroblasts. The 
authors monitored cell viability of USP8 depleted cells and cells treated with 
one of two EGFR inhibitors gefitinib or erlotinib using Giemsa staining. As 
expected, gefitinib resistant cells did not respond to the EGFR inhibitors, 
however depletion of USP8 for 72 hours markedly reduced cell viability. In 
contrast, the two normal lung cell lines showed reduced cell viability in 
response to EGFR inhibition but were insensitive to USP8 depletion.  
Comparison of the RTK phosphorylation profile of the USP8 depleted cells by 
RTK array identified a decrease in EGFR, ERBB2, ERBB3 and MET 
phosphorylation upon USP8 depletion. The authors found that this was due 
to a reduction in basal receptor levels as assessed by western blotting. Byun 
et al. further extended their work to the alleged USP8 inhibitor 9-
Ethyloxyimino-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile and found that 
H1650, H1975 and a number of both gefitinib resistant and sensitive NSCLC 
cell lines showed reduced viability in the presence of this inhibitor in contrast 
to normal human lung cells. The proposed USP8 inhibitor also caused a 
reduction in the levels of EGFR, ErbB2, ErbB3 and c-MET as well as 
phosphorylated forms of downstream effectors STAT3, ERK and AKT, which 
was not evident in cells treated with gefitinib. 
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Since I had previously been working on a link between USP8 and the PI3K 
pathway and had observed a synthetic effect on cell viability, I wanted to 
investigate the above findings by Byun et al. further. 
 
4.1 Objective 
In this chapter I set out to assess whether USP8 depletion and inhibition 
reduces cell viability by affecting RTK protein levels.  
 
4.2 Results 
 
4.2.1. siRNA-mediated depletion reveals two isoforms of USP8 
expressed in lung cancer cell lines 
First I set out to characterise our USP8 siRNA oligos in the two EGFR 
mutant, gefitinib resistant NSCLC lines described by Byun et al (Byun, Lee et 
al. 2013). These cell lines carry a point mutation or deletion respectively in 
EGFR that renders the kinase constitutively active (figure 4.1.A). In the case 
of the H1975 cells, a second mutation in the kinase domain of the receptor 
(T790M) renders the cells gefitinib resistant. In the H1650 cells a secondary, 
unknown mechanism is responsible for their resistance to gefitinib. The 
USP8 siRNA oligos I used are shown in figure 4.1.B and their recognition 
sequences are mapped to the domain structures of USP8 isoforms in figure 
4.1.C.  
USP8 depletion for 48 hours in both cell lines clearly showed that all oligos 
reduce USP8 protein levels efficiently (figure 4.1.D). However it became clear 
that USP8 separated by SDS-PAGE as a doublet (close up – figure 4.1.E). I 
found that some of the siRNA oligos depleted both bands of the USP8 
doublet. However the Qi3 and Qi4 siRNA mapped to a region unique to only 
the larger (figure 4.1.Ca) of the two known isoforms and consequently only 
depleted one band of the USP8 doublet. Interestingly the Dh1 oligo depletes 
both USP8 bands yet since it maps to the MIT domain which is missing from 
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USP8 siRNA oligo sequences (Dh2 is only used in chapter 5). (C) USP8 isoforms 
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isoform b (figure 4.1.Cb) one might expect only one band to be affected. For 
this reason I propose a third isoform that is missing the section recognised by 
the Qi3 and Qi4 oligos but retains the MIT domain (figure 4.1.Cc).  
 
4.2.2. The effect of USP8 depletion on RTK expression levels in H1975 
and H1650 lung cancer cells 
Once I had confirmed the effectiveness of the siRNA oligos I looked at the 
basal growth factor receptor expression levels in these two cell lines. The 
H1650 cells express slightly more EGFR and clearly more ERBB2 but 
considerably less ERBB3 and MET than the H1975 cells (figure 4.2.A). Given 
that USP8 is a long-lived protein with a reported half-life of over 80 hours I 
used a 120 hour knockdown protocol with reseeding between the two siRNA 
treatments (Schwanhausser, Busse et al. 2011).  
I used three different negative control siRNAs: non-targeting SiC and NT1 as 
well as an siRNA targeting another unrelated DUB, TRABID (TBD). As 
previously observed in a number of cell lines, USP8 depletion resulted in a 
loss of HRS protein in both H1650 and H1975 cells (figure 4.2.B) (Row, Prior 
et al. 2006). The ERBB3 levels in H1650 cells vary across conditions but the 
changes are not consistently associated with USP8 depletion. In fact I 
repeated this experiment five times with siRNA depletion time courses 
ranging from 72 to 120 hours and saw no consistent changes in ErbB3 levels 
upon USP8 depletion. The same is true for EGFR and MET protein levels, 
which are not consistently reduced in either cell line. One thing to note is that 
the Qi2 oligo dramatically reduced EGFR protein levels in both cell lines 
however I noticed that this oligo is highly toxic to the cells and thus this is 
most likely an off target effect. Although in this particular experiment it 
appears that EGFR levels are also more mildly reduced by the other USP8-
targeting siRNAs, this effect was not reproducible over the course of five 
experiments. 
99
42
42
42
116
116
116
158
158
USP8
HRS
Actin
Actin
Actin
ERBB3
EGFR
MET
siRNA: S
iC
Q
i1
Q
i2
D
h1
TB
D
N
T1
H1975
158
158
42
116
116
116
42
H1650
USP8
HRS
ERBB3
EGFR
(reprobed
after USP8)
Actin
MET
Actin
EGFR
ACTIN
ERBB2 ERBB3 MET
H
19
75
H
16
50
siRNA: S
iC
Q
i1
Q
i2
D
h1
TB
D
N
T1
A.
B.
H
19
75
H
16
50
H
19
75
H
16
50
H
19
75
H
16
50
158
42
Figure 4.2. Effect of USP8 depletion on RTK expression levels in H1975 
and H1650 lung cancer cells. (A) Western blot showing RTK levels in NP40
lysates dervied from H1975 and H1650 cell lines. (B) H1975 and H1650 cells 
were treated with siRNAs targeting USP8 (Qi1, Qi2, Dh1), Trabid (TBD) or non-
targeting siRNAs (SiC and NT1) for 120h. Blots are representative of five individual
experiments with depletion durations ranging from 72-150h (n=5). Cells were lysed 
in NP40 buffer and samples analysed by western blotting as indicated.The dotted 
lines separate western blots from distinct gels each with corresponding actin as
a loading control. 
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 4.2.3. USP8 inhibition does not consistently affect RTK or HRS levels in 
H1975 or H1650 cells  
As an alternate approach, I used a small selection of previously reported 
USP8 inhibitors in both H1650 and H1975 cells. I treated the two cell lines for 
18 hours with the inhibitors at the indicated concentrations (figure 4.3.A and 
figure 4.3.B represent two independent experiments).  
In H1975 cells EGFR expression levels were not markedly affected by the 
USP8 inhibitors in either experiment. In the H1650 cells, however, the two 
USP8 inhibitors in both experiments consistently reduced EGFR levels. The 
41108 inhibitor is marketed as a USP7 inhibitor however unpublished data 
from Forma Therapeutics suggested that this may also inhibit USP8 to some 
degree (figure 4.3.C). In both H1650 and H1975 cells this inhibitor increases 
the levels of EGFR. Neither did USP8 inhibition decrease HRS levels in the 
H1975 cells (figure 4.3.B). In the second experiment I also assessed the 
effect of these putative USP8 inhibitors on HRS. Neither inhibitor reproduced 
the effect of USP8 depletion as HRS protein levels were unaffected in both 
cell lines. The variation across all three putative USP8 inhibitors and the two 
individual experiments make this data hard to interpret and therefore 
inconclusive.  
In contrast, the validated USP7 inhibitor, P22077, consistently reduced 
EGFR protein levels in both cell lines. 
 
4.2.4. USP8 depletion decreases cell viability as assessed by crystal 
violet staining and cell counting 
As described above, Byun and colleagues reported that USP8 depletion 
reduced viability of H1650 and H1975 cells. Whilst the authors saw a striking 
effect by 48 hours of depletion, I only observed a mild reduction in cell 
viability after 72-96 hours. For this reason I first decided to assess cell 
viability in a semi-quantitative manner using crystal violet staining after long-
term USP8 depletion. Cells were treated for 120 hours with two hits of USP8 
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Figure 4.3. USP8 inhibition does not consistently affect RTK or HRS levels 
in H1975 or H1650 cells across two independent experiments. (A and B) 
H1975 and H1650 cells were treated with USP8 inihibitors (397 and 659 at 1µM 
or 2.5µM), USP7 inhibitors (P2207 at 50µM and 41108 at 1µM or 2.5µM) or DMSO. 
Lysates were separated by SDS-PAGE and probed for the indicated proteins. 
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relevant blot (n=2). (C) The inhibitors used and their IC50s for a range of targets. 
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targeting siRNA, fixed with methanol and stained with crystal violet followed 
by several washes with PBS (figure 4.4.A). The plates were then imaged 
using an Epson Perfection 3200 PhotoScanner (figure 4.4.B). Here, a slight 
reduction in cell viability is detectable when comparing the USP8 depleted 
H1975 cells to those treated with NT1 non-targeting control siRNA. This is 
particularly clear with the Qi2 oligo. This staining also highlights a mild effect 
of the SiC non-targeting control oligo compared to the NT1 siRNA. The effect 
on cell viability is dramatic in the H1650 cells with a clear reduction in cell 
viability across all three USP8 siRNA oligos compared to all three control 
siRNA oligos. In the same experiment, I also reseeded USP8-depleted cells 
48 hours after the first siRNA treatment into three separate six well plates at 
an equal density. I then used an automatic cell counter to count the cells at 
72 hours, 120 hours and 150 hours after the initial transfection (figure 4.4.C). 
In the H1975 cells a reduction in cell number is apparent with all three USP8 
targeting siRNAs when compared to NT1. In particular the Qi2 treated cells 
decline in number from the time of reseeding for the remainder of the 
experiment whereas the Qi1 and Dh1 treated cells begin to grow after 
reseeding before the effect on viability becomes apparent at 120 hours. The 
Dh1 treated cells exhibit the least growth inhibition of the three siRNA oligos.  
The effect is even more striking in the H1650 cells (figure 4.4.C). Here, the 
three USP8 siRNA treated wells exhibit either no change in cell number over 
the course of the experiment (Dh1, Q1) or a clear decline in cell number 
(Qi2). An effect on viability with the SiC control siRNA oligo is apparent. 
Figure 4.4.D shows an exact repeat of this experiment with the two cell lines. 
Comparing the three USP8 depleted samples to the NT1 control treated 
samples it is clear in both cell lines that viability is consistently reduced. 
Again, the Dh1 treated H1975 cells grow well at earlier time points before 
reaching a plateau at 120 hours. As seen above, the Qi2 siRNA reduces cell 
numbers drastically across the duration of the experiment indicating the 
potential for off target toxicity effects. In this case there is a clear effect on 
viability with the SiC control siRNA oligo in both cell lines confirming the 
notion that this control oligo exerts some toxicity on the cells. 
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Figure 4.4. USP8 depletion decreases cell viability as assessed by crystal
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 4.2.5. USP8 depletion in H1650 cells results in increased annexin V 
staining indicative of increased apoptosis  
The cell viability effect was most striking in the H1650 cells and therefore it 
made sense to focus on this cell line for follow up studies. In order to 
investigate whether this effect is caused by apoptotic cell death I used 
annexin V staining in live H1650 cells. I incubated cells depleted of USP8 for 
120 hours with annexin V-FITC for 20 minutes prior to imaging. In these 
experiments I replaced the non-targeting SiC oligo with an alternative control 
siRNA (NT3). In figure 4.5 it is clear that compared to the two non-targeting 
control siRNA (NT1, NT3) treated cells, the USP8 siRNA treated cells 
accumulate considerably more annexin V-FITC staining. This suggests that 
the effect USP8 depletion has on viability is at least in part due to an increase 
in apoptosis. 
 
4.3. Summary of results 
 Differential immunoblot banding patterns with a variety of USP8 siRNA 
oligos alludes to the existence of an as yet unreported USP8 isoform 
 There is no consistent effect of USP8 depletion on basal EGFR levels 
 Long-term USP8 depletion reduces cell viability in both H1650 and 
H1975 cells – an increase in apoptosis is reported in the H1650 cells 
 
4.4. Discussion 
The aim of this chapter was to explore and extend the findings by Byun and 
colleages describing the effect of USP8 depletion on cell viability and basal 
RTK levels in non-small lung cancer cells.  
The initial, unexpected finding was one alluding to the existence of a third, as 
yet unreported, isoform of USP8. Data from Ensembl describes three protein-
coding transcripts USP8_001, USP8_002 and USP8_003. Transcripts 001 
and 003 both encode the full length, 1118 amino acid, predicted 128kDa 
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Figure 4.5. USP8 depletion in H1650 cells results in increased annexin V
staining indicative of increased apoptosis. Cells were treated with USP8 
targeting (Qi1, Qi2, Dh1 or Dh2) or non-targeting (NT1 or NT3) siRNA for 120h 
using a two-hit protocol with reseeding at 48h following the first transfection.
The cells were then incubated with FITC conjugated annexin V (green) for 30min 
and imaged with a Nikon TiEclipse microscope (n=1). The scale bar is 400µm wide.
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protein CCCDS10137 (Uniprot reference: 40818-1). Transcript 002, however, 
encodes a shorter 1012 amino acid, predicted 115kDa protein CCCDS61632 
(Uniprot reference: 40818-2). The second isoform misses the amino acids 35 
to 111 corresponding to exons 2 and 3 which encodes most of the MIT 
domain (see figure 5.1.C) and amino acids 601 to 629 corresponding to exon 
11. When I mapped the sequence of our available siRNA oligos I found that 
the oligos Qi3, Qi4 and Dh1 would only target one of the two isoforms 
however the banding patterns seen by western blotting showed that the Dh1 
oligo depleted both bands of the observed doublet. This led me to propose a 
third USP8 isoform that retains exons 2 and 3, thus the MIT domain, but 
loses amino acids 601 to 629. This would have a predicted molecular weight 
of 124kDa. The presence of this isoform might simply be brought about by 
the loss of one exon, exon 11, by alternative splicing. I would need to use 
PCR primers specific for the proposed isoform to confirm this hypothesis by 
RT-PCR. If the second band is this proposed third isoform and not the known 
second isoform of USP8 it would indicate that either the antibody I used does 
not recognise this second isoform (which it should since the epitope is not 
within the MIT domain region – see figure 5.1.C) or that these cells do not 
express detectable levels of this second isoform.  
The most important finding I made was to confirm that USP8 depletion does 
indeed reduce cell viability in H1975 cells and most strikingly in the H1650 
cells. These are both gefitinib resistant EGFR mutant NSCLC cell lines 
however they do carry very different mutations in EGFR and in other 
proteins. In particular H1975 cells have an L858R and T790M mutation in 
EGFR and a G118D mutation in PI3K p110a whilst H1650 cells have a Δ746-
750 mutation in EGFR and a C1524R mutation in PI3K p110a (figure 4.1.A). 
In fact according to the Catalogue of Somatic Mutations in Cancer (COSMIC) 
the H1650 cells carry 227 known mutations and the H1975 cells carry 612.  
A key finding here is that in the H1650 cells the reduction in cell viability with 
USP8 depletion can at least partially be explained by an increase in 
apoptosis. This is supported in the literature in a number of ways. Firstly, 
Byun et al. and Jeong et al. show that both H1650 cells and gefitinib resistant 
HCC827GR cells exhibit increased apoptosis upon USP8 depletion or 
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inhibition respectively (Byun, Lee et al. 2013, Jeong, Lee et al. 2016). USP8 
has been linked to mediation of death receptor induced apoptosis through its 
regulation of FLIPL levels (Jeong, Lee et al. 2016). Here USP8 depletion 
prevents protection of FLIPL from ubiquitin-dependent proteasomal 
degradation and renders cells more susceptible to activation of the apoptotic 
pathway whilst USP8 overexpression enhances the stability of FLIPL. Thus 
USP8 was proposed to regulate the stability of this long form of FLIP but not 
the short form, FLIPS. Both the short and long forms of FLIP play a role in 
death receptor mediated, extrinsic, apoptosis. Typically, death receptors such 
as TRAIL recruit initiator caspases 8 and 10 and adaptors allowing the 
formation of the death inducing signalling complex (DISC) (Yang, Wilson et 
al. 2010, Safa 2013). Caspases 8 and 10 can activate downstream caspases 
and also feed into the intrinsic, mitochondrial apoptotic pathway through 
cleavage of the pro-apoptotic BCL2 family member, Bid. Truncated Bid 
triggers release of Cytochrome C from the mitochondria thus activating the 
intrinsic pathway (Safa 2013). 
Long and short forms of FLIP act against apoptosis through their binding with 
death receptors and inhibition of caspase 8 and 10 activation (Peter 2004, 
Safa 2013). Caspase 8 activation relies on the homodimerisation of pro-
caspase 8 and subsequent cleavage of the pro form (Lavrik and Krammer 
2012). FLIPL is structurally similar to and the same length as caspase 8 but is 
catalytically inactive and has been shown to inhibit caspase 8 activation 
(Peter 2004, Safa 2013). However FLIPL has also been shown to play a pro-
apoptotic role through caspase 8 activation via its heterodimerisation with 
pro-caspase 8 in some circumstances. In particular this might be dependent 
on the levels of FLIPs (Safa 2013). 
Importantly, Jeong and colleagues found that overexpression of FLIPL could 
rescue the effect of USP8 depletion on sensitivity to TRAIL. This suggests 
that maintenance of specific FLIPL levels, or perhaps the ratio of FLIPL to 
FLIPs, is required to suppress apoptosis. Whilst Jeong et al. found a role for 
USP8 in regulating FLIPL stability in a number of cancer cells routinely used 
in the lab, Panner et al. looked at glioblastoma multiforme primary cells and 
found a role for USP8 in the regulation of FLIPs stability (Panner, Crane et al. 
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2010). This, the authors reported, was due to regulation of USP8 by AKT 
which lead to the deubiquitylation of the FLIPs E3 ligase AIP4 and 
subsequent degradation of FLIPs. This could, in principle, make cells more 
sensitive to death receptor mediated apoptosis although the authors did not 
directly show this with their data. Importantly, in both studies USP8 was 
proposed to increase the ratio of FLIPL to FLIPs. 
It is also possible that USP8 depletion leads to a defect in cell proliferation. 
Immortalised MEFs from inducible USP8-knockout mice showed growth 
arrest once USP8 depletion was induced (Niendorf, Oksche et al. 2007). This 
was evidenced in both a reduction in cell number and a reduction in 
bromodeoxyuridine incorporation into replicating DNA which indicates cell 
proliferation. USP8 activity has also been linked to this DNA synthesis phase 
(S-phase) of the cell cycle. USP8 phosphoryation was reported to inhibit DUB 
activity through 14-3-3 protein binding to p-S680-USP8. Dephosphorylation 
and dissociation from 14-3-3 in the S-phase enhanced USP8 activity 
(Mizuno, Kitamura et al. 2007). Naviglio et al. reported that USP8 inhibition 
through microinjection of fibroblasts with an anti-sense plasmid blocked cells 
from entering S-phase (Naviglio, Mattecucci et al. 1998). Conversely, recent 
studies have linked USP8 expression to the levels of a member of the 
inhibitor of apoptosis protein (IAP) family, BRUCE (Sippel, Rajala et al. 2009, 
Ge, Che et al. 2015, Ge, Che et al. 2015). In neural progenitor cells, 
treatment with a synthetic growth hormone dexamethasone led to an 
increase in USP8 levels and subsequent destabilisation of BRUCE through 
the stabilisation of E3 ligase Nrdp1 by USP8 (Sippel, Rajala et al. 2009). This 
promoted the proliferation of these neural progenitor cells. Other studies link 
USP8 and BRUCE via their joint recruitment to double strand breaks (Ge, 
Che et al. 2015, Ge, Che et al. 2015). 
The effect of USP8 depletion on H1650 cell viability reported in this chapter is 
evident only after a prolonged knockdown protocol. However, in chapter 
three I described a synthetic lethal effect between PI3K pathway inhibition 
and USP8 depletion in FKHRL1-U2OS, U2OS and H1975 cells. Of course if 
there is a link between USP8 and the PI3K pathway as my data in chapter 3 
suggested then it may make sense that disruption of USP8 could lead to 
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increased cell death since the AKT-PI3K pathway is a known regulator of 
apoptosis. However my data in chapter three showed that, at least in 
FKHRL1-U2OS, U2OS, H1975 and to some degree H1650 cells, there is a 
requirement for simultaneous depletion of USP8 and inhibition of the PI3K 
pathway to stimulate this cell death.  
Synthetic lethality is an effect in which combining two or more non-lethal 
mutations results in cell death. This terminology is also used to describe 
synthetic effects observed due to simultaneous loss of function induced by 
RNAi or drug inhibition. This may be of particular therapeutic benefit as 
cancer cells with acquired mutations in particular pathways might 
subsequently be sensitised to drugs inhibiting other pathways. As such, 
synthetic lethality screens are now used in order to identify potential 
therapeutic targets in cancer cells. One example of success in this area 
comes from the use of PARP inhibitors in BRCA mutant breast cancers. In 
this case the homozygous loss of BRCA sensitises cells to PARP inhibition 
(Farmer, McCabe et al. 2005). 
To fully explain the reason for USP8 depletion induced cell death requires 
further research, which I begin to explore in chapter five. 
Importantly, I was unable to confirm any significant and specific changes in 
growth factor receptor levels upon USP8 depletion alone. USP8 is a 
deubiquitylase that regulates the levels of a number of growth factor 
receptors. This is best characterised for EGFR and specifically observed 
following acute EGF stimulation. USP8 depletion in HeLa cells severely 
delays the downregulation of EGFR and MET in response to their respective 
ligands (Row, Prior et al. 2006, Row, Liu et al. 2007). USP8 overexpression 
stabilises the levels of the E3 ligase Nrdp1 which itself regulates ERBB3 
levels (Wu, Yen et al. 2004, Cao, Wu et al. 2007). It would be of interest to 
perform a time course stimulation of the H1975 and H1650 cell lines with 
EGF, NRG1 or HGF and see how the receptor levels respond with and 
without USP8 depletion. There is evidence from USP8 knockout mice that 
points to a reduction in global basal EGFR levels with removal of this DUB. 
This may suggest that complete ablation of the protein is required to see this 
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effect on basal growth factor levels as RNAi may not remove the protein 
entirely. With the advent of CRISPR technology, future work may elucidate 
this further as complete knockout cell lines can be produced.  
One might also study this further using USP8 inhibitors however current 
commercially available USP8 inhibitors are not truly specific for USP8. For 
example, the USP8 inhibitors I used above also inhibit USP7, USP5, UCHL1 
and UCHL3 (Colombo, Vallese et al. 2010, Ritorto, Ewan et al. 2014). In 
particular, many USP inhibitors target the catalytic cysteine of DUBs and are 
thus unable to discriminate between different members of the family. 
Matthias Trost and colleagues analysed DUB activity using a MALDI-TOF 
based mass spectrometry technique. They considered 11 DUB inhibitors and 
found that none of the compounds, including one for USP8 and the 
USP7/USP8 41108 inhibitor used in this chapter, were specific for only a 
single DUB and many inhibited the majority of DUBs in their panel (Ritorto, 
Ewan et al. 2014).  
The findings in this chapter led me to conclude that there may be another 
reason for the effect of USP8 depletion on cell viability. Conversation with the 
biopharmaceutical company, Amgen suggested a new avenue to follow up in 
this vein, which I discuss in chapter five.   
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Chapter five: The role of USP8 in the 
regulation of ROS management and 
cell death 
In March 2015, Olivier P. Nolan-Stevaux PhD, a Senior Scientist in the 
Department of Oncology at the biopharmaceutical company Amgen Inc., 
contacted us to discuss preliminary data concerning cell viability effects they 
observed upon USP8 depletion. Their findings, described below, spoke to my 
own findings described in chapter four. 
Initially Amgen screened 53 cell lines by RNA interference with three 
genomic siRNA libraries looking for effects on cell viability. They identified 
three cell lines that showed sensitivity to both USP8 and HRS depletion; 
breast cancer cells HCC1954 and HCC70 and primitive neuro-ectodermal 
tumour cells PFSK1. HRS sensitivity is of interest here since it is a core 
component of the ESCRT-0 complex that USP8 interacts with as part of its 
function in endocytic trafficking. Importantly, depletion of USP8 has been 
shown to reduce HRS levels in a number of cell lines thus sensitivity to both 
USP8 and HRS increases the confidence in these observations (Row, Prior 
et al. 2006) (see also chapter four, figure 4.2). Amgen further validated this 
sensitivity to USP8 depletion in the two breast cancer cell lines HCC1954 
and HCC70. They went on to show that both lines were also sensitive to 
depletion of TSG101 and PTPN23, two further ESCRT components of the 
multi-vesicular body (MVB) sorting pathway. This finding further supports a 
requirement for endocytic trafficking for viability of these cells. 
Comparison of the RNA expression profiles of the three identified cell lines 
initially led Amgen to identify the squamous cell carcinoma (SQCC) marker 
Serpin B3 as a potential common denominator even though these cell lines 
did not belong to the SQCC type. These three cell lines expressed more of 
this marker than any of the other 50 cell lines tested in the initial screen. 
Amgen followed this finding up by analysing other cell lines of the SQCC type 
and identified a further two cell lines with USP8, TSG101 and PTPN23 
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sensitivity. However, these were Serpin B3 negative lung SQCC cell lines 
CALU1 and EBC1. At this stage it became clear that Serpin B3 expression is 
not a universal marker for USP8 sensitivity. 
In a further attempt to identify any common mutations between USP8 
dependent cell lines, Amgen performed an unbiased association study 
across the entire pool of cell lines they had previously studied. They found 
that two of the USP8-dependent cell lines (CALU1 and EBC1) had a mutation 
in the NFE2L2 gene and two cell lines (PFSK1 and HCC70) had a mutation 
in the NFE2L3 gene. One USP8-independent cell line (LK2) also had a 
mutation in NFE2L2. 
As discussed in the introduction, the protein product of NFE2L2 is NRF2. 
NRF2 is a protein involved in the ability of the cell to respond to reactive 
oxygen species (ROS) and mismanagement of this system can lead to a 
decrease in cell viability. With this in mind it was a logical step to further 
investigate a link between USP8 sensitivity and NRF2. 
 
5.1. Objective 
In this chapter, my main objective was to establish if there is a link between 
USP8 and the NRF2/KEAP1 pathway as suggested by the data from Amgen 
described above. I also intended to explore a functional role of the 
NRF2/KEAP1 pathway in the reduced cell viability observed in USP8 
depleted cells.  
 
5.2. Results 
 
5.2.1. Testing the specificity of different NRF2 and KEAP1 antibodies by 
western blotting and by RNA interference 
Whilst reviewing the literature I came across a common problem with western 
blot analysis of NRF2. Whilst the predicted molecular weight of this protein is 
approximately 70kDa, studies in the literature consistently show it running at 
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Figure 5.1. Testing the specificity of NRF2
and KEAP1 antibodies by western blotting 
as tested by RNAi. (A) The 72h knockdown
protocol with siRNA-transfection on day 1 (D1) 
and lysis on day 4 (D4). (B) H1650 cells were 
depleted with NRF2 siRNA or non-targeting 
controls (NT1, NT3) for 72h and probed for 
NRF2 or KEAP1 with abcam or protein-tech 
antibodies as indicated  (n=1). (C) H1650 cells 
were depleted with KEAP1, NRF2 or USP8 
siRNA for 72h and probed for KEAP1 (abcam), 
NRF2 (abcam) or USP8 as indicated (n=1). 
Actin was used as a loading control. A putative 
KEAP1 dimer (KEAP1*) is indicated by an 
asterisk in B and C.
KEAP1*
KEAP1*
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around 100kDa on western blots. In order to verify the behaviour of NRF2 
and its inhibitor, KEAP1, on my gels I decided to first test two independent 
antibodies against each protein. Furthermore I used RNA interference in 
H1650 cells against each protein to identify specific and non-specific bands. 
Figure 5.1.A introduces the RNA interference protocol. H1650 cells were 
treated with siRNA against NRF2, KEAP1, USP8 or non-targeting controls 
(NT1 or NT3) the day after seeding. The cells were lysed in NP40 buffer 72 
hours after the transfection.  
H1650 cells express wild-type NRF2, however their sensitivity to USP8 
depletion makes them an interesting point of study in the first instance. In 
figure 5.1.B it is clear that NRF2 depletion removed a band running between 
the 66 and 97 kDa marker that was recognised by both NRF2 antibodies. 
Although other studies find this band running a little higher, this finding 
suggests that in 4-12% NuPAGE gradient gels with MOPS-based running 
buffer, the protein runs at its predicted molecular weight. NRF2 depletion also 
decreased KEAP1 levels as detected with both KEAP1 antibodies (figure 
5.1.B). The predicted molecular weight of KEAP1 is also 70kDa but on these 
gels it runs just under the 66kDa marker. In this panel I also identified a 
second KEAP1 band just under the 158kDa marker that followed the same 
pattern as the major KEAP1 band. This leads me to suggest that this may 
correspond to a dimeric form of KEAP1.  
In order to test the KEAP1 antibodies, I depleted KEAP1 using a pool of four 
siRNA oligos (Figure 5.1.C.) This led to a marked reduction of both afore-
mentioned bands confirming that these are specific for KEAP1.  
Concurrently, I treated cells with siRNA oligos targeting NRF2 and 
reconfirmed the reduction in KEAP1 levels with NRF2 knockdown. KEAP1 is 
a known transcriptional target of NRF2 acting as a negative feedback 
regulator of the transcription factor thus it makes sense that depletion of 
NRF2 reduces KEAP1 levels (Chorley, Campbell et al. 2012). Finally, I also 
treated cells with two individual USP8-targeting siRNA oligos. This revealed a 
clear decrease in KEAP1 levels in cells depleted of USP8. 
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5.2.2. USP8 knockdown results in a decrease in KEAP1 protein levels in 
H1650 cells 
In order to further investigate the reduction in KEAP1 protein levels upon 
USP8 depletion I subjected the same NSCLC H1650 cells to a longer RNA 
interference protocol (figure 5.2.A). Cells were treated twice over 120 hours 
with siRNA using a two hit protocol and were reseeded between the hits on 
day three. Using three independent USP8 oligos – Qi1, Dh1 and Dh2 – I 
observed a reduction in KEAP1 levels with two different KEAP1 antibodies 
that was apparent for both the major KEAP1 band and the higher molecular 
weight band (figure 5.2.B).  
Whilst this reduction in KEAP1 levels could suggest KEAP1 may be 
stabilised by USP8, it could, in principle, also indicate a redistribution of the 
protein.  In order to ensure that I had solubilised all proteins, I compared my 
standard NP40 lysis protocol to RIPA lysis in figure 5.2.C. Lysis with RIPA 
buffer, which contains SDS, sodium deoxycholate and triton X-100 allows for 
extraction of nuclear as well as cytosolic proteins. The presence of ionic 
detergent in RIPA buffer allows better solubilisation of proteins and the 
disruption of non-covalent bonds. NP40 buffer, however, relies on the 
gentler, non-ionic detergent Nonidet P-40 which is non-denaturing. I found a 
similar reduction in KEAP1 levels upon USP8 depletion using the RIPA lysis 
protocol. Interestingly, the RIPA lysis also highlighted an increase in NRF2 
levels. This may indicate an increase in the nuclear pool of NRF2 as a result 
of USP8 depletion and subsequent KEAP1 reduction. Figure 5.2.D shows a 
quantitation of several 120 hour USP8 depletion experiments all using the 
NP40 lysis buffer protocol confirming the reduction in KEAP1 protein levels. 
Error bars indicating standard deviation are shown where the number of 
experiments exceeded three.  
 
5.2.3. USP8 depletion in EBC1 cells reduces KEAP1 protein levels  
As discussed above, Amgen found that EBC1 cells are sensitive to USP8 
depletion. These cells have a heterozygous D77V mutation in NRF2, which 
prevents KEAP1 from coupling to the protein. I first performed a 96 hour 
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Figure 5.2. USP8 depletion decreases KEAP1 protein levels in H1650 cells.
(A) The 120h protocol entails knockdown (KD) on days 1 (D1) and 4 (D4), re-
seeding on day 3 (D3) and lysis on day 6 (D6). (B) H1650 cells depleted with 
USP8 siRNA for 120h were lysed with NP40 lysis buffer (n=4). Proteins were 
separated by SDS-PAGE then blotted with the indicated abcam/protein tech 
antibodies. Actin was used as a loading control for each of the blots divided by 
the dotted line. (C) H1650 cells depleted with USP8 siRNA for 120h were lysed 
with NP40 (n=4) or RIPA buffer (n=1), separated by SDS-PAGE and blotted with 
the indicated antibodies. (D) Quantitation of KEAP1 and NRF2 protein levels from 
several independent experiments using the protocol shown in A. Relative protein 
levels are expressed as a percentage of those seen in cells targeted with control 
siRNA (NT1). Error bars show standard deviation for Dh1 (n=4) and Dh2 (n=3), 
range for Qi2 (n=2), NT1 set at 100% (n=4).
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knockdown in the EBC1 cells (figure 5.3.A). I found that KEAP1 levels were 
indeed reduced upon USP8 depletion. Since this was the first time I had 
depleted USP8 in this cell line I also analysed the levels of HRS (figure 
5.3.A). HRS levels were also reduced in USP8-depleted EBC1 cells just as I 
previously observed in H1650 and H1975 cells (chapter 4 figure 4.2). USP8 
is a long-lived protein with an 80 hour half-life and a 120h knockdown 
protocol tends to result in a better knockdown (see chapter four, figure 4.2; 
(Schwanhausser, Busse et al. 2011)). Therefore I performed the longer, two 
hit protocol as described in figure 5.3.2. This gave a very good USP8 
depletion in these cells and further confirmed the reduction in KEAP1 in cells 
lysed with NP40 buffer (figure 5.3.B).  
In this experiment I also depleted the cells of HRS since Amgen had found 
that these cells are sensitive to knockdown of HRS as well. Here I found a 
similar reduction in KEAP1 levels as with the USP8 depletion. I further 
validated the specificity of the antibody in these cells by KEAP1 siRNA. 
In addition to the KEAP1 reduction in figure 5.3.B, I also identified a mild 
increase in NRF2 levels upon USP8 and HRS depletion that is only evident in 
this longer knockdown experiment and mirrors my observation in RIPA 
extracted H1650 lysates (see figure 5.2). 
 
5.2.4. HRS depletion and its effect on KEAP1 protein levels in H1650 
and EBC1 cells  
Following up on the finding that HRS depletion caused a decrease in KEAP1 
protein levels, I depleted it in both H1650 (figure 5.4.A) and EBC1 (figure 
5.4.B) cells using the same 120h knockdown protocol as described above 
(figure 5.4.C). It is evident that HRS depletion reduced KEAP1 levels to a 
similar level as USP8 depletion in both cell lines. The high molecular weight, 
putative dimeric band for KEAP1 is clearly evident, albeit only in H1650 cells. 
This band is decreased to the same degree in both USP8 and HRS depleted 
cells (figure 5.4.A). In both cell lines I found an increase in NRF2 levels upon 
USP8 and HRS depletion although this is most striking in the EBC1 cells. 
Note that all these lysates were prepared using NP40 lysis buffer. 
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Figure 5.3. Deacreased KEAP1 protein levels in USP8-depleted EBC1 cells.
(A) EBC1 cells treated with USP8 siRNA (Qi1, Dh1, Dh2) for 96h were lysed
with NP40 lysis buffer, separated by SDS-PAGE and blotted with the indicated 
antibodies (n=1). Actin represents loading for the above immuno-blots. Bar chart 
shows corresponding quantitation of relative NRF2 and KEAP1 protein levels. 
Schematic shows protocol with knockdown on day 1 (D1) and lysis on day 5 (D5). 
(B) EBC1 cells treated with USP8 siRNA (Qi1, Dh1, Dh2) for 120h were lysed with 
NP40 buffer, separated by SDS-PAGE and blotted with the indicated antibodies 
(n=1). Actin represents loading for the above immuno-blots. Bar chart shows 
corresponding quantitation of relative NRF2 and KEAP1 protein levels. Schematic 
shows protocol with knockdowns on day 1 (D1) and day 4 (D4), reseeding on day 
3 (D3) and lysis on day 6 (D6).
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Figure 5.4. HRS depletion and its effect on KEAP1 and NRF2 protein levels 
in H1650 and EBC1 cells. (A and B) H1650 cells (A) or EBC1 cells (B) were 
treated with USP8 or HRS siRNA for 120h, lysed with NP40 buffer and separated 
by SDS-PAGE. Blots were probed with the indicated antibodies and protein levels
quantitated as indicated (n=1 for each cell line). Actin represents loading for each 
of the above immuno-blots (C) The 120h protocol involves a knockdown on days 1
(D1) and 4 (D4), reseeding on day 3 (D3) and lysis on day 6 (D6). KEAP* indicates 
the putative KEAP1 dimer.
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 5.2.5. KEAP1 mRNA levels do not change upon USP8 depletion 
The levels of a particular protein in a cell are dependent on the balance 
between the rate of protein synthesis and the rate of protein degradation. 
Changes in KEAP1 protein levels following USP8 depletion could indicate 
changes in protein stability, especially since USP8 is a DUB, and thus may 
rescue proteins from degradation. However, the rate of protein synthesis 
could alternatively be affected. In order to test this, I used quantitative qRT-
PCR to analyse the levels of KEAP1 mRNA. Figure 5.5.A shows that KEAP1 
mRNA levels are clearly decreased by KEAP1- but not USP8- or HRS- 
targeting siRNA in EBC1 cells. If anything there is a trend towards an 
increase in KEAP1 mRNA upon USP8 and HRS depletion. Likewise in 
H1650 cells, USP8 and HRS depletion do not affect KEAP1 mRNA (figure 
5.5.B). In contrast NRF2 siRNA does have a mild effect, in keeping with the 
above mentioned transcriptional regulation of KEAP1 by NRF1.  
 
5.2.6. USP8 depleted H1650 cell viability is not rescued by treatment 
with the ROS scavenger N-acetyl cysteine 
In addition to understanding the mechanism by which KEAP1 may be 
decreased upon USP8 depletion, I also wanted to find out whether the effect 
of USP8 depletion on cell viability might be linked to changes in NRF2 or 
KEAP1. Cells with a deregulated ROS management pathway may be less 
able to handle this stress and therefore undergo cell death more readily. 
This leads to the following question: do cells depleted of USP8 have an 
impaired ability to handle basal ROS levels and could this contribute to the 
effects on cell viability? If this were the case, one would expect that ROS 
scavengers such as N-acetyl cysteine (NAC) may rescue the reduced cell 
viability triggered by USP8 depletion. 
I tested this theory by treating USP8 depleted cells with NAC (figure 5.6.A). 
The literature reports that NAC may be toxic to cells over long time periods. 
For this reason I added the NAC for only the last 36 hours of the 120 hour 
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Figure 5.5. KEAP1 mRNA levels do not change with USP8 depletion. (A)
Experimental procedure with RNAi KD on day 1 (D1) and day 4 (D4) and 
re-seeding on day 3 (D3) (B) EBC-1 cells were depleted of USP8, HRS or 
KEAP1 for 120h. RNA extraction and reverse transcription preceded qPCR 
with KEAP1 specific primers (n=1). (C) H1650 cells were depleted of USP8, 
HRS or NRF2 for 120h. RNA extraction and reverse transcription preceded 
qPCR with KEAP1 specific primers (n=1). 
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Figure 5.6. USP8 depleted H1650 cell viability is not rescued by treatment
with the ROS scavenger N-acetyl cysteine. USP8 depleted cells were treated
with the ROS scavenger N-acetyl cysteine (NAC) at a concentration of 10mM 
according to the protocol time-line indicated. Cells were fixed and stained with 
crystal violet to identify and changes in cell viability. Cells of two independent 
experiments were counted following 120h or 96h depletion (A and B respectively).
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RNAi protocol. The cells were reseeded the day before this treatment and 
either fixed with methanol prior to crystal violet staining or counted with an 
automatic cell counter after 120 hours of RNAi.  
In USP8 depleted H1650 cells that were not treated with NAC the reduction 
in cell viability is striking with both crystal violet staining and cell counting. It is 
also clear from the NT1 treated control cells that there is little, if any, 
additional cell death with NAC treatment. This allays the fears about toxicity. 
However, the addition of NAC to USP8 depleted cells does not rescue the 
cell number as assessed either by crystal violet staining or cell counting.  
In this experiment the cells were depleted of USP8 for a long time and the 
cells were subjected to considerable stress with reseeding in between the 
two siRNA treatments. In figure 5.5.B I mitigated this by ending the 
experiment 24 hours earlier, 96 hours after knockdown, avoiding the need for 
reseeding and a second siRNA hit. In this case, the effect of USP8 depletion 
on cell viability is less striking with crystal violet staining, although still evident 
with cell counting. Also with this protocol I was unable to detect any rescue of 
cell viability in NAC-treated cells.  
 
5.2.7. H1650 cells are sensitised to ROS induction as assessed by live 
cell imaging 
I next asked the question whether USP8 depleted cells are more sensitive to 
ROS. To answer this, I used the ROS inducer tert-butyl hydroperoxide 
(tBHP). When designing this experiment I applied a shorter RNAi protocol. A 
72 hour protocol gives sufficient USP8 depletion, as evidenced in figure 
5.1.C. However, from my own observations in handling the H1650 cells – the 
effects on cell viability become most evident at 96 hours. By selecting this 
shorter protocol I could preclude cell death from USP8 depletion itself and 
focus on any sensitisation to cell death provoked by the ROS inducer. In 
figure 5.7 the control cells were loaded with FITC-annexin V after 72 hours of 
USP8 depletion and, though only a single time point is presented here, the 
cells were imaged every hour by live-cell imaging. Here any cell death due to 
USP8 depletion is negligible. Conversely with a 6 hour tBHP treatment there 
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Figure 5.7. USP8 depleted H1650 cells are sensitised to ROS induction. H1650
cells were treated with siUSP8 or control oligos (NT1, NT3) for 72h prior to addition
of 100µM tert-butyle hydroperoxide (tBHP) or H2O vehicle (control). The cells were 
pre-loaded with FITC-annexin V for 30min. Cells were imaged using a Nikon 
TiEclipse (20x objective) hourly and the 6h time-point is presented here (n=1). The 
scale bar is 400µm in width.
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is a prominent increase in annexin V staining in siUSP8, but not siNT1 
treated cells. This indicates that H1650 cells depleted of USP8 are more 
sensitive to ROS than control cells.  
 
5.2.8. USP8 depleted cells are sensitised to ROS induction as assessed 
by FACS analysis 
Investigating this sensitisation to ROS in a more quantitative fashion, I used 
FACS analysis with propidium iodide (PI) and FITC-annexin V staining 
following USP8 depletion and subsequent tBHP treatment. H1650 cells 
depleted for 72 hours of USP8 were treated with tBHP or vehicle control 
(H2O) for 6 or 24 hours (as shown in protocol 5.8.A and figure 5.8.B.) and 
10,000 events were measured for each condition as illustrated in the gated 
plots for the Qi1 oligo. The proportion of total cells stained either with PI or 
annexin V is presented. Here, despite some slight variation across the NT1 
controls for each of the three conditions there is a clear and striking effect 
following 24 hours of tBHP treatment. The fold increase in cell death with 
tBHP in combination with USP8 depletion ranges from approximately 3-fold 
(with the Dh1 siRNA) to approximately 7-fold (with the Dh2 siRNA). I 
repeated the same experiment focusing on only the 24 hour time point (figure 
5.8.C). Here I also included an HRS depleted and a KEAP1 depleted sample.  
It is important to note the differences in scale between figure 5.8.B and 5.8.C. 
Whilst the largest percentage of cell death in panel B was a little over 70%, in 
panel C it was just below 20%. Part of this may be due to variations in 
seeding density as higher cell confluency appears to confer some level of 
protection to these cells. Despite this, there is still an evident increase in cell 
death when combining tBHP and both the Qi1 and Dh2 siRNA with a 
maximum fold increase of over 7-fold. As with figure 5.8.B the least striking 
effect is seen when combining tBHP with the Dh1 oligo. Whilst there is a 
slight increase in cell death combining tBHP with HRS depletion, the 
proportion is too small to draw any definitive conclusions from this single 
experiment. It may be difficult to see increases in cell death as HRS depletion 
is generally very inefficient unless the knockdown is conducted for longer 
than 96 hours. Note that the half-life of HRS is 41 hours (Schwanhausser, 
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Figure 5.8. USP8 depleted H1650 cells are sensitised to ROS induction. (A)
Experimental procedure with RNAi KD on day 1 (D1) and tBHP treatment on day 
4 (D4). (B) USP8 depleted cells were treated with tBHP for the indicated times. 
Cells were trypsinised, stained with PI and FITC-annexin V prior to FACS analysis. 
(C) USP8 depleted cells were treated with tBHP for 24h, trypsinised, stained with 
PI and FITC-annexin V then analysed by FACS. (A) and (B) constitute two 
independent experiments (n=2).
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Busse et al. 2011). Disappointingly, there is no evidence of increased cell 
death upon KEAP1-depletion indicating that the effect of USP8-depletion on 
cell viability is likely not due to the reduction of KEAP1 (figure 5.8.B). 
 
5.2.9. USP8 depleted EBC1 cells are not sensitised to ROS induction as 
assessed by live-cell imaging  
Next I carried out the same tBHP live-cell imaging experiment as in figure 5.7 
this time focusing on EBC1 cells (figure 5.9). As described above I depleted 
the cells of USP8 or HRS or KEAP1 for 72 hours before the addition of the 
ROS inducer. The cells were incubated with FITC-annexin V and imaged 
once per hour to monitor apoptosis. One time point is presented in figure 5.9. 
It is clear that there is no increase in cell death upon short-term treatment 
with siRNAs targeting USP8, HRS or KEAP1 and that viability is not 
differentially affected by the addition of tBHP for 6 hours. This suggests 
EBC1 cells are not sensitised to ROS induced cell death by short-term 
depletion of USP8, HRS or KEAP1. 
 
5.2.10. USP8 depleted EBC1 cells are not sensitised to ROS induction 
as assessed by FACS analysis 
To confirm this in a more quantitative manner I employed FACS analysis with 
PI and annexin V staining in the EBC1 cells. The cells were treated with 
tBHP for 24 hours before staining with the two dyes and the proportion of 
total cells stained with either marker of cell death presented in figure 5.10. 
Whilst there is a low level of cell death in the cells depleted of USP8, HRS or 
KEAP1 compared to the control targeted cells, this is not increased with 
tBHP treatment. This confirms that EBC1 cells are not sensitised to ROS 
induction by depletion of these proteins.  The gated plots in figure 5.10.C 
show the increase of events detected in the upper right quadrant (PI/FITC 
stained) with USP8 depletion when compared to NT1 in both control and 
tBHP treated cells.  
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Figure 5.9. USP8 depleted EBC1 cells are not sensitised to ROS induction.
EBC1 cells were treated with USP8, control (NT1), HRS or KEAP1 siRNA oligos 
for 72h prior to additionof 100µM tert-butyle hydroperoxide (tBHP) or control (n=1). 
The cells were pre-loaded with FITC-annexin V for 30min. Cells were imaged using 
a Nikon TiEclipse hourly and the 6h time-point presented here.
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 5.3. Summary of results 
 Depletion of USP8 or HRS reduces KEAP1 protein levels in two cell 
lines with reported sensitivity to USP8 depletion from two different 
cancer backgrounds (NSCLC and SQCC) 
 Reduction in KEAP1 protein levels was not due to a decrease in 
KEAP1 mRNA levels 
 The cell viability defect caused by USP8 depletion in H1650 cells 
(described in chapter four) was not rescued by treatment with a ROS 
scavenger 
 USP8-depleted H1650, but not EBC1, cells were sensitised to ROS 
induction  
 
5.4. Discussion 
In this chapter the chief aim was to investigate a suggested link between 
USP8 and HRS depletion and the NRF2/KEAP1 pathway. Data from Amgen 
provided evidence that some cell lines with sensitivity to USP8 depletion 
carried mutations in NRF2 preventing its interaction with and regulation by its 
inhibitor, KEAP1. This led us to investigate the ability of USP8-depleted cells 
to manage ROS levels within the cell and the levels of both NRF2 and 
KEAP1. 
 
5.4.1. USP8 and KEAP1 
I showed above that USP8 depletion has apparent and consistent effects on 
KEAP1 protein levels within both the NSCLC H1650 and the SQCC EBC1 
cells. I have shown that this is not due to a change in gene expression as the 
mRNA levels remain unchanged thus indicating either a change in protein 
stability or a change in translation of the protein. One question remaining is 
how USP8-depletion brings about this reduction in KEAP1 levels. USP8 is a 
DUB that regulates the levels of a number of proteins including STAM and 
several membrane spanning receptors such as EGFR and Smoothened 
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(Row, Prior et al. 2006, Alwan and van Leeuwen 2007, Xia, Jia et al. 2012). It 
is thus conceivable that changes in KEAP1 levels in response to USP8 
depletion are due to changes in the protein’s stability. A simple way to assess 
this would be to perform a cycloheximide chase experiment under USP8 
depletion conditions to identify changes in protein turnover. Additionally, 
lysosomal and proteasomal inhibitors could be employed to see whether 
these can rescue KEAP1 protein levels.  
Whilst KEAP1 is cytosolic, its levels can be regulated by autophagy. KEAP1 
has been shown to interact with the selective autophagy receptor, p62. 
Selective autophagy of protein aggregates is known as aggrephagy 
(Svenning and Johansen 2013). p62 is recruited to ubiquitylated protein 
aggregates via its ability to interact with ubiquitin. It then recruits the 
autophagic machinery through its LC3 interacting region (LIR) allowing 
protein aggregates to be enveloped by the autophagosome (Katsuragi, 
Ichimura et al. 2015). The autophagosome ultimately fuses with the lysosome 
forming the autolysosome where its contents are degraded. KEAP1 has been 
linked to this pathway through an interaction between the DGR of KEAP1 
and the STGE motif within the KEAP1 interacting region (KIR) of p62 
(Komatsu, Kurokawa et al. 2010). This interaction is facilitated by 
phosphorylation of aggregated p62 by mTORC1 and subsequently allows 
release and activation of NRF2 (Komatsu, Kurokawa et al. 2010, Ichimura, 
Waguri et al. 2013). Preliminary experiments undertaken by Amgen show 
that USP8-depleted U2OS cells stably expressing GFP-p62, accumulate p62 
positive punctae or aggregates upon USP8 depletion. Thus it is possible that 
USP8 depletion enhances the formation of p62-positive aggregates that may 
sequester KEAP1 into autophagosomes.  
In line with this, a recent study reported that USP8 depletion by dsRNA in 
Drosophila increased basal autophagy identified by an accumulation of GFP-
LC3B positive dots (Jacomin, Bescond et al. 2015). However the authors 
went on to show that USP8 depletion caused a block in autophagic flux since 
the accumulation of autophagosomes was not accompanied by an increase 
in the number of autolysosomes. In addition, large perinuclear lysosomes 
were lost in USP8-depleted cells whilst smaller vesicles were retained 
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(Jacomin, Bescond et al. 2015). The authors suggested that these vesicles 
may correspond to vesicles transporting lysosomal enzymes from the 
biosynthetic pathway. In fact, USP8 depletion in HeLa cells had previously 
been shown to prevent recycling of the mannose 6 phosphate receptor 
(M6PR) back from endosomes to the TGN (MacDonald, Urbe et al. 2014). As 
a result newly synthesized lysosomal enzymes (Cathepsin D) failed to be 
delivered to the lysosome and instead were found to be secreted in the 
medium. Over a long period this may result in the accumulation of non-
functional lysosomes that are depleted of lysosomal enzymes.  
A block in autophagic flux could also in principle reflect the destabilisation of 
ESCRT-0 components in USP8-depleted cells. The ESCRT machinery has 
also been linked to aggrephagy. In particular, depletion of the ESCRT-0 
component HRS increases p62 levels and ubiquitylated proteins in mice 
(Oshima, Hasegawa et al. 2016). The same study showed a block in 
autophagic flux in HRS-depleted PC12 cells alongside accumulation of p62. 
Given that USP8 is known to regulate HRS and STAM protein levels, one 
might expect USP8 depletion to inhibit aggrephagy and thus prevent 
degradation of protein aggregates (Row, Prior et al. 2006).  
In principle it is possible that USP8 depletion causes the sequestration of 
KEAP1, through its interaction with p62, in autophagosomes which are not 
subsequently degraded due to an additional block in autophagic flux. If 
KEAP1 is sequestered in autophagosomes which are unable to fuse with the 
lysosome one might see a reduction in cytosolic KEAP1 as it is sequestered 
within membrane bound structures. However it seems unlikely that the 
reduction in KEAP1 I observed in USP8-depleted cells is due to its 
sequestration and failed degradation as I saw a similar reduction in KEAP1 
with RIPA lysis. RIPA lysis buffer contains SDS detergent and should extract 
proteins sequestered within such membrane structures. This was shown in a 
recent proteomics study which sought to isolate autophagosomes and 
identify proteins within (Dengjel, Hoyer-Hansen et al. 2012). The authors 
used SDS lysis to solubilise autophagosomal proteins prior to processing the 
samples for mass spectrometry and were able to identify key 
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autophagosomal proteins such as LC3 and p62 (Dengjel, Hoyer-Hansen et 
al. 2012).  
Importantly, USP8 itself has been proposed to reduce the clearance of α-
synuclein positive protein aggregates (Lewy bodies) through its removal of 
K63-linked ubiquitin chains from α-synuclein (Alexopoulou, Lang et al. 2016). 
Overexpression of wild-type USP8 was shown to reduce ubiquitylation of 
endogenous α-synuclein whilst USP8-depletion promoted its lysosomal 
degradation (Alexopoulou, Lang et al. 2016). It is unclear at the moment 
whether the autophagy machinery is involved in this process.  
A number of experiments might be useful to assess the potential role of 
USP8 and the association of KEAP1 with the autophagic pathway. Firstly it 
will be important to understand if USP8 depletion causes any changes in the 
levels and/or distribution of key autophagy components such as LC3-II and 
p62. This can be assessed by western blotting and immunofluorescence. 
Secondly, if p62 is important in recruiting KEAP1 to autophagosomes then 
one might expect depletion of p62 would rescue the reduction in KEAP1 
levels with USP8 depletion. Additionally – as mentioned above – lysosomal 
inhibitors could provide information on this pathway since the lysosomal 
inhibitor bafilomycin blocks autophagy. If this inhibition rescues the KEAP1 
levels we can have some level of confidence that the pathways are linked. 
In addition to understanding how KEAP1 is degraded - it would be of interest 
to determine if KEAP1 is a direct substrate of USP8. Co-immunoprecipitation 
would tell us whether USP8 and KEAP1 interact directly. We can also assess 
the ubiquitylation status of KEAP1 upon USP8 depletion or co-expression 
with a catalytically inactive USP8-mutant. 
 
5.4.2. USP8 and ROS 
The other key finding in this chapter is that H1650 cells, but not EBC1 cells, 
are sensitised to ROS induction with USP8 depletion. This could, in part, be 
due to the different NRF2 status in the two cell lines. As mentioned above, 
EBC1 cells have a mutation in one of the two KEAP1 binding domains, the 
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ETGE motif. This motif is absolutely required for the NRF2-KEAP1 interaction 
and therefore mutation in this motif uncouples NRF2 from its inhibitor, 
KEAP1. H1650 cells however have wild-type NRF2, which should be under 
the control of KEAP1. A loss of KEAP1 in USP8-depleted cells should 
therefore result in the stabilisation of NRF2. Surprisingly I observed an 
increase in NRF2 protein levels not just in H1650 but even most strikingly in 
EBC1 cells (see figure 5.4). It would be interesting to see whether this also 
results in the increased transcription of NRF2-responsive genes. This could 
be assessed by qRT-PCR using primers for transcriptional targets of NRF2 
such as NQO1, or using an NRF2-responsive Luciferase reporter. 
Importantly, it is unlikely that the loss of KEAP1 protein levels is directly 
responsible for the sensitisation of USP8-depleted cells to ROS as a) KEAP1 
levels are decreased equally in both sensitised (H1650) and non-sensitised 
(EBC1) cell lines, and b) direct KEAP1 depletion by siRNA in H1650 cells 
does not sensitise cells to ROS.  
It is possible that USP8 depletion increases the basal ROS levels in the cells, 
which make any additional increase in ROS more problematic for the cells. In 
order to test this I attempted to use a probe for ROS using live cell imaging. 
The probe I used was CM-H2DCFDA which upon oxidation generates a 
fluorescent adduct which can be measured by flow cytometry or fluorescent 
microscopy. Whilst this attempt was unsuccessful, researchers at Amgen did 
work with a similar probe and did not see a detectable increase in ROS in 
USP8-depleted EBC1, HCC70 or LK2 cells. However they did not assess 
ROS levels in H1650 cells, thus this negative result needs confirming.  
Although the USP8-depleted cells do not have increased basal levels of 
ROS, it is still possible that the cells are less well equipped to deal with ROS 
and that this might explain the synthetic lethal effect of combining ROS 
induction with USP8 depletion. Investigating changes in transcription of 
downstream effectors of NRF2, such as NQO1, by qRT-PCR would tell us if 
the pathway is responding as expected. Interestingly, a recent study has 
provided further evidence that this pathway is linked to autophagy by 
suggesting that p62 might be under transcriptional control of NRF2 (Jain, 
Lamark et al. 2010). If cells without NRF2 have reduced autophagic gene 
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expression then we could consider that the reverse may be true: NRF2 
released from its inhibition by depleted KEAP1 levels could lead to increased 
autophagy.  Investigating whether cells depleted of USP8, and therefore 
KEAP1, show increased expression of autophagy related genes would be an 
interesting question to answer.  
KEAP1 has also been linked to regulation of cell death. KEAP1 is reported to 
interact with PGAM5, an outer mitochondrial protein which binds to the anti-
apoptotic BCL2 family member BCL-XL (Stepkowski and Kruszewski 2011). 
PGAM5 is a phosphatase which can dephosphorylate apoptosis signalling 
kinase 1 (ASK1) and therefore prevent apoptosis. If KEAP1 is degraded by 
autophagy, one might suppose that PGAM5 is recruited to autophagosomes 
through this interaction with KEAP1. This might sensitise cells to stress such 
as ROS induction. However, KEAP1-deficient MEFs are resistant to cell 
death by ROS induction due to a failure to activate ASK1 (Stepkowski and 
Kruszewski 2011). This lends weight to the argument that the synthetic cell 
death induced by ROS in USP8-depleted cells is not caused by a loss in 
KEAP1. It would thus also be of interest to monitor the levels of apoptosis 
related proteins upon USP8 depletion in relation to the cell death effects 
identified. 
Overall this chapter has answered some interesting and novel questions 
about a potential link between the NRF2/KEAP1 pathway and USP8 and led 
to several avenues worthy of further investigation. It also offers some hint for 
ways to explore the finding in the previous chapter that USP8 depletion 
causes cell death.  
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Chapter six: final discussion 
In this thesis I report that USP8-depletion reduces cell viability of a NSCLC 
cell line (chapter 4) and that combination of USP8-depletion with ROS 
induction has an additive effect in that cell line (chapter 5). Meanwhile, a 
USP8-depleted SQCC cell line is not sensitised to ROS induced cell death 
(chapter 5). USP8-depletion has an additional synthetic lethal effect when 
combined with PI3K pathway inhibition in U2OS cells stably expressing 
FOXO3, parental U2OS cells and H1975 cells (chapter 3).  
 
6.1. USP8 and cell viability 
My findings in this thesis point to multiple roles for USP8 in cell viability. 
There are two key findings: 1) USP8 plays an unidentified role in cell viability 
and 2) USP8-depletion sensitises some cells to additional stresses.  
USP8-depletion reduces cell viability of two NSCLC cell lines reported here. 
Cell numbers were reduced in H1975 and H1650 cells upon 120 hour USP8 
depletion and FITC-annexin V staining was increased in the H1650 cells 
(figures 4.4 and 4.5). Whilst I do not show data here pertaining to the cell 
viability effect of USP8-depletion on EBC1 cells, Amgen found these cells 
and a number of others (HCC70, HCC1954 – see chapter 5) to be sensitive 
to both USP8- and HRS- depletion. In the course of my experiments, I also 
observed a reduction in cell viability upon USP8-depletion in EBC1 cells.   
This is in line with evidence, discussed throughout this thesis, that USP8 
depletion reduces cell viability in NSCLC cell lines (Panner, Crane et al. 
2010, Byun, Lee et al. 2013). In addition, USP8 depletion reduces the 
viability of three multiple myeloma cell lines (KMS11, 8226 and JJN3) 
(Tiedemann, Zhu et al. 2012). USP8 was found by two of three analyses in a 
genome-wide pooled, shRNA screen of gene essentiality to be essential for 
proliferation in NSCLC cells (Cheung, Cowley et al. 2011). The genetic 
knockout of USP8 in mice is embryonically lethal (Niendorf, Oksche et al. 
2007). 
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In particular, I noticed the cell viability effect was most evident following long 
USP8-depletion protocols. In figure 5.7, H1650 cells treated with USP8 
siRNA for approximately 78 hours do not undergo apoptosis, whereas cells 
treated for 120 hour with USP8 siRNAs do (figure 4.5). RNAi experiments are 
typically performed on shorter time scales which may conceal the effect of 
USP8- depletion on cell viability. In order to assess the extent of the effect of 
USP8-depletion on cell viability, it would therefore be of interest to treat a 
panel of cancer and non-cancer cells with USP8 siRNA over long, 120 hour 
experiments. This reliance on longer knockdown experiments may also 
allude to a requirement for a complete USP8 knockdown in order to elicit this 
effect. The embryonic lethality of USP8 knockout in mice lends weight to this 
argument. Another way to test this would be the generation of CRISPR 
knockout cell lines which would allow for complete removal of USP8.  
The other effect USP8-depletion has on cell viability is the sensitisation of 
U2OS cells, U2OS stably expressing GFP-FOXO3 and H1975 cells to PI3K 
pathway inhibition. This pathway is frequently mutated in cancer leading to its 
hyperactivation, with the gene for the p110α subunit (PIK3CA) one of the 
most commonly mutated genes in breast cancer (Kan, Jaiswal et al. 2010). 
Inhibitors of the pathway such as class I PI3K inhibitor GDC-0491 and the 
p110α inhibitor GDC-0032 are under clinical evaluation (Thorpe, Yuzugullu et 
al. 2015). In addition I observed a USP8-depletion dependent sensitisation to 
cell death by ROS induction, which I will discuss below.  
 
6.2. USP8 and ROS 
My results suggest that the sensitisation of USP8-depleted cells to ROS is 
not universal: Only H1650 but not EBC1 cells showed enhanced apoptotic 
cell death in response to treatment with tBHP.  One way in which H1650 and 
EBC1 cells differ is their mutational status of NRF2. H1650 cells have wild-
type NRF2, whilst the EBC1 cells carry a heterozygous mutation which 
disrupts the binding of NRF2 to its inhibitor, KEAP1.  
In chapter five I showed that USP8 depletion reduces the protein levels of 
KEAP1. This would mean H1650 cells depleted of USP8 might already be 
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sensitised to ROS induction as a reduction in KEAP1 levels releases some 
NRF2 from its inhibition. Further disruption of the NRF2-KEAP1 interaction by 
ROS induction might then enhance transcription of downstream NRF2 
effectors. Whether this is truly the case would be an interesting question, 
which could be answered using luciferase assays or qRT-PCR to assess the 
basal mRNA levels of downstream NRF2 targets such as NQO1. Conversely, 
half of the NRF2 in EBC1 cells is already uncoupled from KEAP1 through the 
heterozygous D77V mutation. USP8 depletion reduces KEAP1 levels which 
might allow the release of the wild-type NRF2 from its inhibition but ROS 
induction does not have an additive effect. Why EBC1 cells are not sensitised 
remains to be investigated. It is also possible that the mechanism for this 
sensitisation does not hinge on the decrease in KEAP1 as KEAP1-depletion 
does not sensitise H1650 cells to ROS induction. 
Both H1650 and EBC1 cells are NSCLC cell lines however H1650s are 
derived from epithelial adenocarcinoma whereas EBC1 are derived from 
squamous cell carcinoma. H1650 cells have an activating mutation in EGFR 
(Δ746-750). According to the catalogue of somatic mutations in cancer 
(COSMIC), EBC1 cells do not carry an EGFR mutation. EBC1 cells, 
however, do carry a MET amplification (Lutterbach, Zeng et al. 2007).  
Studies have shown that a phosphatase involved in the regulation of both 
EGFR and MET, PTP1B, can be inactivated through ROS oxidation of its 
active site cysteine (Lee, Kwon et al. 1998, Tonks 2005, Heppner and van 
der Vliet 2016). In addition, PTP1B depletion delays ligand-induced 
degradation of EGFR and MET by preventing their internalisation (Sangwan, 
Abella et al. 2011). One difference between these two cell lines is their 
potential sensitivity to ligand-activation. In the case of EBC1 cells MET is 
amplified but not constitutively activated thus should be sensitive to activation 
by its ligand, HGF. Conversely the mutation in EGFR the H1650s carry, leads 
to constitutive activation of the receptor thus these cells should not be 
sensitive to activation by EGF. MET and EGFR signalling pathways bear 
some similiarities to one another in that both activate downstream MAPK and 
PI3K signalling pathways (Organ and Tsao 2011). Based on the studies in 
PTP1B, one would expect that both cell lines have a reduction in PTP1B 
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activation with ROS induction and therefore delayed ligand-induced 
degradation of MET and EGFR. USP8 is linked to the ligand-induced 
downregulation of both of these receptors; therefore one future avenue for 
investigation might be whether ligand treatment alters the sensitisation to 
ROS. This is of particular interest as each cell line should have different 
ligand responses as described above (Row, Prior et al. 2006).  
 
6.3. USP8 substrates 
USP8 is a DUB with many reported substrates (see chapter one). The 
reduction in KEAP1 levels following USP8 depletion might point to KEAP1 as 
a novel substrate. It would be of interest to see if the two proteins interact 
directly and to assess the ubiquitylation status of KEAP1 both upon USP8 
depletion and overexpression of wild-type versus catalytically inactive USP8. 
Many USP8 substrates are degraded by the lysosome. However, KEAP1 can 
be sequestered in autophagosomes and degraded by autophagy (Taguchi, 
Fujikawa et al. 2012). USP8 has also been linked to regulation of this 
pathway and has been linked to the degradation of aggregated proteins such 
as α-synuclein (Jacomin, Bescond et al. 2015, Alexopoulou, Lang et al. 
2016). It would therefore be interesting to see if blocking autophagy rescues 
the effect of USP8 depletion on KEAP1 levels.  
One way to investigate cell surface USP8 substrates in an unbiased way is to 
combine mass spectrometry with cell surface biotinylation. In preliminary 
experiments which are not reported within the context of this thesis, I treated 
SILAC labelled MCF7 cells with USP8 siRNA oligos (Dh1 or Dh2) or non-
targeting (NT1) siRNA. In order to identify proteomic changes on the cell 
surface I labelled cell surface proteins with membrane impermeable biotin. I 
lysed the cells in NP40 buffer then mixed the lysates 1:1:1 and used a 
streptavidin pulldown to isolate biotin labelled proteins. I then used 
LC/MS/MS to quantitate the protein levels across light (NT1), medium (Dh1) 
and heavy (Dh2) labelled cells. In this first preliminary experiment 
approximately 40% of the proteins identified were surface proteins. Selecting 
only proteins that were enriched or de-enriched beyond a set threshold I 
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found two proteins that were of interest for follow up. In both Dh1 and Dh2 
treated cells the collagen RTK receptor discoidin domain receptor 1 (DDR1) 
was enriched. Dh1 treated cells had almost five times as much DDR1 and 
Dh2 treated cells had twice as much of this receptor compared to the NT1 
treated cells. Meanwhile a subunit of the integrin α2/β1 collagen receptor, 
integrin α2 (ITGA2) was de-enriched compared to control treated cells by one 
and one and a half times in Dh1 and Dh2 treated cells, respectively. I 
confirmed these changes biochemically using western blotting in MCF7 cells. 
Here we have two collagen receptors changing in opposing directions with 
USP8 depletion which may hint at a compensatory mechanism. Interestingly, 
both proteins are involved in the migration of cells. In particular, DDR1 has 
been shown to play a role in the formation of linear invadosomes whereas 
ITGA2 is enriched in focal adhesions (Juin, Di Martino et al. 2014). In fact, 
collagen mediated epithelial to mesenchymal transition (EMT) has been 
linked to cooperative α2/β1 and DDR1 signalling (Shintani, Fukumoto et al. 
2008). One might postulate that an increase in DDR1 and a decrease in 
ITGA2 encourages migration of USP8 depleted cells although this would 
require much further investigation. One way to assess this would be to use 
live-cell imaging of cells as they adhere to collagen and see if USP8 
depletion alters this adhesion. Live-cell imaging would also tell us if USP8 
depletion alters the motility of cells on a collagen substrate. 
 
6.4. USP8 and disease 
Recent studies have linked USP8 to Cushing’s disease (CD). Cushing’s 
disease is caused by pituitary corticotroph adenomas which secrete elevated 
levels of adrenocorticotropic hormone (ACTH).  
The first of these studies used exome sequencing to identify protein-altering 
mutations in corticotroph adenomas (Reincke, Sbiera et al. 2015). Four of ten 
tumours derived from patients with CD had a somatic missense mutation in 
USP8. All of these mutations were between amino acids 713 and 720 
corresponding to the region conferring 14-3-3 binding. Previous studies have 
shown that USP8 binding to 14-3-3 inhibits its activity and that 
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phosphorylation of S680 in the M phase ablates this binding (Mizuno, 
Kitamura et al. 2007). Reincke et al. reported that the USP8-mutants, which 
they identified in an additional six of seventeen corticotroph adenoma 
tumours, showed reduced or no 14-3-3 protein binding. In addition they 
identified a 90kDa and a 40kDa USP8 band by western blotting, which they 
proposed might correspond to proteolytical cleavage products. The 40kDa, 
C-terminal region is cleaved between amino acids 714 and 715 and has high 
DUB activity as it contains the USP domain (see figure 4.3 for USP8 domain 
structure). This short USP8 fragment does not comprise the MIT domain and 
only retains one of the three SH3 domains required for localisation to the 
ESCRT machinery. COS7 cells transfected with the active point mutants 
lacking 14-3-3 binding or the 40kDa truncated USP8 showed reduced 
ubiquitylated EGFR and increased recycling of this receptor to the plasma 
membrane following EGF-stimulated internalisation.  
Subsequent studies have reiterated that USP8 gain-of-function mutations are 
associated with CD. In the same year, Ma et al. reported three types of USP8 
mutation in 8 out of 12 ACTH-secreting pituitary adenomas identified by 
whole-exome sequencing (Ma, Song et al. 2015). Following up with targeted 
sequencing they found 17 USP8 variants across an additional 67 of 103 
ACTH-secreting pituitary adenomas. Again, USP8 mutation disrupted 14-3-3 
interaction and increased EGFR protein abundance. Importantly, USP8 
depletion or EGFR inhibition with the small molecule inhibitor, gefitinib, 
reduced ACTH secretion in primary cells derived from patient tumours. In fact 
the presence of USP8 mutations is also correlated with a positive response 
to the CD treatment pasireotide (Hayashi, Inoshita et al. 2016). 
Studies in mice showed that the EGFR pathway is essential for the synthesis 
of the ACTH precursor proopiomelanocortin (POMC) (Fukuoka, Cooper et al. 
2011). Gefitinib treatment inhibits hyper-secretion of ACTH, inhibits 
proliferation and enhances apoptosis of corticotroph tumour cells in mouse 
models. Since USP8 is a major regulator of EGFR trafficking, its 
hyperactivation might promote ACTH secretion by promoting the recycling of 
EGFR to the plasma membrane and thereby increasing EGFR levels at the 
cell surface. 
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A role for USP8 activity in gefitinib resistant non-small cell lung cancer cells 
(NSCLC) has also been suggested (Byun, Lee et al. 2013). USP8 depletion 
reduced the viability of H1650 and H1975 cells. The authors reported a 
reduction in basal growth factor receptor levels such as EGFR, ERBB3 and 
MET. This was a finding I was unable to reproduce in the same cells in 
chapter four. However I did see an effect on cell viability following long-term 
(120 hours) depletion of USP8 in these cells. Whilst the reason for the 
decrease in the survival of these cells is unclear, it is possible that these 
cells, which have constitutively active EGFR, are particularly reliant on the 
EGFR pathway through oncogene addiction (Sharma and Settleman 2007). 
USP8 depletion delays EGFR degradation however the receptor is still 
internalised and is stalled at enlarged, aberrant endosomes in its 
ubiquitylated state (Row, Prior et al. 2006). Although there is some evidence 
that receptors can still signal from endosomes, typically endocytosis 
attenuates signalling (Sorkin and von Zastrow 2009). Thus cells with an 
activating EGFR mutation (and possible oncogene addiction) might be 
sensitised to cell death by entrapment of the active EGFR within the lumen of 
the endosome or multi-vesicular body.  
 
6.5. USP8 as a drug target 
In chapter four I showed that USP8 depletion reduced cell viability of H1975 
and in particular, H1650 cells. Byun and colleagues also reported this effect 
which they were able to extend to an USP8 inhibitor (Byun, Lee et al. 2013). 
This was shown to be due to an increase in apoptosis (also see figure 4.5) 
(Jeong 2015). The literature suggests that this is specific to gefitinib resistant 
NSCLC. This makes USP8 a promising target in gefitinib resistant NSCLC. 
My results confirm that USP8 depletion in H1650 results in reduced cell 
viability. Future work might be useful to establish the effect of USP8 depletion 
on cell viability in a range of cancer types to investigate this further. In 
particular we should like to compare the effect of USP8 depletion in MCF10A 
parental cell lines with MCF10A expressing constitutively active EGFR. As 
mentioned above, USP8 depletion also reduced cell viability in multiple 
myeloma cells (Tiedemann, Zhu et al. 2012).  
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USP8 is also of general interest as a therapeutic target in cancer due to its 
role in the regulation of receptors often associated with tumourigenesis. 
Amongst the proposed substrates of USP8 are EGFR and MET. EGFR 
family members have been linked to lung cancer, breast cancer and 
glioblastoma, whilst MET receptor is linked to gastric and oesophageal 
carcinomas, medulloblastomas and liver metastases from colon cancer 
(Organ and Tsao 2011, Lemmon, Schlessinger et al. 2014). 
USP8 depletion delays the EGF-induced degradation of EGFR; therefore at 
face value USP8 inhibition might not hold promise in EGFR positive cancers. 
However, the effect of USP8 inhibition on constitutively active EGFR has not 
yet been studied. Furthermore, inhibiting the catalytic activity of USP8 may 
not be equivalent to removing the whole protein by siRNA. In addition there 
are studies that suggest USP8 depletion enhances EGFR degradation – this 
may depend on the level and duration of USP8 depletion since conditional 
USP8 knockout mice also have reduced basal EGFR levels (Niendorf, 
Oksche et al. 2007). Mizuno et al. noted that they only saw endosomal 
aberration in 20-30% of USP8-depleted cells and proposed that cells without 
a complete USP8 depletion might degrade EGFR more rapidly (Mizuno, 
Kobayashi et al. 2006). The use of USP8 inhibition in cancer treatment has 
yet to be established, in part due to the lack of commercially available, 
specific USP8 inhibitors. As discussed in chapter five, the currently available 
USP8 inhibitors also inhibit a variety of other DUBs (Ritorto, Ewan et al. 
2014).   
Another way USP8 might be of interest as a therapeutic target in cancer is in 
combinatorial therapies. I described above the synthetic lethal effect of 
combining USP8 depletion and PI3K pathway inhibition and that the PI3K 
pathway is frequently mutated in cancer. In fact, the PI3K pathway has been 
proposed as a target for combinatorial therapies before. This is of particular 
use when cancer cells have acquired resistance to inhibitors at other levels 
(either up or downstream) of the pathway (Thorpe, Yuzugullu et al. 2015). 
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6.6. Concluding remarks 
USP8 is a promiscuous DUB which is involved in the regulation of a whole 
range of pathways, substrates and ubiquitin chain-linkages. It has been 
linked to the regulation of endocytosis of cell surface proteins such as EGFR 
and MET, stability of cytosolic proteins such as Nrdp1 and STAM, delivery of 
lysosomal enzymes such as Cathepsin D, autophagic flux and selective 
autophagy (Row, Prior et al. 2006, Durcan, Tang et al. 2014, MacDonald, 
Urbe et al. 2014, Jacomin, Bescond et al. 2015). Here, I report a novel role 
for USP8 in regulating KEAP1 protein levels and reducing the sensitivity of 
cells to ROS. Whether the mechanism by which USP8 promotes the turnover 
of KEAP1 is linked to the endocytic pathway remains to be investigated.   
Importantly, I show that USP8 is important in cancer cell viability. Preliminary, 
unpublished data hint at an additional role for USP8 in migration and outlines 
a technique for unbiased investigation of novel USP8 substrates. USP8 
depletion has effects on endosomal morphology, global ubiquitin levels and 
the accumulation of ubiquitylated proteins at the endosome (Row, Prior et al. 
2006). All of these suggest that USP8 depletion has pleiotropic effects on a 
number of pathways.  
This DUB plays a role in the regulation of a number of proteins upregulated in 
cancer making USP8 an interesting potential drug target. However the 
pleiotropic effects described above, and that there is a potential variability in 
response depending on the degree and duration of USP8-depletion make its 
role as a drug target, complicated.  
This thesis provides many new avenues for investigation to establish the role 
of USP8 in novel pathways such as ROS management and cell viability.   
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